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Abstract 
Abstract 
Proteins are the fundamental building blocks of all living cells and they carry out nearly 
all cell functions. Proteins predominantly act as part of multiprotein complexes to carry 
out these functions. The association of protein isoforms and post-translationally 
modified forms in protein complexes can influence their subcellular location, activity 
and substrate specificity. It is therefore crucial to characterise protein complexes at 
the level of the protein isoforms and post-translationally modified forms they contain 
to fully decipher the network of signalling and regulatory pathways within cells.  
The aim of my work has been to develop a technique to study protein complexes 
through the use of size exclusion chromatography (SEC) combined with tandem mass 
spectrometry. Combining these approaches has enabled an in-depth analysis of 
protein complexes in U2OS cells, including those involving post-translationally 
modified proteins and protein isoforms. The data presented in this thesis provide a 
proof of concept, together with forming a useful resource, which can be used 
alongside pull-down analyses to differentiate the interaction partners involved in 
different protein complexes. This combined approach minimises the need for multiple 
IP analyses and facilitates a more targeted approach in dissecting the components of 
individual protein complexes.  
I developed this technique further by utilising in vivo crosslinking prior to denaturing 
SEC. This approach enabled more efficient recovery and detection of proteins 
previously underrepresented using native SEC analysis, including many membrane 
complexes, thereby providing a more complete picture of endogenous protein 
complexes. 
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Abstract 
I have applied the native SEC/MS approach in a study of the interactions between the 
MRFAP1-MORF4L1 proteins. I demonstrated that this complex is distinct from the 
larger complex involving interactions between the MRGBP-MORF4L1 proteins. In 
addition, I also demonstrate that the native SEC/MS technique can be extended to 
assess the effect of drugs on protein-protein interactions.  
Overall, the methods I present in this thesis enable the rapid, proteome-wide analysis 
of endogenous protein complexes, which will advance the future study of protein 
complexes in biology. 
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Chapter 1: Introduction 
Chapter 1: Introduction  
All living organisms are made up of cells. From human cells to a unicellular bacterium, 
proteins form the major component of the machines that perform basic cell functions. 
Proteins are the building blocks of all living things and they define the structure, 
function and regulation of cells. Protein is made continuously throughout a cell’s 
lifetime, and is encoded by the heritable message held within DNA as genes. As a 
result, to understand how cells function at a molecular level, we need to understand 
what proteins are and what proteins do.  
The proteome is the entire set of proteins expressed within a cell or organ system and 
proteomics is the large-scale study of these proteins. As proteins are the key players in 
cell function, studying the proteins actively expressed in a cell provides the greatest 
insight into the factors regulating cell biology.  Modifications to proteins can alter 
protein function, localisation, interaction sites and interaction partners - information 
which would not be apparent by studying genes (the genome) or RNA transcribed from 
genes (the transcriptome). As will be discussed in more detail in the following section, 
one gene can code for multiple different proteins therefore the total number of 
proteins in humans is in vast excess of the ~21, 000 known protein coding genes. It is 
not only the sheer number of proteins that make the proteome more complex than 
the genome, but the fact that the proteome differs from cell to cell and varies with 
time and in response to environmental stimuli increases the challenges faced by the 
proteomics community.  
Proteomics has become synonymous with mass spectrometry and technological 
advances in this technique over the last decade have opened the door to the in-depth, 
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high-throughput analysis of proteins. The advances are such that recent studies have 
been able to demonstrate that there are over 10, 000 proteins in one cell type alone, 
all identified from one experiment [Beck et al., 2011; Nagaraj et al., 2011]. In the 
Lamond laboratory, application of mass spectrometry in the study of proteomics has 
enabled the calculation of global protein turnover rates [Boisvert et al., 2012], 
comparison of proteins expressed between subcellular compartments, including 
protein isoforms [Ahmad et al., 2012], analysis of differential protein degradation rates 
between cellular compartments [Larance et al., 2013] and in the analysis of protein 
expression during the different phases of the cell cycle [Ly et al., 2014]. By being able 
to measure such protein parameters on a large scale, we have gained great insight into 
the regulation of cell function at the molecular level, in both time and space.  
1.1 Protein Biology 
1.1.1 Protein synthesis 
DNA and genes 
All living cells store hereditary information in DNA. To optimise the safe and compact 
storage of DNA, it forms a double helix, which is further compacted by winding around 
an octamer of histone proteins to form a nucleosome, the basic unit of chromatin 
(Figure 1.1). Information within DNA relates to protein sequences, RNA sequences and 
binding domains for RNA molecules and proteins. Therefore, the genome (all the 
genetic information carried in DNA) contains information not only regarding which 
proteins to synthesise but also when and where this is to occur.  
One of the major milestones of modern science has been the completion of the 
Human Genome Project, which was developed to map the entirety of the human 
23 
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genome [Lander et al., 2001]. The human genome is now known to contain ~21, 000 
protein coding genes [Clamp et al., 2007] and although greater knowledge of the 
genome provides an understanding of the genetic defects in some diseases [Lander, 
2011] it does not always provide the greatest understanding behind cell biology as 
genes themselves are non-functioning. Although the genetic code is generally identical 
from one cell to the next in humans (excluding special cases, such as plasma cells, 
gametes and tumour cells), it is known that the expression of genes varies greatly from 
one cell type to another and even within one cell type, gene expression can vary at 
different points in time. Modification of histone molecules within chromatin, for 
example by histone acetylation and deacetylation complexes, can act as a signal for 
either chromatin relaxation, or chromatin compaction, respectively, thereby defining 
whether protein coding genes held within DNA can be transcribed at a specific point in 
time. Unravelling of the chromatin and opening of the DNA helix permits DNA-binding 
proteins (transcription factors) and RNA polymerase II to bind specific DNA sequences 
(the promoter) to initiate gene transcription (Figure 1.1). 
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Figure 1.1 Schematic overview of protein synthesis 
RNA to protein 
Transcription and translation are the processes by which an RNA product or protein is 
made. As the RNA polymerase II passes along the DNA, it forms pre-messenger RNA 
(pre-mRNA). There are more mRNA transcripts than there are genes in the human 
genome and this is, in part, due to RNA splicing. Pre-mRNA contains coding (exons) and 
non-coding (introns) sequences and in order for the sequence to be accurately 
translated into a protein, the non-coding sequences need to be removed to form 
mRNA. Variation in this process can lead either to the formation of different versions 
of the same protein (protein splice isoform), or to an entirely new protein altogether, 
all encoded from the same gene. Splicing may create or remove a protein interaction 
interface for binding interaction partners, thereby increasing protein functional 
diversity. The resultant mRNA is then transferred from the nucleus to the cytoplasm 
where protein synthesis takes place in ribosomes. Here, the mRNA code is read by 
transfer RNA (tRNA), and the encoded amino acids are linked to form a protein 
sequence.  
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Transcriptomics is the study of the set of RNA molecules transcribed from genes, either 
in a cell at a given point in time, or in response to different environmental stimuli. 
However, evidence suggests that not all mRNA is translated into protein and several 
studies report that mRNA levels do not uniformly reflect protein levels [Gygi et al., 
1999b; Maier et al., 2009; Lundberg et al., 2010; Vogel et al., 2010; Nagaraj et al., 
2011; Schwanhausser et al., 2011; Ly et al., 2014]. Although two studies do show a 
high correlation between mRNA and protein levels, statistical analysis does not suggest 
this correlation is high enough to reliably use mRNA levels as a predictor for protein 
expression [Lundberg et al., 2010; Ly et al., 2014]. Such discrepancies could be due to 
differences in translational efficiency [Man and Pilpel, 2007; Spruill and McDermott, 
2009], post-translational modification of proteins [Ly et al., 2014], or to variations in 
the rate of protein degradation/half-life [Varshavsky, 1996]. This evidence highlights 
the importance of studying cell biology at the protein level for a greater understanding 
of cell function. 
1.1.2 Protein Regulation 
Overall protein quantity is regulated at the level of both production and degradation. It 
is known that proteins vary widely in their turnover rates, with some being present for 
only a few minutes (e.g. p53) [Haupt et al., 1997] and others surviving for more than a 
month or even longer (e.g. histones and nuclear pore complex components) [Toyama 
et al.], although the majority of proteins, in the setting of cell culture, have a turnover 
in the region of 20 hours [Boisvert et al., 2012]. Not only is the rate of protein synthesis 
important in the regulation of protein concentrations but the rate of protein 
degradation also plays a significant role. Various processes are involved in both, and 
these are summarised in Figure 1.2. 
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Figure 1.2. Factors influencing protein regulation. 
 
Regulation of protein synthesis 
As all cells in an organism contain the same DNA, it is this regulation of gene 
expression that gives a cell control over its structure and function, and forms the basis 
of cellular differentiation. The processes of transcription and translation have been 
described previously in this section but there are many factors which control the rate 
at which genes are expressed and proteins synthesised to enable a cell to respond 
accurately to changes in cell state and/or environment. These rate controlling steps 
occur throughout the pathway from DNA to protein and include: regulating when and 
how often a mRNA is transcribed; altering the splicing and processing of mRNA; 
regulating which mRNAs are translated by the ribosome and their rates of translation; 
degrading some mRNAs in the cytoplasm prior to translation, regulating rates of 
protein degradation; and by modifying the final protein product to alter functional 
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capacity e.g. by either cleavage or by post translational modification. In some cases, 
regulation of gene transcription is particularly important during certain situations.  
Transcription rates can be affected by proteins binding directly to DNA at specific sites 
around the coding region (i.e. promoter and enhancer sites). Such events may block 
RNA polymerase binding sites, or mask activation surfaces of activating proteins, 
thereby preventing a gene being transcribed. For example, conjugation of SUMO2 to 
specificity protein 1 (Sp1), a major transcription factor, attenuates DNA binding, 
impairs the interaction between Sp1 and the co-activator p300, and leads to the 
recruitment of the repressor, Sp3 to gene promoters, thereby negatively regulating 
gene expression [Gong et al., 2014]. Alternatively, the binding of some proteins to DNA 
can enhance transcription by assisting RNA polymerase binding. For example, 
transcription initiation by RNA polymerase II requires the co-ordinated interaction of 
several transcription factors to form the preinitiation complex at the core promoter 
[Nikolov and Burley, 1997]. This complex facilitates the recruitment of RNA polymerase 
II to DNA and therefore enhances transcription. 
Transcription factors themselves can be phosphorylated, in addition to other 
modifications (glycosylation, acetylation, ubiquitination and sumoylation), inhibiting 
their ability to either bind DNA, recruit RNA polymerase II, or promote transcription 
elongation [Tootle and Rebay, 2005]. In some cases, activation of a signalling cascade 
reverses the modification process, thereby activating the transcription factor and 
facilitating transcription, in response to a cellular stimulus. One example of this 
process has been described by Okamura et al., where dephosphorylation of the NFAT1 
transcription factor masks a nuclear export signal, exposes a nuclear localisation signal, 
and promotes transcriptional activity [Okamura et al.]. 
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Modifications to histone tails, such as methylation, can facilitate additional histone 
modifications (acetylation or deacetylation) which either promote, or suppress, gene 
expression through the regulation of chromatin structure. Methylation, acetylation 
and deacetylation processes can involve the function of a common protein. One 
example of this is MORF4L1. This protein has a N-terminal chromodomain through 
which it binds di/tri methylated histone H3 on K36, and an MRG domain at its C-
terminus (Figure 1.3) [Zhang et al., 2006a]. The MRG domain is known to interact with 
components of histone acetylation [Cai et al., 2003] and histone deacetylation 
complexes [Kumar et al., 2011] thereby regulating chromatin structure and gene 
expression (Figure 1.3A,B). In addition, this protein has been demonstrated to have a 
role in regulating methylation of histone H3K4 through an interaction with RBP2 
[Hayakawa et al., 2007] (Figure 1.3C). Consequently, factors affecting MORF4L1 
binding to its interaction partners will affect gene expression and transcription.  
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Figure 1.3. Schematic diagram of the MORF4L1 protein and its role in the 
regulation of protein synthesis.  
The MORF4L1 protein binds to methylated tails of Histone H3 via its 
chromodomain. The MRG domain for MORF4L1 is the binding domain for many 
interacting proteins. A, the NuA4 histone acetyltransferase complex binds the 
MRG domain to facilitate the acetylation of histone H4 which opens out 
chromatin. B, Histone deacetlyation complexes (e.g. sin3A complex) also bind the 
MRG domain leading to chromatin compaction. C, RBP2 interacts with MORF4L1 
to regulate methylation of Histone H3. 
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It is clear to see how the alteration of any factor which changes the expression levels, 
structure or function of any protein involved in transcription activation could have 
huge implications on the rate of transcription and therefore protein synthesis. 
Protein loss and degradation 
Aside from transcription, loss of protein expression obviously also affects total protein 
levels. Some proteins are secreted and therefore intracellular levels are reduced 
however degradation of proteins is a major factor in protein regulation. There are two 
main pathways for intracellular protein degradation i.e. the proteasome and 
autophagy-lysosomal systems (Figure 1.2). In general, short lived proteins such as 
those involved in cell cycle regulation, are degraded by the proteasome and longer 
living proteins are degraded by the lysosome [Ohsumi, 2006]. 
Many copies of the proteasome are present throughout the cytosol and nucleus of the 
cell. Proteins that have not formed properly or those that fail to fold are rapidly 
degraded following synthesis. Other proteins which must be quickly regulated in 
response to different cell sates can also be degraded via this pathway. The 26S 
proteasome is an ATP-dependent protease comprising a core (20S) particle and a 19S 
regulatory cap [Peters et al., 1993; Adams, 2003]. The regulatory cap is made up of at 
least 19 subunits [Sharon et al., 2006], several of which are ATPases, believed to be 
important for unfolding proteins before they are passed into the cylindrical core where 
proteolysis takes place. The regulatory cap is involved in recognising proteins which 
contain a tag or modification indicating that they have been targeted for degradation 
(including the K48-ubiquitin chain) [Clague and Urbé, 2010]. These markers for 
degradation can be added to a protein as the end result of a signalling pathway 
[Glickman and Ciechanover, 2002]. Some proteins are continuously degraded after 
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synthesis as part of a biological process, such as the tumour suppressor gene p53. This 
rapid degradation results in only a low level of the protein under normal growth 
conditions. However, oncogene activation leads to sequestration of the E3 ligase 
Mdm2 and thus prevents p53 degradation and as a result, there is a rapid increase in 
p53 levels (Figure 1.4) [Haupt et al., 1997]. This demonstrates how regulation of 
protein degradation can be used to rapidly respond to altered cell states 
independently of transcription activation. MG132 is an inhibitor of the 26S proteasome 
and it has been used for the study of this degradation pathway [Tatham et al., 2011; 
Leidecker et al., 2012; Larance et al., 2013]. 
 
Figure 1.4. Schematic diagram of p53 regulation by the ARF/Mdm2 pathway. 
 
Lysosomes are membrane bound organelles which are involved in the destruction of 
proteins, nucleic acids, lipids and other cellular debris. Material is delivered to the 
lysosome in vesicles where lysosomal hydrolases break down digested molecules. 
Endocytolysis involves the process of taking up macromolecules from extracellular 
32 
Chapter 1: Introduction 
fluid, in vesicles, for degradation. A second pathway involving the lysosome however is 
autophagy [Feng et al., 2014]. This pathway for degradation involves cytoplasmic 
proteins and organelles of the cell itself becoming enclosed in a double membrane, 
thus creating an autophagosome, which then fuses with a lysosome for degradation, 
forming the autolysosome. Similarly to the proteasome, amino acids resulting from 
lysosomal degradation can be re-used within the cell for future protein synthesis [Feng 
et al., 2014]. The autophagosome is not always present in a cell – it forms quickly and 
disappears under the regulation of autophagy activating signals [Lamb et al., 2013]. 
Dysregulation of the autophagy pathway has been implicated in some human diseases, 
such as Crohn’s disease [Murthy et al., 2014], cancer and neurodegeneration [Choi et 
al., 2013] and a knockout mouse model has demonstrated that autophagy is essential 
for post-natal survival [Kuma et al., 2004]. Although autophagy has been described as a 
non-selective degradation process, ubiquitin modification has also been shown to 
direct degradation via this pathway [Clague and Urbé, 2010]. Modification of proteins 
by a ubiquitin side chain (K63-linked ubiquitin chain) is recognised by p62 and NBR1 
and therefore targeted for autophagy-mediated degradation [Kirkin et al., 2009]. 
Evidence suggests there is crosstalk between the proteasomal and autophagy 
regulation pathways. Which pathways are selected for different proteins may relate to 
subcellular localisation, ubiquitin chain length and linkage type [Clague and Urbé, 
2010; Driscoll and Chowdhury, 2012]. 
1.1.3 Protein structure 
Amino acids are a family of 20 molecules within a cell that have a similar basic 
structure. These molecules all have an amino group (H2N) at one end termed the N-
terminus, and a carboxylic acid group (COOH) at the other, termed the C terminus. 
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Linked to both these termini is a carbon atom, termed the -carbon, which attaches to 
a side chain (Figure 1.5).  
 
Figure 1.5. Basic structure of an amino acid 
 
Each side chain can have different properties; five form ions in solution at physiological 
pH and therefore carry either a positive (histidine, lysine and arginine), or negative 
charge (aspartic acid and glutamic acid). Some of the side chains are hydrophilic  and 
others are hydrophobic (Table 1.1). It is this variability in the side chain that 
distinguishes the chemical properties of the 20 different amino acids. Amino acids can 
link together, the C-terminus of one amino acid binding to the N-terminus of the next, 
forming a peptide bond between the two. The linear sequence of amino acids is known 
as the protein primary structure (Figure 1.6). 
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Table 1.1 Properties of amino acids 
 
Figure 1.6. Primary, secondary, tertiary and quaternary protein structures. 
 
(http://en.wikipedia.org/wiki/Protein_structure#mediaviewer/File:Main_protein
_structure_levels_en.svg) 
Amino Acid Abbreviation (3 letter) Abbreviation (1 letter) Side chain property
Lysine Lys K Basic
Arginine Arg R Basic
Histidine His H Basic
Aspartic acid Asp D Acidic
Glutamic acid Glu E Acidic
Asparagine Asn N Uncharged polar
Glutamine Gln Q Uncharged polar
Alanine Ala A Nonpolar
Valine Val V Nonpolar
Leucine Leu L Nonpolar
Isoleucine Ile I Nonpolar
Proline Pro P Nonpolar
Phenylalanine Phe F Nonpolar
Methionine Met M Nonpolar
Tryptophan Trp W Nonpolar
Glycine Gly G Nonpolar
Cysteine Cys C Nonpolar
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In addition to the peptide bonds between amino acids, hydrogen bonds can also form 
between the main-chain peptide groups. These can cause a protein to fold in certain 
ways to form highly regular local sub-structures such as the alpha-helix and the beta 
sheet. These substructures are referred to as the protein secondary structure (Figure 
1.6).  
Chains of typically between 50 to 2000 amino acids then fold up in an organised 
fashion, dependent on the properties of the amino acid side chains, to form the 3D 
structures of proteins, known as the tertiary structure (Figure 1.6). Proteins will fold in 
the most energy efficient way to accommodate opposing forces of hydrophobic and 
hydrophilic amino acids. The addition of some solvents can lead to unfolding 
(denaturing) of proteins by disrupting the non-covalent interactions, but many 
proteins will spontaneously re-fold again after this has been removed. In other cases 
protein folding requires the action of protein chaperones to ensure it occurs correctly. 
The quaternary structure is the 3D structure of a multi-subunit protein, held together 
by the same forces which regulate the tertiary structure. 
Although each protein contains a unique sequence of amino acids, some large proteins 
contain amino acid sequences which are capable of folding largely independently of 
the remainder of the protein. These sequences can form structural domains and 
although they can be made of different linear combinations of amino acids, if the 
overall properties are similar, it can lead these domains to act in predictable way. 
These are often the modular units which facilitate the different functions of a protein 
(for example, the chromodomain and MRG domain of MORF4L1 (Figure 1.3). Mapping 
the structural domains can help decipher the probable structure of a protein [Kelley 
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and Sternberg, 2009], and protein domains have been used to determine possible 
protein-protein interactions [Wojcik and Schächter, 2001; Memisevic et al., 2013].  
1.1.4 Protein modifications 
As discussed previously, the complexity of the human proteome is much greater than 
that of the genome. Even more complexity is added to the proteome at a post-
translational level through proteolytic cleavage and by the addition of post-
translational chemical modifications (PTMs) of the amino acid side chains. Such 
modifications alter the structural and chemical properties of the amino acids and 
thereby can alter protein function (Figure 1.7).  
 
Figure 1.7. Post-translational modifications increase the complexity of the 
proteome. 
http://www.piercenet.com/method/overview-post-translational-modification 
 
A post-translational modification of a protein refers to the conjugation of a small 
chemical group (e.g. PO4, OH, CH3 etc.) or even a small peptide (e.g. SUMO, NEDD8, 
ubiquitin) to the side chain of an amino acid in a protein to increase functional 
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diversity. PTMs offer a very rapid and dynamic way to regulate protein activity and 
they do this in many ways, for example by altering protein-protein interactions by 
altering binding sites, inducing a conformational change to alter protein function and 
altering protein localisation (Figure 1.8). PTMs are catalysed by enzymatic activity and 
many are reversible with separate enzymes used to add or remove the modification 
(e.g. kinases and phosphatases). There are a vast number of different types of PTM, 
many of which may be detected at multiple residues. Furthermore, multiple PTMs can 
be present on the same protein, further increasing combinatorial complexity [Khoury 
et al., 2011]. Some of the common PTMs are described in the following paragraphs. 
 
Figure 1.8. Summary of the biological effects of post-translational modifications 
 
Phosphorylation 
One of the most widely studied PTMs is phosphorylation, which involves the addition 
of a phosphate group by a kinase to the hydroxyl group on the side chains of serine, 
threonine and/or tyrosine residues. This modification is reversible, and is removed by 
phosphatases (Figure 1.9). The addition or removal of a phosphate group can change 
the strength of physical protein-protein interactions, affect protein stability and alter 
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protein dynamics (reviewed by [Johnson, 2009; Nishi et al., 2011]). Phosphoproteomic 
analyses have demonstrated that most mammalian proteins can be phosphorylated 
and therefore phosphorylation has a vast role in protein regulation [Olsen et al., 2006; 
Olsen et al., 2010]. Phosphorylation plays critical roles in the regulation of many 
cellular processes including regulation of metabolism, cell signalling and cell migration. 
For example, syndecan-4 phosphorylation has recently been identified as a key 
regulator of focal adhesion dynamics and cell migration through the regulation of 
integrin recycling [Morgan et al., 2013]. The reversibility of phosphorylation makes this 
PTM eminently suitable for signal transduction, which allows a cell to react rapidly in 
response to intracellular or extracellular stimuli. A protein sensing a stimulus as a 
result of ligand binding, protein cleavage or any other stimulus can then activate 
second messengers and signalling enzymes through the activation of protein kinases. 
The signal amplification resulting from such an enzyme cascade can lead to the 
activation of a global cellular function from one molecule. One example of this is the 
activation of cell proliferation, via the ERK module, by a single growth factor [Cowan 
and Storey, 2003]. Signalling pathways involving TOR (a protein kinase) are also known 
to regulate growth related processes [Wullschleger et al., 2006]. In addition, TOR also 
controls many aspects of cell metabolism, including amino acid biosynthesis and 
glucose homeostasis, and inhibitors of this pathway have been highlighted as being of 
potential benefit for the treatment of cancer, cardiovascular disease, autoimmunity 
and metabolic disorders [Wullschleger et al., 2006].  
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Figure 1.9. Schematic diagram of phosphorylation.  
Phosphate groups are added and removed from a protein by kinases and 
phosphatases, respectively.  
 
Ubiquitination 
Ubiquitin is a small peptide which can be conjugated to lysine residues in proteins 
[Pickart and Eddins, 2004]. The ubiquitination process occurs in three stages: 
activation, conjugation and ligation and these stages involve ubiquitin activating 
enzymes (E1), ubiquitin conjugating enzymes (E2) and ubiquitin ligases (E3) 
respectively (Figure 1.10) [Pickart and Eddins, 2004]. The result is the conjugation of 
ubiquitin to lysine residues or to the amino group of a protein’s N-terminus [Pickart 
and Eddins, 2004]. Ubiquitination, like many PTMs, is reversible, a process facilitated 
by deubiquitinating enzymes (DUBs) [Wilkinson, 1997]. As described in the previous 
section, ubiquitination has a major role regulating protein degradation via the 
proteasome and autophagosome [Clague and Urbé, 2010]. The formation of 
polyubiquitin chains is a key factor in this regulatory process, with ubiquitin chains at 
lysine 48 being recognised as a degradation signal by the proteasome [Clague and 
Urbé, 2010], and ubiquitin chains at lysine 63 being targeted for autophagy mediated 
degradation [Kirkin et al., 2009]. Other types of ubiquitin conjugates are involved in 
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the regulation of many different cellular processes, independently of proteolytic 
degradation, including gene transcription, DNA repair and replication, and intracellular 
trafficking [Haglund and Dikic, 2005]. This regulation may occur through the ability of 
ubiquitin to mediate protein-protein interactions, its role in receptor endocytosis and 
its role in the regulation of NF-B signalling [Haglund and Dikic, 2005]. Ubiquitination 
can induce conformational changes in proteins to alter subcellular localisation. For 
example, ubiquitination of p53 induces a conformational change which exposes a 
nuclear export signal. p53 is subsequently expressed in the cytosol where it possibly 
inhibits transcriptional activity and may promote cytoplasmic apoptotic function 
[Carter et al., 2007].  
 
Figure 1.10. Schematic diagram of ubiquitination.  
Ubiquitin is activated in a two-step reaction involving the E1 ubiquitin-activating 
enzyme. E2 ubiquitin conjugating enzymes catalyst the transfer of ubiquitin from 
the E1 enzyme to the active site on the E2 enzyme. E3 ubiquitin ligases catalyse 
the final step in the ubiquitination cascade in which the ubiquitin is transferred 
to the target protein. 
 
 Methylation 
Protein methylation involves the addition of a methyl group, typically to arginine or 
lysine residues of a protein. Arginine can be methylated once or twice whereas lysine 
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can be methylated up to three times [Kouzarides, 2007; Zhang et al., 2012]. The 
majority of the information available about methylation concerns its role in histone 
modification and consequently gene expression. In general, methylation of histone H3 
lysine residues K4, K36 and K79 are linked to activation of transcription, whereas di 
and tri-methylation on H3K9, H3K27 and H4K20 are associated with gene silencing 
[Kouzarides, 2007; Zhang et al., 2012]. Histone lysine methylation has also been 
associated with other chromatin-associated processes including replication [Rivera et 
al., 2014] and DNA-repair [Kouzarides, 2007]. Although histones are the predominant 
proteins modified by methylation, evidence also suggests that some non-histone 
proteins including: p53, transcription factors and DNA-modifying enzymes are 
methylated [Zhang et al., 2012]. 
Acetylation 
Acetylation is a PTM in which an acetyl group is added to proteins, classically to the 
amino group on the side chain of lysine residues. This reaction relies on acetyl-
coenzyme A as the acetyl donor group and is catalysed by acetyltransferases (Figure 
1.11). As described in section 1.1.2, acetylation of lysine residues in histone tails is a 
vital part of gene regulation as this opens chromatin to facilitate transcription [Kuo and 
Allis, 1998]. Deacetylation is the removal of the acetyl group and in the context of 
histone deacetylation, proteins involved in this process inhibit gene transcription by 
helping chromatin to return to its closed state [Kuo and Allis, 1998]. 
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Figure 1.11. Schematic diagram of acetylation.  
Acetyltransferases catalyse the addition of an acetyl group onto a target protein 
and deacetylation complexes perform the reverse action. 
 
NEDDylation 
NEDDylation is a very similar process to ubiquitination in that it involves the 
conjugation of a small ubiquitin like peptide, NEDD8, to substrate proteins through an 
enzyme cascade involving an E1 activating enzyme, E2 conjugating enzyme and E3 
ligase. Known NEDD8 substrates include cullins, p53, p73, Mdm2, pVHL, BCA3, EGFR, 
APP and L11 [Rabut and Peter, 2008; Xirodimas, 2008; Watson et al., 2011]. 
NEDDylation is known to induce conformational changes, preclude certain interactions 
and provide a novel binding surface (reviewed by [Rabut and Peter, 2008]).  
Stoichiometry of PTMs 
Overall abundance is not always an accurate indicator of the functional activity of a 
protein, which is why it is important to analyse proteins at the level of PTMs. For 
example, the overall abundance of a protein may be stable but the constant addition 
and removal of a PTM in response to changing cellular or environmental stimuli can 
activate or deactivate the functional capacity of that protein. Therefore, not only are 
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the different sites of modifications on a peptide of interest, but knowing the 
stoichiometry of a specific PTM at each site on a protein is important and can provide 
clues as to its role and functional significance [Olsen and Mann, 2013]. PTM 
stoichiometry relates to the proportion of modified and unmodified residues present 
at the site of modification in a protein, and reflects the balance between rates of 
enzymatic PTM addition and removal, which can vary over time and thereby regulate 
cell function. For example, the stoichiometry of cyclin-dependent kinase 
phosphorylation is known to vary throughout the cell cycle, reflecting the regulatory 
role this protein has during mitosis [Olsen et al., 2010]. High PTM stoichiometry has 
been reported to be a good indication that a site may be functional [Olsen and Mann, 
2013]. However, it is also acknowledged that the converse does not hold true, because 
even a small pool of protein that bears a modification may specifically correlate with a 
subset of protein that varies in activity over time and /or space when compared to the 
non-modified form across the entire cell.  
The stoichiometry of a PTM required to complete a function in a cell will vary 
depending on the type of modification, the site of the modification, the subcellular 
localisation and the environmental stimulus, in addition to countless other parameters. 
Ongoing research in this field will provide invaluable information regarding cell 
regulation and function. 
 
Almost every aspect of cell biology and pathogenesis is affected by PTMs and the 
diversity of effects conferred on a protein as a result of PTMs demonstrates why 
knowledge of proteins at the post-translational level is vital for a greater 
understanding of cell biology. Altered expression or activity of a protein can be the 
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trigger for a wide range of human diseases therefore it is hardly surprising that 
pharmaceutical companies are targeting PTM components for drug development 
strategies [Cohen, 2009; Cohen and Tcherpakov, 2010].   
1.2 Protein Analysis 
1.2.1 Mass spectrometry as a tool to study proteins 
Mass spectrometry is a technique used in the proteomics field to separate and identify 
the peptides contained in a complex protein mixture on the basis of their mass-to-
charge ratio. This is achieved through the use of a mass spectrometer, which utilises 
electromagnetic fields to control the movement of charged molecules (ions) within the 
instrument. A total cell lysate contains a huge number of proteins which is a very 
complex mixture, even more so at the peptide level. To reduce the complexity of a 
sample prior to injection into a mass spectrometer, samples can be separated into 
multiple fractions, usually by reverse phase liquid chromatography (RPLC). RPLC 
utilises peptide affinity for non-polar beads (packed in a column) in a buffer which 
varies from mostly aqueous (2% acetonitrile in water) to mostly organic, non-polar 
(80% acetonitrile) over the time it takes for a sample to be run. The beads have linear 
octadecane groups (C18) attached to the surface by covalent bonds. C18 groups are 
hydrophobic (non-polar) and can bind polar molecules (i.e. charged peptides) in a 
highly polar solvent such as water. The polarity of the solvent is then reduced by 
increasing the concentration of acetonitrile. As the solvent polarity matches or exceeds 
the non-polarity of a molecule bound to C18, the molecule will elute into the buffer 
flowing through the column at that time. Different molecules will elute at different 
acetonitrile concentrations as their varying polarity will require different degrees of 
non-polarity to elute from the beads. This facilitates sample separation prior to 
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injection into the mass spectrometer. Mass spectrometric measurements are 
performed in the gas phase on ionised peptides. To generate either negatively or 
positively charged gas phase peptide ions from the eluate of RPLC, electrospray 
ionisation is usually used as the ion source. The charged peptides are then passed to a 
mass analyser, which separates ionised analytes on the basis of their mass-to-charge 
ratio (m/z) and then they pass to a detector which registers the number of ions with a 
specific m/z ratio. Figure 1.12 describes the basic structure of a mass spectrometer. 
 
Figure 1.12. Overview of a mass spectrometer.  
 (http://www.lamondlab.com/MSResource/index.php) 
 
To enable ions to move as freely as possible, the mass spectrometer is maintained in a 
vacuum chamber. Once passed from the ion source into the chamber, the rate of 
movement of an ion is controlled by its mass (m) and its charge state (z) and the mass 
spectrometer measures these in a mass-to-charge ratio (m/z). The separation of ions in 
the instrument takes place in the mass analyser which separates the ions on the basis 
of their m/z ratio to permit their separate detection. There are four basic types of mass 
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analyser used in the proteomics field: ion trap, time of flight (TOF), quadrupole and 
Fourier transform ion cyclotron [Aebersold and Mann, 2003]. These analysers can 
either be used individually, or combined, to take advantage of the strength and 
weaknesses of each approach in their powers of resolution, sensitivity and detecting 
mass accuracy.  
The mass spectrometers used in this thesis were the LTQ Orbitrap Velos and the Q 
Exactive, both from Thermo Scientific Fisher. The Velos system uses a combination of a 
low resolution linear ion trap and an orbital ion trap. The linear ion trap performs the 
initial scan to identify charged peptides before sending them to the orbital ion trap for 
ion fragmentation. The orbital ion trap radially traps ions between a central spindle 
electrode and an outer barrel-like electrode. The ions orbit the central spindle and 
oscillate along the axis of the electric field. The frequency of the ion oscillations allows 
a mass/charge value to be calculated. By combining the two forms of ion trap, the 
instrument provides better mass resolution, high mass accuracy, large dynamic range 
and high mass/charge range  [Hu et al., 2005]. The Q Exactive is a hybrid quadrupole-
Orbitrap instrument that does not have a linear ion trap. Therefore, the Orbitrap is the 
main mass analyser for this instrument. 
Mass-to-charge ratio data is used in the generation of a mass spectrum, which shows a 
graph of the relative intensity of all ions detected in the mass spectrometer within a 
defined period of time as a function of their m/z ratio. To convert the peptide spectral 
data obtained from the mass spectrometer into protein identifications, specialist 
software is used, such as Mascot and Andromeda [Perkins et al., 1999; Cox et al., 
2011]. Mascot takes a probability based approach to match peptide sequences from a 
database to tandem mass spectra, but as this is a commercial product, the exact 
47 
Chapter 1: Introduction 
methodology behind the software is not known [Perkins et al., 1999]. Andromeda 
compares identified peptides to a library of hypothetical peptides, taking fixed and 
variable modifications into account. The probability score is calculated by counting the 
number of matches between the theoretical peptide fragment masses and the 
observed fragment ion spectral peaks. The higher the number of matches, the less 
likely the fragment has occurred by chance and hence a high probability score will be 
conferred to that peptide. Higher sequence coverage of a protein by the peptide 
identifications will lead to greater confidence in the true identification of a protein 
[Cox et al., 2011]. In addition, to determine the false discovery rate (FDR) of these 
identifications, the database search is also performed on a decoy database containing 
reversed protein sequences. The scoring thresholds are then adjusted to achieve a 
particular FDR, in most cases 1% at both the protein and the peptide level. MaxQuant 
software, which contains Andromeda as a search engine, provides quantitative data on 
peptides and their cognate proteins [Cox and Mann, 2008].  
Top-down vs bottom up proteomics 
The approach described above, whereby protein-containing samples are digested into 
peptides prior to mass spectrometric analysis, is referred to as a “bottom-up” 
approach. Trypsin is the most commonly used protease in mass spectrometry and it 
cleaves peptides on the carboxyl side of arginine and lysine residues. LysC is an 
additional agent which is becoming more frequently used, and this also cleaves 
peptides at the carboxyl side of lysine residues. Combination of tryspin and LysC 
digestion has been reported to improve sequence coverage by 8% [Ly et al., 2014]. 
Top-down proteomics refers to an approach where intact proteins are ionised directly 
and then analysed by MS. In theory, this approach would permit wider coverage of 
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protein sequences and PTMs but technical difficulties in this approach, not least 
resolution limits, mean it has so far lagged behind bottom-up proteomics [Kelleher, 
2004; Catherman et al., 2014].  
1.2.2 Sample fractionation prior to MS 
To improve the depth of sequence coverage, with the aim of identifying a higher 
number of proteins within a sample, many sample fractionation techniques have been 
employed prior to MS analysis. Liquid chromatography has been widely used, relying 
on the differential separation of an analyte between a liquid mobile phase and a 
stationary phase. As discussed above, reverse-phase liquid chromatography uses a 
non-polar stationary phase and a polar mobile phase which allows more hydrophilic 
analytes to elute from a chromatography column first and more hydrophobic analytes 
last. Hydrophobic interaction liquid chromatography (HILIC) uses a polar stationary 
phase and non-polar mobile phase, with increasing water concentration, which causes 
hydrophobic analytes to elute first and hydrophilic analytes last [Alpert, 1990]. Ion 
exchange chromatography uses a salt gradient to differentially elute analytes on the 
basis of charge [Ritorto et al., 2013]. Separating proteins on the basis of size by SDS-
PAGE has also been used prior to extraction and digestion as a non-LC based approach 
[Larance et al., 2012]. In addition, isoelectric focusing relies on differences in isoelectric 
point to separate different analytes [Cargile et al., 2004]. Fractionating cells into their 
different compartments, i.e. cytoplasm, membrane, soluble nuclear component, 
chromatin bound proteins etc. has also been applied [Boisvert et al., 2012; Larance et 
al., 2013]. All of these techniques generate multiple fractions from a single sample, 
which can then be introduced to the MS instrument sequentially with the aim of 
capturing more peptide identifications. 
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1.2.3 Protein quantification by mass spectrometry 
The proteomic field has improved protein detection through advances in both sample 
preparation and instrument technology. However, as the proteome is dynamic, the 
focus of several groups has been to develop techniques to quantitate the relative 
abundance of proteins across multiple samples. Several approaches for protein 
quantitation by isotopic labelling exist (see [Tao and Aebersold, 2003] and [Goshe and 
Smith, 2003] for reviews). These techniques rely on the use of chemically identical, but 
mass-differentiated, stable isotopes, which can be used to label different sample 
groups. On mixing the samples and analysing by MS, the analyte from one sample 
represents a standard against which the chemically identical analyte from the other 
sample can be compared. Some of the most commonly used techniques are described 
in more detail below. 
The first technique developed was Isotope-coded affinity tags (ICAT) [Gygi et al., 
1999a]. This technique involves the addition of a reagent comprising an affinity tag 
(biotin), an isotopically labelled linker (heavy or light deuterium) and a thiol specific 
reactive group, to a cellular lysate prior to trypsin digestion and affinity purification for 
biotin. The reagent binds to cysteine residues in proteins and is therefore limited to 
the analysis of peptides containing this residue, which reduces sequence coverage. 
Isobaric tagging for relative and absolute quantitation (iTRAQ) involves the addition of 
a reporter tag to a sample after trypsin digestion, therefore at the peptide level [Ross 
et al., 2004]. The isobaric tags form an amide linkage to any amine residue, i.e. either 
N-terminal, or within a lysine side chain. Quantitation of peptides with this approach, 
unlike ICAT, is deduced from the relative concentration of reporter ions and therefore 
is calculated at the MS/MS level, rather than MS level. An advantage of this approach 
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over ICAT is that all peptides are potentially available for analysis thus providing 
greater sequence coverage. In addition, the availability of multiple different tags 
enables multiple different experimental parameters to be compared at one time. 
Alternatively, a selected number of experimental conditions can be compared and a 
different set of tags can be used to label synthetic peptides for use as reference 
proteins for absolute protein quantitation.  
Stable isotope labelling by amino acids in cell culture (SILAC) was developed as an 
alternative approach in 2002 [Ong et al., 2002a] and the principles of this technique 
are depicted in Figure 1.13. This was one of the most effective approaches to label 
amino acids in vivo to enable relative protein quantitation. Cell culture medium 
depleted of a specific standard amino acid is supplemented with an isotopically 
labelled form of the same amino acid, which is then incorporated into proteins, usually 
with little or no effect on cell growth. Protein containing lysates incorporating “heavy” 
or “light” amino acids can be mixed immediately after harvesting, therefore 
eliminating experimental variability between the experimental and control groups in 
the subsequent digestion and sample preparation steps. Amino acids which have been 
isotopically labelled for the SILAC approach include leucine [Ong et al., 2002a], tyrosine 
[Ibarrola et al., 2004], arginine [Ong et al., 2002b] and lysine [Martinović et al., 2002]. 
This tag-less approach holds advantages over other quantitative approaches as it 
permits the analysis of the whole proteome and PTMs can also be studied. The SILAC 
approach has been developed to incorporate three isotopic labels thereby facilitating 
the comparison of a wider range of experimental scenarios. This triple SILAC approach 
[Blagoev et al., 2004] has been widely used in the Lamond laboratory for the study of 
protein turnover [Boisvert et al., 2012], turnover and subcellular localisation of protein 
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isoforms [Ahmad et al., 2012], proteome changes in response to drug treatment 
[Larance et al., 2012] and global subcellular characterisation of protein degradation 
[Larance et al., 2013]. The SILAC approach to quantitative proteomics has been 
extended by multiple groups to include nematodes [Larance et al., 2011], mice [Krüger 
et al.], yeast [Gruhler et al., 2005] and drosophila [Xu et al., 2012]. 
 
Figure 1.13. Schematic diagram of a triple SILAC experiment.  
Schematic diagram of a triple SILAC experiment involving “light”, “medium” and 
“heavy” labelled peptides. 
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1.3 Protein Interaction Analysis 
1.3.1 The study of protein-protein interactions 
The majority of proteins function as part of multiprotein complexes and not as isolated 
polypeptides. Simply generating a list of proteins is not biologically useful when trying 
to understand cellular machinery – all the protein interactions, and complexes they 
form must be delineated too. These protein complexes range from simple homodimers 
to large structures composed of many different polypeptides. Protein complexes vary 
in their size and shape from small globular dimers, such as 14-3-3 proteins, to large 
elongated filaments of variable length, such as microtubules. The wide variety of 
possible protein–protein interactions (PPI) within multiprotein complexes contributes 
to the diversity of functions that are involved in cellular processes and regulatory 
mechanisms. Several methods have been utilised over the years to study PPIs, some of 
which are described in the following paragraphs. 
Yeast two-hybrid screen  
Early efforts for high-throughput analysis of PPIs were predominantly undertaken in 
yeast and included the use of the yeast two-hybrid screen (Y2H). The screen is a 
molecular biology technique that has been used for many years to identify novel 
protein interaction partners. This approach uses a split transcription factor, one 
domain (the binding domain) fused to a bait protein in a plasmid, and the other (the 
activation domain) fused to another protein expressed most often as part of a 
“screening library” which may contain all the proteins expressed in an organism. If the 
bait and a target protein interact, the two transcription factor components are 
activated, and transcription of a downstream reporter ensues in the nucleus of yeast 
(Figure 1.14).  
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Figure 1.14. Schematic diagram of a yeast two-hybrid screen set-up. 
 
Limitations of this approach are numerous, and include the inability of environmental 
factors to be taken into account on PPIs. In addition, the Y2H approach requires the 
cDNA library to be well annotated to improve the accuracy of results which is not 
always the case [Stelzl and Wanker, 2006]. False positive interactions are common, 
therefore validation of results by as many alternative approaches as possible is 
recommended [von Mering et al., 2002; Tikhmyanova et al., 2007]. The requirement 
that interacting proteins must translocate into the yeast nucleus demonstrates that 
this approach is not appropriate for the study of membrane proteins, cytosolic 
proteins, or proteins contained in other subcellular compartments [Bruckner et al., 
2009]. Reports of bias against the detection of proteins involved in translation have 
also been associated with the Y2H screening method [von Mering et al., 2002]. As 
mentioned previously, post translational modifications have a significant role to play in 
PPI networks and some PTMs are not generated in yeast therefore a huge amount of 
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data regarding PPIs is not possible to detect by this approach [Bruckner et al., 2009]. 
Although, the Y2H screen can provide useful information in the study of PPIs, the 
binary nature of the interactions limit their usefulness for high-throughput analysis of 
large interaction networks.  
Co-immunoprecipitation 
Co-immunoprecipitation (co-IP) is perhaps one of the simplest and most widely used 
techniques to study PPIs. Antibodies raised against a target protein, or to a “tag”, are 
added to a mixture of cellular proteins (Figure 1.15). An affinity reagent (e.g. IgG) 
linked to a solid bead matrix can then be used to immunoprecipitate the antibody and 
proteins interacting with the target protein, before eluting from the matrix. Interacting 
proteins can then be identified by immunoblotting. This technique requires the 
availability of highly specific antibodies, which are not always available and are 
expensive to create. 
 
Figure 1.15. Schematic illustration of a typical immunoprecipitation analysis. 
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Protein affinity chromatography 
Protein affinity chromatography involves the attachment of a bait protein to polymer 
beads which are then packed into a column. Cellular proteins are then passed through 
the column and interacting proteins will be trapped by the target-bead bait. 
Interacting proteins can then be eluted from the beads and identified by a variety of 
techniques. 
Co-IP and affinity purifications have similar limitations in that in order to be pulled 
down, a PPI needs to be stable enough in the chosen experimental conditions. 
Therefore, either weakly associated, or transient, interactions may not be identified. In 
addition, either antibody binding sites, or parts of the protein involved in the covalent 
attachment to beads, may be involved in other PPIs, which would therefore not be 
identified in studies utilising this approach. In attempts to resolve this, epitope-“tags” 
(e.g. green fluorescent protein, (GFP)) can be expressed at either the C- or N-termini of 
proteins through recombinant DNA techniques and immunoprecipitation can be 
performed using antibodies to the protein tag. Alternatively, recombinant DNA 
techniques can be used to fuse a small enzyme, such as glutathione S-transferase 
(GST), to the bait protein, prior to binding the resulting fusion protein to glutathione 
beads. The beads can then be used to pull down interacting proteins from a cellular 
protein mixture for further analysis. Expressed, tagged proteins are often under the 
control of an inducible promoter and as a result, altering the stoichiometry of the 
protein of interest may affect the protein complexes it interacts with. 
Tandem affinity purification 
Tandem affinity purification relies on the same principle as epitope tagging, except two 
successive tags are used instead of one. The TAP tag comprises a ProtA IgG binding-
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unit and calmodulin binding protein (CBP), specifically selected as they enable efficient 
pull down when expressed at low/near endogenous protein levels in cells [Rigaut et al., 
1999]. The tag is fused to a clone of interest, and then expressed in a cell. After cell 
lysis the TAP tag is pulled down using IgG-trap beads as bait. The bound proteins are 
then eluted from the beads by cleaving a specific part of the TAP tag. The second tag 
remains bound to the protein of interest. Therefore, a second pull down for this tag 
can be performed before eluting the immunoprecipitated proteins. The rationale for 
this double tagging approach is to reduce non-specific background on the basis that 
non-specific protein interactions are reduced even more-so than with single tag 
methods.  
A major limitation of all these tag-based approaches is that tagging a protein can alter 
protein structure and as a result may preclude the formation of some interactions 
[Goel et al., 2000; Rumlová et al., 2001]. Additionally, some non-specific interactions 
may occur as a result of proteins binding either beads, or tags, rather than the bait 
protein itself. Therefore, adequate control IPs must be run in parallel to identify 
specific interaction partners. 
Such antibody-antigen methods for studying PPIs require a degree of prior knowledge 
about potential interaction partners to guide further investigations. The advent of 
mass spectrometry as a technique for studying proteins, however, changed this 
immensely by providing a high-throughput, unbiased approach for the identification of 
truly unknown PPIs. 
Size exclusion chromatography 
Size-exclusion chromatography (SEC) is a well-established technique used to separate 
proteins and protein complexes in solution on the basis of their shape/size (rotational 
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cross-section) [Wheaton and Bauman, 1953]. SEC has been extensively used as an 
intermediate step in conventional multistep biochemical protein purification 
strategies. In the study of protein interactions, researchers have traditionally targeted 
SEC fractions for specific proteins of interest by immunoblotting, but its use for 
monitoring protein complexes has been limited [Olinares et al., 2010]. 
The apparatus for SEC involves a column packed with polymer beads, with each bead 
designed to contain multiple pores of a defined size. A protein containing sample is 
pumped through the column at a continuous rate and as the proteins are contained in 
a liquid, they are free to rotate. Proteins vary widely in structure, from linear to 
globular, therefore rotation in three dimensions increases their cross-sectional size and 
it is this size that dictates passage through pores, rather than molecular weight. 
Depending on pore size, either large proteins, or large protein complexes, will not fit 
into any of the pores and will therefore migrate through the column rapidly and elute 
in the first fractions. The earliest fractions where large proteins and complexes cannot 
be separated at all are termed the “void”. Smaller proteins and complexes pass into 
the pores and as a result, their migratory progress through the column is slower in 
comparison to larger proteins, essentially because they must move through a larger 
volume. As a result, the proteins in an analyte will be separated in the column on the 
basis of rotational cross-section size, with the largest proteins or complexes eluting 
early and smaller proteins/complexes eluting last. The eluate produced by the column 
over time is collected in multiple fractions. If proteins interact they would be expected 
to co-elute in the same fractions. A schematic diagram of this process is described in 
Figure 1.16. 
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Figure 1.16. Schematic diagram summarising size exclusion chromatography. 
Native proteins and protein complexes are separated on the basis of rotational 
cross-section size. Larger proteins/complexes elute in the earliest fractions and 
smaller proteins/complexes elute later from the column. 
 
Protein microarrays 
Additional in vitro approaches for detecting PPIs include protein microarrays. This is a 
high-throughput method which enables the identification of protein interactions and 
function. In principle, the technique involves binding a protein (or several proteins) to 
a support medium, then probing with fluorescently labelled molecules. Any reaction 
between the probe and immobilised protein emits a fluorescent signal which is then 
read by a laser scanner [MacBeath and Schreiber, 2000]. This approach has the 
advantage that it can be carried out on a large scale in an automated process. 
However, the preparation of proteins to analyse can be a limiting factor as it requires 
high-quality and comprehensive expression libraries and array product methods that 
yield a large number of functionally active proteins [Droit et al., 2005]. In addition, 
non-specific interactions and cross-reactivity can be problematic in this technique. This 
approach also provides only a binary output (i.e. either proteins interact or they do 
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not) and does not readily enable the quantitation of protein abundance, or the 
measurement of PTM states [Wolf-Yadlin et al., 2009]. 
X-ray crystallography  
X-ray crystallography enables the visualisation of protein structures at an atomic level 
and as a result, it can show how proteins interact with other molecules [Garman, 
2014]. This technique can be applied to study the conformational change undertaken 
by a protein in response to a modification. Applications of this approach rely on the 
ability to crystallise a protein of interest and it is not suitable for large scale analyses of 
protein interactions in a system-wide study. 
1.3.2 LC-MS/MS applied to protein complex analysis 
The affinity purification tagging approach is now widely used in combination with mass 
spectrometry and is advantageous in that many different complexes can be compared 
using an identical antibody, or other affinity-purification method, targeted to the tag 
on the bait (for examples, see Refs. [Ho et al., 2002; Gavin et al., 2006; Ewing et al., 
2007]; for reviews, see [Chang, 2006; Collins and Choudhary, 2008] and [Gingras et al., 
2007]). In contrast, it is harder to compare directly the results from 
immunoprecipitation of different endogenous protein complexes by MS because each 
specific antibody that is used has different affinities and properties. Malovannaya et al. 
have developed a high-throughput approach for the identification of endogenous 
protein complexes through cross referencing the results of over 1,000 individual 
endogenous immunoprecipitations combined with LC-MS/MS [Malovannaya et al., 
2010]. By utilising this approach, the same group were able to study the endogenous 
coregulator complexome and identify previously unreported proteins in this network 
[Malovannaya et al., 2011]. Although endogenous IPs avoid the problems associated 
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with an epitope tag, and enable the experiment to be performed in near endogenous 
conditions, the sheer cost involved in large scale antibody production is beyond the 
scope of most laboratories. Attempts have been made to produce antibodies on a 
large scale to explore the human proteome by tissue analysis [Nilsson et al., 2005] but 
the suitability of these antibodies for interaction analysis would need to be tested 
further. 
To determine whether co-purifying proteins are either bona fide interaction partners, 
or non-specific contaminants, quantitative proteomic approaches based on the SILAC 
approach have been combined with affinity purification [Trinkle-Mulcahy et al., 2006; 
Trinkle-Mulcahy et al., 2008; Hubner et al., 2010]. Additional data analysis procedures, 
including the use of a “super experiment” database that predicts the likelihood of non-
specific protein interactions based on the frequency with which any given protein is 
co-purified across many separate experiments, can also help to define the composition 
of protein complexes [Boulon et al., 2010]. The combination of AP-MS with 
quantitative proteomics can also be used to study the dynamic changes in protein 
interactions such as those that change in response to inhibition of NEDDylation 
[Larance et al., 2012]. Nonetheless, affinity purification strategies have a limited ability 
to distinguish multiple related complexes that may differ with respect to isoforms and 
PTMs. They are also costly and difficult to implement for large-scale studies to survey 
cellular complexes, and thus not well suited to study variations in complexes under 
different cellular growth conditions and responses. 
For system-wide studies of the composition and dynamics of protein complexes, 
alternative methods, in addition to immune-affinity purification, are required for 
convenient separation, characterization, and comparison of cellular protein complexes. 
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To address this, a number of studies have utilized various forms of differential 
centrifugation, column chromatography or native gel electrophoresis, to isolate 
complexes or organelles of interest, in combination with mass-spectrometry-based 
proteomics. 
The use of ultracentrifugation permits the fractionation of protein complexes on the 
basis of differential sedimentation rate, which is predominantly determined by 
molecular weight. This approach combined with a sucrose density gradient has been 
used for the isolation of ribosomal subunits prior to MS analysis in Arabidopsis [Chang 
et al., 2005] and yeast [Link et al., 1999]. Although this can be an easily applied 
technique, disadvantages include the contamination of the isolated fractions by 
proteins with a similar sedimentation co-efficient [Chang, 2006]. 
Protein complexes have also been separated using blue native polyacrylamide gel 
electrophoresis (BN-PAGE) [Camacho-Carvajal et al., 2004; Heide et al., 2012].This 
approach involves loading a protein containing analyte into a gel matrix which then 
separates complexes on the basis of their molecular weight, in a range from 10kDa to 
10MDa. In comparison to some gel filtration columns and centrifugation approaches, 
the resolution obtained by BN-PAGE is high. However, disadvantages of this approach 
include the limited amount of protein that can be loaded into the gel in one run. In 
addition, isolation of the complexes involves gel cutting and in-gel digestion which 
introduces error and variability when comparing biological and/or technical replicates. 
Ion-exchange chromatography (IEX) was utilised by Havugimana et al. in what was one 
of the first attempts to separate all identifiable protein complexes within the nuclear 
and cytoplasmic extracts of two cell lines (HeLa and HEK293 cells), using a continuous 
in-solution approach [Havugimana et al., 2012]. The novelty in this study lay in the use 
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of multiple column combinations to validate and score protein co-elution patterns, 
increasing the probability that co-eluting fractions were interacting. A disadvantage of 
this approach, however, is that the salt concentrations in the buffers for ion exchange 
can perturb some PPIs, thereby preventing their detection.  
Size exclusion chromatography is a different chromatographic approach, which has 
been utilised in combination with LC-MS/MS to study the native protein complexes in 
plant chloroplasts [Olinares et al., 2010] and large cytosolic complexes in mammalian 
cells [Kristensen et al., 2012]. The advantage of the SEC system for protein complex 
analysis is that almost any buffer can be used. As a result, the lysis of cells in a buffer 
containing physiological levels of salt will preserve many native protein complexes and 
separating these by SEC permits further analysis of the composition of native protein 
complexes. 
1.3.4 Bioinformatics in protein complex analysis 
Interaction Prediction 
One significant difficulty raised by large-scale protein complex analyses is data 
management. As increasing numbers of large-scale experiments are being performed, 
there is a greater need for tools to analyse, visualise, validate and manage the data.  
In the previous sections I have described different in vitro techniques used to study 
PPIs. Several in silico approaches (i.e. computational analysis) have also been 
employed to predict protein interaction sites on the basis of protein sequences [Ofran 
and Rost, 2003; Hosur et al., 2011], evolutionary preservation of protein interaction 
sites [Lichtarge and Sowa, 2002; Glaser et al., 2003], gene expression [Grigoriev, 2001] 
and protein structure [Aloy and Russell, 2002, 2003; Singh et al., 2010]. These 
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approaches have been reviewed previously [Ethier et al., 2006; Rao et al., 2014]. As 
more data emerges about different proteins, these databases will expand and will act 
as a valuable guide to potential protein interactions. However, many of the predicted 
interactions remain to be proven experimentally and it remains to be established by 
experiment under which circumstances (e.g. cell type, compartment, cell cycle phase) 
these interactions occur. 
Protein interaction databases 
As I have illustrated in the previous sections, no large scale PPI experiment is immune 
to false positive interactions. Although there are discrepancies in protein interactions 
derived by different experimental techniques, several databases have been developed 
that collate interaction data to increase confidence in results [Droit et al., 2005]. Some 
of these are summarised in Table 1.2. As many medium to large scale studies develop 
their own databases for protein interaction analyses, this list is not exhaustive.  
 
Table 1.2. Representative selection of publicly available protein interaction 
databases 
 
STRING is a visualisation tool which allows the user to identify their protein(s) of 
interest and its interactions with other proteins are depicted by a ball and string model 
[Snel et al., 2000; Szklarczyk et al., 2010]. This database collates both experimental and 
predictive data from published databases. However, selection bias in the original 
Database Name Source link Data source
DIP http://dip.doe-mbi.ucla.edu/dip/Main.cgi Collated experimentally derived interactions
BioGrid http://thebiogrid.org Collated experimentally derived interactions
HitPredict http://mintdb.hgc.jp/htp/ IntAct, BioGrid, HPRD
MINT http://mint.bio.uniroma2.it/mint/ Collated experimentally derived interactions
IntAct http://ebi.ac.uk/intact Collated experimentally derived interactions
APID http://bioinfow.dep.usal.es/apid/index.htmBIND, BioGrid, DIP, HDRP, IntAct, MINT
BIND http://bind.ca Collated experimentally derived interactions
STRING http://string-db.org Collated experimentally derived interactions, text mining, interologs, gene expression
MPPI http://mips.helmholtz-muenchen.de/proj/ppi/collated experimentally derived interactions
HPRD http://hprd.org collated experimentally derived interactions
64 
Chapter 1: Introduction 
experiments may mean that interaction data are only available for previously 
annotated proteins. These databases, however, focus on protein interaction partners 
and do not easily discriminate separate protein complexes.  
The CORUM database, compiled using a variety of information from the literature 
describing protein interactions and assemblies, provides the largest public dataset of 
protein complexes [Ruepp et al., 2010]. CORUM contains information relating to 
~1,970 protein complexes identified in human cells. However, these proteins are 
formed from proteins encoded by only ~16% of the known protein coding genes, 
indicating that many forms of protein complexes remain to be identified and 
characterised.  
Computational mathematical analysis of protein complex networks 
Protein complex identification is the next step in determining protein function beyond 
simple PPIs. Lappe and Holm describe a method to unravel protein interaction 
networks through the collective analysis of multiple pull down experiments combined 
with mathematical modelling based on proteins (nodes) and their interactions (edges) 
[Lappe and Holm, 2004]. They used analysis of the yeast proteome to test their theory 
and on the basis of these results, propose that 90% of the human interactome could 
be analysed from the collective analysis of 10,000 pull down experiments [Lappe and 
Holm, 2004]. Malovannaya et al. combined large scale endogenous IP analyses (>1,000 
endogenous pull down analyses) with a “near neighbour network” analysis to identify 
reciprocal protein-protein interactions. Clustering analysis of the top IP results co-
immunoprecipitating with the protein of interest, enabled this group to identify 
possible protein complex components [Malovannaya et al., 2010]. The same group 
used this approach to identify previously unknown protein interactions in the human 
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coregulator complexome [Malovannaya et al., 2011]. Limitations of this approach stem 
from the high cost and impracticality of performing such large scale endogenous 
immunoprecipitations for most laboratories.  
Hierarchical clustering has been used in combination with size exclusion 
chromatography and mass spectrometry to analyse megadalton complexes in the 
chloroplast stroma of Arabidopsis thaliana [Olinares et al., 2010]. This approach 
clusters proteins on the basis of the similarity of their elution profiles, the assumption 
being that proteins with similar profiles form part of the same protein complex. 
Olinares et al. utilised this approach to separate chloroplast ribosomes in different 
states of assembly, and enabled the identification of plastid homologues of prokaryotic 
ribosome assembly factors as well as proteins involved in co-translational 
modifications, targeting and folding. Kristensen et al. [Kristensen et al., 2012] also 
combined SEC and quantitative mass spectrometry with hierarchical clustering to study 
the effect on the interactome of EGF stimulation. Havugimana et al. [Havugimana et 
al., 2012] performed an analysis of human protein complexes utilising hierarchical 
clustering of chromatography and sucrose gradient data, combined with predicted 
protein interaction from evolutionary data, mRNA co-expression and domain co-
occurrence. This dataset provides information regarding previously unreported 
complexes with specific functional, evolutionary and disease-related biological 
attributes.  
Although current methods are unable to predict interactions and protein complex 
components with 100% accuracy, the development of computational methods from a 
range of experimental techniques will provide an invaluable resource for guiding 
future laboratory based experiments.  
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1.4 Summary 
Studying cell biology at the protein level with the current techniques available provides 
a very detailed analysis of cell function, which would not be possible by studying the 
genetic code or mRNA at the transcriptional level. Large scale proteomic analysis has 
enabled the detailed study of protein localisation at the subcellular level, including the 
localisation of distinct protein isoforms, demonstrating that different isoforms may 
have different functions [Ahmad et al., 2012]. The study of protein turnover rates 
demonstrated that regulation of protein expression can vary between subcellular 
compartments without necessarily altering overall protein levels [Larance et al., 2013]. 
This suggests that regulation of protein expression at the subcellular level is important 
in regulating cell function. The proteomics approaches utilised in current studies has 
also enabled the most in-depth analysis to date of the proteome as it changes 
throughout the cell cycle, demonstrating again that RNA transcription does not 
accurately reflect protein expression throughout this process [Ly et al., 2014]. In 
addition to all of the above, the mass spectrometry approach also enables the study of 
protein abundance through quantitative analysis [Goshe and Smith, 2003; Tao and 
Aebersold, 2003], and the study of PTMs on a large, high-throughput scale [Olsen et 
al., 2006; Choudhary et al., 2009; Wagner et al., 2011; Tammsalu et al., 2014]. Because 
all of these factors are involved in protein interactions, it is important to utilise a 
technique that enables all of these factors to be studied to facilitate a greater 
understanding of cell function.  
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Chapter 2: Materials and methods  
2.1 General materials 
PhosStop protease inhibitor cocktail tablets and Complete EDTA-free protease 
inhibitor tablets were obtained from Roche. NuPAGE Bis-Tris gels, NuPAGE Tris-acetate 
gels and NuPAGE LDS sample buffer were from Life Technologies and TCEP was from 
Thermo Fisher Scientific (77720). MLN4924 was a generous gift from Sir Philip Cohen. 
All chemicals were obtained from Sigma unless otherwise specified. Testes from 
C57BL/6 mice were generously donated by members of the Cantrell Laboratory 
(University of Dundee). Human testicular tissues were a generous gift form the 
Department of Pathology, Edinburgh Royal Infirmary. 
2.2 Antibodies 
The antibodies utilised in this thesis are listed in Table 2.1. 
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Table 2.1. Antibodies used for experiments described within this thesis. 
 
2.3 General solutions 
TBS PBS 
150mM NaCl 137mM NaCl 
10mM Tris pH 7.4 2.7mM KCl 
 10mM Na2HPO4 
 1.8mM KH2PO4 
TBST 
150mM NaCl 
10mM Tris pH 7.4 
0.1% Tween 20 
  
Antibody Company Catalogue number Source Utility
MRFAP ProteinTech Group 11639-1-AP Rabbit WB, IF
MORF4L1 Santa Cruz sc-26528-R Rabbit WB, IP, IF
VprBP Bethyl A310-887A Rabbit WB, IP
MRGBP Sigma/Atlas antibodies HPA017012 Rabbit WB
MRGBP Tebu-bio H00055257-B01P Mouse IF
Lamin A/C Cell Signalling technololgy #4777 Mouse WB
GFP Roche 11814460001 Mouse WB
Histone H3 (D1H2) Cell Signalling Technology 4499 Rabbit WB
CUL3 Cell Signalling Technology #2759 Rabbit WB
eIF2 Cell Signalling Technology #2103 Mouse WB
Phospho-eIF2 Cell Signalling Technology #3398 Rabbit WB
Fibrillarin Abcam ab18380 Mouse IF
Tubulin/DM1A Sigma T6199 Mouse WB, IF
GAPDH Abcam ab8245 Mouse WB
NEDD8 Cell Signalling Technology #2745 Rabbit WB
PAF Abcam ab56773 Mouse WB
Beta-actin Abcam ab8227 Rabbit WB
Alexa Fluor 488 Invitrogen A21202 Mouse IF
Alexa Fluor 594 Invitrogen A21207 Rabbit IF
HRP conjugated antibody Thermo PA1-84824 Mouse WB
HRP conjugated antibody Thermo 31460 Rabbit WB
Alexa Fluor 680 Invitrogen A21058 Mouse WB
Anti-IgG IRDye 800 Tebu-bio 611-132-003 Rabbit WB
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2.4 Tissue culture 
2.4.1 Cell lines and solutions 
 U2OS, HaCaT, Tera 1 and U138 cells were purchased from the American Type 
Culture Collection (ATCC). 
 The wild type LAP1-MRFAP1 and LAP1-7KR MRFAP1 U2OS cell lines were a 
generous gift from Dr Mark Larance, University of Dundee. 
Denaturing lysis buffer: 
2% SDS 
10mM HEPES pH 7.4 
1mM EDTA 
250mM Sucrose 
1x Complete EDTA-free protease inhibitor tablet per 50ml lysis buffer and 1 x PhosStop 
tablet per 10ml buffer. 
 
2.4.2 Tissue culture conditions 
U2OS, U138 and HaCaT cells were grown in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Life Technologies) supplemented with 10% foetal calf serum (FCS, Life 
Technologies), 100U/L penicillin, and 100μg/L streptomycin.  
U2OS cells expressing LAP1-tagged MRFAP1 and the LAP1-7KR MRFAP1 mutants were 
grown in DMEM supplemented with 10% FCS, 100U/L penicillin, and 100μg/L 
streptomycin, 150μg/ml hygromycin B and 15μg/ml blasticidine HCl. 
Tera-1 cells were cultured in McCoy's 5a medium (Life Technologies) supplemented 
with 20% FCS, 100U/L penicillin, and 100μg/L streptomycin. 
All cell lines were grown at 37 °C in 5% CO2 and passaged at ∼80% confluence. 
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2.4.3 SILAC Labelling 
For SILAC labelling of U2OS cells, arginine- and lysine-free Dulbecco's modified Eagle's 
medium (Life Technologies) was used and supplemented with stable isotope-labelled 
arginine (Cambridge Isotopes) to a final concentration of 42g/ml and lysine 
(Cambridge Isotopes) to a final concentration of 72g/ml, in addition to dialysed FCS 
(Life Technologies). The final concentrations of arginine and lysine used in the SILAC 
medium were half of those contained in standard medium to suppress arginine to 
proline conversion [Ong et al., 2002a]. The final medium was filtered through a 0.2m 
filter. Cells were passaged three times (1:6 split) before commencing an experiment, to 
ensure adequate labelling of proteins was obtained. 
2.4.4 Cell lysis 
Unless otherwise stated, cells were harvested at ~80% confluence. Cells were washed 
in PBS (10-20ml depending on whether a 10 or 15cm dish was used) then lysed in 200-
500l of denaturing lysis buffer, pre-warmed to 37oC. The lysates were heated to 65oC 
for 10 minutes then sonicated for 3 x 10 second bursts at 10% power (Branson Digital 
Sonifier 250). The lysate was centrifuged at 17,000g for 10 minutes using a Heraeus 
Pico17 centrifuge (Thermo Fisher Scientific) and the supernatant was transferred to a 
clean Eppendorf tube. BCA quantitation assay was performed on the supernatant as 
per section 2.16. An aliquot of lysate was made up to 1mg/ml in 1X LDS sample buffer 
with 25mM TCEP for immunoblotting. 
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2.5 SiRNA knockdown 
2.5.1 Materials 
 ON-TARGETplus Set of 4 Upgrade siRNA for MRFAP1, MRGBP and MORF4L1 
were obtained from Dharmacon (catalogue numbers LU-015093-01-0002, LU-
006381-01-0002, LU-006379-01-0002 respectively) 
 Lamin A/C siRNA targeting the sequence 5’-CUGGACUUCCAGAAGAACA-3’ was 
obtained from Dharmacon. 
 Jumble siRNA targeting the sequence 5’-CAGUCGCGUUUGCGACUGG-3’ was 
obtained from MWG. 
 5X siRNA buffer (Dharmacon (B-002000-UB-100) – 300mM KCl, 30mM HEPES-
pH 7.5, 1.0mM MgCl2). Diluted to 1X with sterile H20. 
 Lipofectamine RNAiMAX (Invitrogen, 13778) 
2.5.2 siRNA knockdown for immunoblotting 
siRNA stocks of 100M and 10M were prepared using 1X siRNA buffer and stored at   
-20oC. 
U2OS cells (1 x 10cm dish per knock-down) were grown to ~40% confluence. Cells were 
washed (5ml per dish) in Opti-MEM (Life Technologies) and 10ml Opti-MEM was added 
to cells. 1ml of Opti-MEM was mixed with 45l of 10 M siRNA stock in a sterile 
Eppendorf tube. 1ml of Opti-MEM was mixed with 30l Lipofectamine RNAiMAX (per 
siRNA knock-down). The RNAiMAX and siRNA dilutions were mixed in a 15ml tube and 
incubated for 15 minutes at room temperature. The mixture was then added to cells 
dropwise, and gently rocked back and forth to mix evenly. The cells were incubated for 
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48 hours at 37oC, 5% CO2. Cells were then harvested as described in section 2.4.4 and 
immunoblotted following SDS-PAGE as described in section 2.6. 
2.5.3 siRNA knockdown for immunofluorescence 
Cells were grown on 13mm glass coverslips in 24-well plates to 50% confluence. 
Medium was removed and the cells were washed in 0.5ml Opti-MEM then a fresh 
0.5ml Opti-MEM was added to each well. 107l Opti-MEM was mixed with 3.21l 
10mM siRNA stock in a 1.5ml Eppendorf. 107l Opti-MEM was mixed with 2.14l 
RNAiMAX in a second Eppendorf tube, and then the two mixtures were combined, 
mixed and left to incubate for 15 minutes at room temperature. The mixture was then 
added to cells dropwise, and gently rocked back and forth to mix evenly. The cells were 
incubated for 48 hours at 37oC, 5% CO2. MLN4924, 1M final concentration, or 10l 
DMSO control was added to cells 18 hours prior to fixation. 
2.5.4 Statistical analysis of siRNA knockdown immunoblots 
Immunoblot band intensity was calculated for each protein using Macbiophotonics 
ImageJ software. The signal intensity for each protein in a replicate was standardised 
against the tubulin signal to correct for errors in total sample loading per lane. The 
corrected signal intensity was then normalised against the “jumbled siRNA” signal as 
an internal control for each blot. Standard deviations were calculated from the results 
across three biological replicates and a pair-wise comparison was analysed between 
the final normalised results for each siRNA knockdown combination. The p-values from 
this comparison were then corrected for the false discovery rate by using the 
Benjamini and Hochberg method by Dr Nick Schurch of the Data Analysis Group, (GRE, 
University of Dundee) [Benjamini and Hochberg, 1995]. 
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2.6 SDS-PAGE and immunoblotting 
2.6.1 Solutions 
Blocking buffer: 
3% non-fat dried milk in TBS with 0.1% Tween 20 
 
Transfer buffer: 
1x NuPAGE transfer buffer (Life Technologies) supplemented with either 10% or 20% 
methanol. 
  
Running buffer: 
MES or MOPS (Life Technologies) 
 
Gel Fixation buffer: Gel washing buffer: 
50% methanol 10% methanol 
10% acetic acid  7% acetic acid 
Milli-Q H2O Milli-Q H2O 
 
2.6.2 SDS-PAGE separation 
Protein samples were dissolved in 1X LDS sample buffer supplemented with 25mM 
TCEP. Equal amounts of protein were loaded for SDS-PAGE with 10μg/lane, except for 
immunoprecipitation eluates, where 10% of the elution volume was loaded, and for 
combined SEC fractions, where protein concentration varied but did not exceed 10g 
per lane. SDS-PAGE was performed using either 3-8% Tris-acetate NuPAGE gels, or 4–
12% (w/v) Bis-Tris NuPAGE gels, using either MES (for low molecular weight proteins), 
or MOPS (higher molecular weight proteins), running buffer at 200V for either 45 
minutes (Bis-Tris gels), or 1 hour 10 minutes (Tris-Acetate gels).  
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2.6.3 Immunoblotting 
For Western blotting, separated proteins were electrophoretically transferred to an 
iBlot nitrocellulose membrane (Life Technologies, IB7010-01). Alternatively, proteins 
were transferred to an Odyssey nitrocellulose membrane with NuPAGE transfer buffer 
for 1 hour 30 minutes at 35V. Membranes were then blocked with 3% non-fat skim 
milk in 0.1% Tween 20 in TBS (TBST) for 1 hour at room temperature with agitation. 
Membranes were then incubated with primary antibody (Table 2.1) (1:1,000 to 
1:5,000) in 3% non-fat milk in TBST overnight at 4°C. After incubation, the membranes 
were washed three times in TBST and incubated with either horseradish peroxidase-
labelled (1:5,000), or Alexa Fluor 680/IRDye 800-labeled, secondary antibodies (Table 
2.1) (1:15,000) in 3% non-fat skim milk in TBST. Proteins were visualized using 
Immobilon chemiluminescent substrate (Millipore) (5ml per membrane) and imaged 
either with a cooled CCD camera (LAS 4000, Fuji), for horseradish peroxidase-labelled 
secondary antibodies, or with a Li-Cor Odyssey CLx imager for Alexa Fluor 680/IrDye 
800-labeled secondary antibodies. Western blots were viewed using either 
Macbiophotonics ImageJ software, or Image Studio Version 2.0 software, when the Li-
Cor system was used. 
2.6.4 SYPRO Ruby protein gel staining 
SYPRO Ruby protein gel staining (Invitrogen, S-12000) was performed on SDS-PAGE 
gels run as above. The gels were fixed twice in 100ml gel fixation buffer for 15 minutes 
at room temperature with agitation. The gel was stained with 50ml SYPRO Ruby 
protein gel staining solution for 2 hours at room temperature, with agitation and 
protected from light. The gel was washed twice in gel washing buffer for 15 minutes at 
room temperature with agitation, and protected from light. The gel was subsequently 
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washed with Milli-Q water for at least 15 minutes and then visualised using the FLA 
5100 imager (Fuji). 
2.6.5 InstantBlue protein staining  
SDS-PAGE gels run as described above were immersed in 20ml InstantBlue staining 
solution (Expedeon, ISB1L) for 1 hour at room temperature. The gel was then washed 
in MilliQ H2O before being scanned by the Li-Cor Odyssey CLx instrument. 
2.7 SEC: Non-crosslinked samples 
2.7.1 Solutions and buffers 
Native cell lysis buffer: 
PBS, pH 7.2 (Gibco, 20012-019)  
EDTA free complete protease inhibitor (1 tablet/50ml)  
PhosStop (1 tablet/10ml) 
 
Denaturing cell lysis buffer: 
PBS containing EDTA free complete protease inhibitors and PhosStop (as above) 
4% SDS 
25mM TCEP 
50mM N-ethylmaleimide 
 
Non-denaturing SEC buffer: 
PBS pH 7.2 (Gibco, 20012-019) 
 
Denaturing SEC buffer: 
0.2% SDS  
100mM NaCl 
10mM NaPO4 
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2.7.2 Cell lysis 
Ten 15-cm dishes (80% confluent) of U2OS cells were scraped, on ice, in 500μl of ice-
cold cell lysis buffer. Total cell lysates were sonicated for 10 seconds, three times in 
total, at 10% power (Branson Digital Sonifier 250) at 4oC and then centrifuged at 
17,000g (Heraeus Pico17 centrifuge, Thermo Fisher Scientific) for 10 minutes at 4oC. 
Samples were filtered through 0.45μm Ultrafree-MC centrifugal filter units (Millipore). 
Bradford assays were performed on the filtrates for protein quantitation (see section 
2.18). 
2.7.3 Tissue lysis 
Both testes from wild type C57/BL6 mice, sacrificed at either 48, or 160 days, were 
washed three times in 10ml of ice cold PBS. Testes were lysed in 500l of ice cold 
native cell lysis buffer and homogenised for 1 minute on setting 4 and 10 seconds on 
setting 6 using an IKA T8.01 S2 mixer, on ice. Lysates were sonicated for 3 x 10 seconds 
at 10% power, on ice (Branson Digital Sonifier 250). The lysates were then centrifuged 
at 17,000g for 10 minutes at 4oC (Heraeus Pico17 centrifuge). The supernatant was 
filtered through a 0.45m Ultrafree-MC centrifugal filter unit (Millipore). A Bradford 
assay was performed on the filtrate for protein quantitation (see section 2.18). 
2.7.4 SEC, trypsin digestion and peptide clean-up 
Using a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific), prepared lysates 
were injected (200μl per injection) onto a Superose 6 10/300GL column (23.5ml 
column volume) (GE Life Sciences) equilibrated with PBS (pH 7.2). The flow rate was 
0.2 ml min−1, and 40 x 200μl fractions were collected using a low protein-binding 96-
deep-well Eppendorf plate. Tris-HCl (1M pH 8.0) was added to each fraction to a final 
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concentration of 0.1M to adjust the pH to 8.0, and trypsin, diluted in 0.1M Tris-HCl, 
was added at ratios of 1:50 - 1:100. The fractions were then incubated for 18 hours at 
37oC. For peptide desalting, trifluoroacetic acid (TFA) was added to a 1% (v/v) final 
concentration and peptides were purified using a Sep-Pak tC18 96-well μ-elution plate. 
The -elution plates were conditioned with the addition of 200μl acetonitrile per well 
and vacuum was used to pull the liquid through the plates. The plates were 
equilibrated by the addition of 200μl of 0.1% TFA to each well, pulled through by 
vacuum manifold. The samples were then loaded in to the plate and pulled through by 
vacuum manifold. The wells were then washed in 800μl 0.1% TFA to remove salts, then 
200μl 0.1% TFA to remove excess buffer and salts. Peptides were eluted in 200μl of 
50% (v/v) acetonitrile/0.1% TFA, and then dried using a Savant SPD 2010 SpeedVac 
concentrator (Thermo Fisher Scientific), prior to resuspension in 5% (v/v) formic acid. 
Peptide concentrations were determined using the CBQCA assay as described in 
section 2.17. 
2.7.5 Denaturing SEC 
For the denaturing SEC, cells were lysed in denaturing cell lysis buffer as described 
above in section 2.7.1. The column was equilibrated with denaturing SEC buffer. The 
lysate was otherwise injected onto the Superose 6 column as described above in 
section 2.7.4. Consecutive elution fractions were combined, heated to 65°C for 10 
minutes, subjected to chloroform methanol precipitation (section 2.15, [Wessel and 
Flügge, 1984]), and resuspended in 1X LDS sample buffer with 25 mm TCEP for 
immunoblotting. 
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2.7.6 SDS-PAGE and immunoblotting of SEC fractions 
For immunoblotting of non-denatured samples, Bradford protein quantitation assays 
were performed on the fractions (section 2.18). 20% SDS was added to each fraction to 
a 2% final concentration, and fractions were heated to 65°C for 10 minutes. 100μl of 
consecutive fractions were combined, and chloroform methanol precipitation was 
performed (section 2.15,[Wessel and Flügge, 1984]). Protein was then resuspended in 
equal volumes of 1X LDS sample buffer, 25mM TCEP so that the maximum 
concentration in the most concentrated fraction was 1mg/ml, and heated to 65°C for 
10 minutes. Combined fractions were analysed via EZQ quantitation assay (section 
2.19). 10μl of each combined fraction was loaded per lane for SDS-PAGE as described 
in section 2.6.2.  
BCA protein quantitation (section 2.16) was performed on denatured samples. Equal 
volumes (14μl) of consecutive samples were combined and made up to a maximum of 
0.1mg/ml in 1X LDS/TCEP. 20μl of sample was loaded per lane for SDS-PAGE (section 
2.6.2). SYPRO Ruby staining was performed as per section 2.6.4. SDS-PAGE and 
immunoblotting was performed as per section 2.6. 
2.7.7 LC-MS/MS and analysis of spectra 
CBQCA quantitation assay was performed on the peptides as described in section 2.17. 
From these results, the injection volume for the strongest fraction was calculated to 
ensure a maximum of 1g of peptide would be injected. The injection volumes were 
kept constant for all fractions to ensure elution profiles could be calculated accurately. 
Using a Thermo Fisher Scientific Ultimate 3000 nanoHPLC system, a maximum of 1μg 
of peptides in 5% (v/v) formic acid (∼10μl) was injected onto an Acclaim PepMap C18 
nano-trap column (Thermo Fisher Scientific). After being washed with 2% (v/v) 
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acetonitrile, 0.1% (v/v) formic acid, peptides were resolved on a 150mm × 75μm 
Acclaim PepMap C18 reverse-phase analytical column over a gradient from 2% 
acetonitrile to 80% acetonitrile over 100 minutes with a flow rate of 300nl min−1.  
The peptides were ionized by nano-electrospray ionization at 1.2kV using a fused silica 
emitter with an internal diameter of 5μm from New Objective. Tandem mass 
spectrometry analysis was carried out on an LTQ Orbitrap Velos mass spectrometer 
(Thermo Fisher Scientific) using collision-induced dissociation fragmentation of 
precursor peptides and fragment ion measurement in the linear ion trap. Data-
dependent acquisition was performed with fragments of the top ten most intense 
peptide ions, a (TOP10) method described previously [Haas et al., 2006]. The RAW data 
produced by the mass spectrometer were analysed using the quantitative proteomics 
software MaxQuant [Cox and Mann, 2008] (version 1.3.0.5). This version of MaxQuant 
includes an integrated search engine, Andromeda [Cox et al., 2011]. The database 
supplied to the search engine for peptide identifications was the human UniProt 
database (June, 2011) containing 109,824 entries. The mass tolerance was set at 6ppm 
for precursor ions, and the MS/MS mass tolerance was set at 0.5Da. The enzyme was 
set as trypsin with up to two missed cleavages. Deamidation of Asn and Gln, oxidation 
of Met, pyro-Glu (with N-term Gln), and phosphorylation (STY) were set as variable 
modifications. N-ethylmaleimide on Cys was searched as a fixed modification. 
Identification was set to a false discovery rate of 1%. To achieve reliable identifications, 
all peptides identified were accepted based on the criteria that the number of hits in 
the “forward” database was at least 100-fold greater than the number of “reverse” 
database hits, thus resulting in a false discovery rate of less than 1%. The output from 
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MaxQuant provided peptide level data as well as protein level data, grouped by 
protein isoforms.  
2.7.8 Data analysis of native SEC fractions 
The following statistical analysis of native SEC fractions was performed by Dr Yasmeen 
Ahmad. To create an elution profile for an individual protein isoform in each of the 
three replicates, the number of peptides observed in each fraction was summed to 
generate a count of peptides per fraction (spectral counts). The resulting spectral 
count profile minima and maxima were normalized within the limits of 0 and 1, 
respectively. The average of the three elution profiles was based on the normalized 
spectral peptide counts for each fraction. Further downstream data interpretation for 
this study was performed primarily using the R language (version 2.15.1). From the 
three biological replicates, it was required that a protein be identified in at least two 
replicates with a minimum of two peptides in each. Proteins labelled as either 
contaminants, or reverse hits, were removed from the analysis. These stringent criteria 
left a subset of 8,165 proteins. For each protein, 120 quantitative measurements were 
recorded across the three replicates and 40 SEC fractions. The first six fractions were 
deemed to contain complexes outside the resolution range of the column and thus 
were excluded from further data analysis.  
To analyse reproducibility between replicates, the peptide count profile across the 
remaining 34 fractions for each replicate was correlated between replicates. A quality 
filter was applied to ensure that a minimum of two out of the three pairwise 
correlations had a positive correlation coefficient. The biological replicates were 
collapsed by averaging to obtain a resultant mean peptide count profile describing the 
behaviour of each protein across the 34 fractions. The standard deviation for the three 
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biological replicates per fraction was also calculated to provide standard error bars on 
the protein profile graphs. The protein count profiles across the 34 fractions were 
normalized using the maximum peptide count for that protein and then hierarchically 
clustered based on Euclidean distance measurement and a “complete” agglomeration 
method. The output of the clustering was presented in a heatmap using the 
RColorBrewer library.  
The gene ontology analysis was carried out using the DAVID Functional Annotation 
Tool for Biological Processes [Huang et al., 2008]. The full Homo sapiens proteome, 
supplied by DAVID, was selected as a background list. When cross-analysing with the 
CORUM dataset, a set proportion of proteins in a complex were required to co-
fractionate to provide sufficient evidence that a complex had been identified. To 
calculate this proportion, the equation max (0.3, 2/n) × 100 was used, meaning either 
30% of the components, or 2 divided by the number of proteins in the complex, 
whichever was greater, multiplied by 100. This approach ensured that for small 
complexes (i.e. containing six or fewer components), more than simply one or two of 
the component proteins needed to co-fractionate before labelling the complex as 
identified.  
2.8 SEC: Crosslinked samples 
2.8.1 Solutions 
Formaldehyde crosslinking solution: 
16% Formaldehyde Solution (w/v), methanol-free ampules (Thermo Fisher Scientific; 
#28909).  
Make up to the desired percentage for crosslinking (e.g. 1-8%) in PBS fresh each time. 
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Quench buffer: 
50mM Glycine in 1X PBS  
Additional 2.5M stock of glycine in PBS. 
 
Cell lysis Buffer: Denaturing SEC buffer: 
4% SDS   0.2% SDS 
100mM NaCl   100mM NaCl 
10mM NaPO4 pH 6.0 10mM NaPO4 pH 6.0  
25mM TCEP  passed through a 0.2m filter 
50mM NEM 
 
2.8.2 Crosslinking and cell lysis 
1 x 15cm dish of U2OS cells (~80% confluent) washed twice in 20ml PBS. Crosslinking 
was performed by the addition of 20ml of formaldehyde crosslinking solution and 
incubated at room temperature for 10 minutes. The crosslinking solution was removed 
then the reaction was quenched by the addition of 20ml quench buffer for 5 minutes. 
A second quench step was performed with a fresh aliquot of quench buffer. Cells were 
washed again in 20ml PBS and drained well. Cells were lysed by scraping in the 
presence of 500l of cell lysis buffer, supplemented with 10l of 2.5M glycine stock. 
The lysate was transferred to a 1.5ml Eppendorf tube then sonicated for 10 seconds x 
6 (separated by 10 second intervals) at 10% power (Branson Digital Sonifier 250). The 
lysates were then incubated in a water bath a 37oC for 30 minutes to aid denaturation 
whilst maintaining crosslinks intact. Lysates were centrifuged at 17,000g for 10 
minutes at room temperature (Heraeus Pico17 centrifuge, Thermo Fisher Scientific). 
The supernatant was filtered through an Ultrafree-MC 0.45m filters (Millipore) at 
12,000g for 5 minutes. EZQ protein quantitation assay was performed on the 
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supernatant as per section 2.19. 450l of filtered supernatant was transferred to a 
glass vial with a v-shaped base for injection onto the SEC column.  
2.8.3 SEC, protease digestion and peptide clean-up 
Using a Dionex Ultimate 3000 HPLC system (Thermo Fisher Scientific), prepared lysates 
were injected (200μl per injection) onto a BioBasic Sec 1000 column (Thermo Fisher 
Scientific) equilibrated with denaturing SEC buffer. This is a 7.8 x 300mm column with 
a volume of approximately 14ml. It contains 5m particles with 1000Å pores. The flow 
rate was 0.5ml min−1, and 48 x 125μl fractions were collected using a 96 well PCR-plate 
(Thermo Fisher Scientific). Eluates were heated to 95oC for 30 minutes using an 
Eppendorf Mastercycler PCR machine when crosslink reversal was required. When 
cooled, tetraethylammonium borohydride (TEAB) (1 M, pH 8.5 (Sigma)) was added to 
each fraction to a final concentration of 0.1M to adjust the pH to 8.0-8.5. Lysyl 
Endopeptidase (LysC) (Wako, 125-02543) diluted in 0.1M TEAB was added at a ratio of 
1:50 (g LysC to g of protein in sample) in a total volume of 50l. The fractions were 
then incubated for 4 hours at 37°C. Trypsin was then added at 1:50 ratio to each well 
in a 50l total volume, diluted in 0.1M TEAB. Fractions were then incubated for 18 
hours at 37oC. SDS removal was performed using 96-well detergent removal spin 
plates (Thermo Fisher Scientific). For peptide desalting, trifluoroacetic acid (TFA) was 
added to a 1% (v/v) final concentration and peptides were purified using a Sep-Pak 
tC18 96-well μ-elution plate as described in section 2.7.4. 
2.8.4 SDS-PAGE and immunoblotting 
For immunoblotting of cell lysates treated with and without formaldehyde, 28l of 
representative fractions were taken from each experimental group, to which 10l of 
4X LDS sample buffer and 2l of 0.5M TCEP were added. The start material (total cell 
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lysate) was made up to 1g/ml in 1X LDS sample buffer supplemented with 25mM 
TCEP in MilliQ H2O. All samples were heated to 95
oC to reverse crosslinks. 30l of each 
sample was loaded onto a 10 well 4-12% Bis-Tris NuPAGE gel and run as described in 
section 2.6.2. SYPRO ruby staining was then performed as described in section 2.6.4. 
To calculate the optimum concentration of formaldehyde for crosslinking, an EZQ 
assay was performed on the total cell lysates of crosslinked cells and the samples 
made up to 1mg/ml with 1X LDS in MilliQ H2O. Samples were not heated further to 
prevent crosslink reversal/breakage. 10l of each sample were loaded onto 4-12% Bis-
Tris NuPAGE gels and run as described in section 2.6.2 before immunoblotting as 
described in section 2.6.3. 
 To assess if fraction sizes correlate with those estimated by the protein standards, 
30l of every fourth fraction was combined with 10l of 4X LDS sample buffer and not 
heated, to retain crosslinks. 30l of each sample was loaded onto either 4-12% Bis-Tris 
NuPAGE gels or 3-8% Tris-acetate gels and run as described in section 2.6.2. SYPRO 
ruby staining was performed as described in section 2.6.4. 
2.8.5 LC-MS/MS and analysis of spectra 
CBQCA quantitation assay was performed on the peptides as described in section 2.17. 
From these results, the injection volume for the strongest fraction was calculated to 
ensure a maximum of 2g of peptide would be injected. The injection volumes were 
kept constant for all fractions to ensure elution profiles could be calculated accurately. 
Using a Thermo Fisher Scientific Ultimate 3000 nanoHPLC system, up to 2μg of 
peptides in 5% (v/v) formic acid (∼10μl) was injected onto an Acclaim PepMap C18 
nano-trap column Thermo Fisher Scientific.  
85 
Chapter 2: Materials and methods 
After being washed with 2% (v/v) acetonitrile/0.1% (v/v) formic acid, peptides were 
resolved on a 50cm EASY-Spray column over a gradient from 2% acetonitrile to 35% 
acetonitrile over 140 minutes with a flow rate of 200nl min−1. The peptides were 
ionized by nano-electrospray ionization at 2kV. Tandem mass spectrometry analysis 
was carried out on a Q Exactive mass spectrometer (Thermo Fisher Scientific) using 
higher energy collisional dissociation (HCD) fragmentation. Precursor peptide and 
fragment ion measurement were performed in the Orbitrap at 60,000 and 15,000 
resolution respectively. Data-dependent acquisition was performed with fragments of 
the top ten most intense peptide ions, a (TOP10) method described previously [Haas et 
al., 2006]. The RAW data produced by the mass spectrometer were analysed using the 
quantitative proteomics software MaxQuant [Cox and Mann, 2008] (version 1.4.1.2). 
This version of MaxQuant includes an integrated search engine, Andromeda [Cox et al., 
2011]. The database supplied to the search engine for peptide identifications was the 
human UniProt database (May, 2014). The mass tolerance was set at 7ppm for 
precursor ions, and the MS/MS mass tolerance was set at 20ppm. The enzyme was set 
either as LysC, or trypsin, with up to two missed cleavages. Deamidation of Asn and 
Gln, oxidation of Met, pyro-Glu (with N-term Gln) were set as variable modifications. 
N-ethylmaleimide on Cys was searched as a fixed modification. Identification was set 
to a false discovery rate of 1%. To achieve reliable identifications, all peptides 
identified were accepted based on the criteria that the number of hits in the “forward” 
database was at least 100-fold greater than the number of “reverse” database hits, 
thus resulting in a false discovery rate of less than 1%. The output from MaxQuant 
provided peptide level data as well as protein level data, grouped by protein isoforms.  
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2.8.6 Data analysis of crosslinked samples 
All data interpretation for this study was performed primarily using the R language 
(version 2.15.1). The following data analysis was performed by Dr Mark Larance. To 
create an elution profile for an individual protein isoform in each of the three 
replicates, the number of peptides observed in each fraction was summed to generate 
a count of peptides per fraction (spectral counts). The resulting spectral count profile 
minima and maxima were normalized within the limits of 0 and 1, respectively. The 
average of the three elution profiles was based on the normalized spectral peptide 
counts for each fraction. From the three biological replicates, it was required that a 
protein be identified in all of the replicates with a minimum of two peptides in each. 
Proteins labelled as either contaminants or reverse hits were removed from the 
analysis. These stringent criteria left a subset of 6,425 proteins. For each protein, 144 
quantitative measurements were recorded across the three replicates and 48 SEC 
fractions. 
To analyse reproducibility between replicates, the peptide count profile across the 48 
fractions for each replicate was correlated between replicates. The normalised spectral 
count profiles across the 48 fractions for each biological replicate were hierarchically 
clustered across the 144 measurements, based on Elucidean distance measurement 
and a “complete” agglomeration method. The output of the clustering was presented 
in a heatmap using the RColorBrewer library. The biological replicates were collapsed 
by averaging to obtain a resultant mean peptide count profile describing the behaviour 
of each protein across the 48 fractions. The standard deviation for the three biological 
replicates per fraction was also calculated to provide standard error bars on the 
protein profile graphs.  
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Subcellular localisation analysis was performed by Dr Yasmeen Ahmad. For this 
analysis, a published dataset in which proteins were separated by subcellular 
fractionation was used as a reference library [Larance et al., 2013]. A protein was 
designated to the subcellular compartment where 80% or more of the total protein 
was detected. Proteins distributed more generally across compartments were 
excluded from the analysis. Proteins identified in the native and the crosslinked 
datasets were then compared to the allocable proteins in the reference dataset. 
2.9 Cloning, expression and purification of GST-MRG  
2.9.1 Cloning of GST-MRG domain 
 pGEX4T1 (GST-empty vector) (GE healthcare) 
 The MRG insert was generated by Genscript by gene synthesis, encoding amino 
acids 191-362 of the MORF4L1 protein  
 (full sequence: H2N-
NRVEVKVKIPEELKPWLVDDWDLITRQKQLFYLPAKKNVDSILEDYANYKKSRGNTDNKE 
YAVNEVVAGIKEYFNVMLGTQLLYKFERPQYAEILADHPDAPMSQVYGAPHLLRLFVRIG 
AMLAYTPLDEKSLALLLNYLHDFLKYLAKNSATLFSASDYEVAPPEYHRKAV-COOH) 
LR reaction: 150ng MRG construct and 150ng pDEST15 plasmid (GST-vector) (Life 
Technologies) were combined and made up to 8l with TE buffer. 2l of LR Clonase II 
Enzyme Mix (Life Technologies, 56485) was added and incubated at room temperature 
for 1 hour. 1l of proteinase K (Life Technologies, Y02759) was then added and the 
reaction was incubated at 37oC for 10 minutes. 
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Transformation: Two aliquots of One Shot BL21 (DE3) chemically competent cells 
(Invitrogen, C6000-03) were thawed on ice for 5 minutes. 1l of pGEX4T1 vector and 
5l of the pDEST15MRG LR reaction were added to separate bacterial vials and mixed 
gently by tapping. The bacteria were incubated on ice for 30 seconds before subjecting 
them to heat shock at 42oC in a water bath for 30 seconds. The reactions were 
returned to ice. 250l of SOC medium (Life Technologies) at room temperature was 
added to the bacteria and mixed gently by tapping. Bacteria were then plated out onto 
LB plates containing ampicillin at 100g/ml and incubated at 37oC overnight 
2.9.2 Materials and solutions for protein expression 
Induction agent: 
1M IPTG (VWR, 437145X) in Milli-Q H2O 
 
Culture medium: 
LB media supplemented with 100g/ml ampicillin 
 
Pellet re-suspension buffer: 
PBS containing 1 x Complete EDTA-free protease inhibitor tablet per 50ml. 
 
Lysozyme: Triton X-100: 
40mg/ml lysozyme (Sigma, L6876) 10% Triton X-100 
50% glycerol in PBS 
in PBS 
 
Glutathione Sepharose 4B Beads: 
Supplied as 80% slurry glutathione sepharose in 20% ethanol (Amersham Biosciences) 
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Elution buffer (50ml):  CNBr coupling buffer: 
50mM Tris-HCl, pH8.0 0.1M NaHCO3 
154mg reduced glutathione 0.5M NaCl 
                       (Sigma, G4251) pH adjusted to 8.3  
 
CNBr rehydration buffer: 
10mM HCl 
 
RIPA buffer: 
0.1% SDS 
0.5% sodium deoxycholate 
1% NP-40 
50mM Tris-HCl pH 7.4 
150mM NaCl 
 
TE buffer: 
10mM Tris-HCl (pH8.0) 
0.1mM EDTA 
 
2.9.3 GST-fusion protein purification, cell lysis and binding to glutathione 
Single colonies of BL21 bacteria expressing GST-empty vector and GST-MRG were 
inoculated separately into 5ml of culture medium and left to grow overnight at 37oC 
with shaking. 5ml of each culture was then used to inoculate 500ml of culture medium 
in separate 2.5L conical flasks. The cultures were grown for ~5 hours at 37oC with 
shaking until the optical density at 600nm reached 0.6-0.8. Protein production was 
then induced by the addition of IPTG to a final concentration of 0.1mM and incubated 
at 37oC for 3-6 hours. Bacterial cells containing the recombinant proteins were 
harvested by centrifugation at 5,250g in a Beckman Coulter SX4750 centrifuge at 4oC 
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for 30 minutes with slow deceleration. The supernatants were discarded and the 
pellets were frozen at -20oC overnight. 
The pellets were resuspended in 50l ice-cold PBS containing protease inhibitors for 
every 1ml of culture volume (25ml each). Lysozyme was added to a 1mg/ml final 
concentration and then incubated at 4oC with rotation for 30 minutes. Triton X-100 
was then added to a 1% final concentration and the cells were sonicated on ice for a 30 
second burst at 10% power (Branson Digital Sonifier 250). The cells were then 
incubated at 4oC with rotation for 30 minutes. The cells were sonicated again for 2 x 30 
seconds at 10% power to ensure cell lysis was complete. The lysates were then 
subjected to centrifugation at 12,000g (Beckman Coulter Avanti J25 centrifuge, rotor 
JA25.5) for 30 minutes at 4oC to pellet cellular debris. 
For each 500ml of culture, 2ml of glutathione beads (~3ml slurry) were washed in 50ml 
of PBS to pre-equilibrate the beads. Beads were pelleted by centrifugation at 2,000g 
for 2 minutes at room temperature with slow deceleration (Beckman Coulter SX4750 
centrifuge). The protein lysates were added to the prepared beads and incubated 
overnight at 4oC on a rotating wheel. Beads were pelleted again at 2,000g for 2 
minutes with slow deceleration before being washed twice with 50ml of 1X PBS, all at 
4oC. The beads were transferred into a plastic filter column then washed in 30ml of 1X 
PBS at room temperature. The GST-fusion proteins were then eluted in 10ml elution 
buffer and collected in 15ml Falcon tubes.  
2.9.4 Coupling protein to CNBr-activated Sepharose 4B 
The GST-MRG and GST-empty vector proteins were buffer exchanged into CNBr buffer 
using 3 x 15 minute centrifugations at 4,000g (Beckman Coulter SX4750 centrifuge) 
through 10kDa molecular weight cut off Amicon Ultra tubes (Millipore). A Bradford 
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protein quantification assay was performed on the purified proteins and aliquots of 
each protein were made up to 50l of both 0.01mg/ml and 0.1mg/ml in 1X LDS sample 
buffer with 25mM TCEP. 10l of each were loaded per lane for SDS-PAGE separation as 
described in section 2.6.2. The gel was then stained with InstantBlue (Expedeon) as 
described in section 2.6.5, to assess protein purity. Sufficient protein was purified to 
make 1.2ml of 1 mg/ml of protein coupled beads. Therefore 700g of CNBr-activated 
sepharose 4B beads (GE Lifesciences, 17-0430-01) were rehydrated in 50ml 10mM HCl 
for 30 minutes. The beads were pelleted at 2,000g for 2 minutes at room temperature 
with slow deceleration (Beckman Coulter SX4750 centrifuge). The CNBr-sepharose was 
washed three more times in 50 ml 10mM HCl using a steri-cup (Millipore) under 
vacuum. The CNBr-sepharose beads were washed in 50ml CNBr coupling buffer in the 
steri-cup under vacuum. The CNBr sepharose beads were then resuspended in 10ml 
CNBr buffer and divided between two 15ml falcon tubes, pelleted and the buffer 
removed. 1.2mg of protein in solution (GST-empty vector and GST-MRG), were added 
to the beads separately and incubated with rotation overnight at room temperature. 
The beads were then pelleted at 2,000g for 2 minutes at room temperature with slow 
deceleration (Beckman Coulter SX4750 centrifuge). The CNBr-sepharose was 
subsequently blocked with 100mM Tris-HCl pH 7.4 for 8 hours at room temperature 
with rotation. The beads were then pelleted and washed 3 times for 5 minutes in 20ml 
RIPA buffer. The beads were finally stored as 50% slurries in 1X TBS with 0.02% NaN3 at 
4oC. 
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2.10 Immunoprecipitation 
2.10.1 Solutions 
Immunoprecipitation buffer: 
50mM Tris-HCl pH 7.4 
150mM NaCl 
5mM NEM 
1% NP-40 
10% glycerol 
10mM EDTA 
1x EDTA free-Complete Protease inhibitor tablet per 50ml buffer 
1x PhosStop tablet per 10ml buffer. 
2.10.2 GFP-immunoprecipitation protocol 
Four 15cm dishes of U2OS cells expressing LAP1-MRFAP1 were grown to ~50% 
confluence. One dish was treated with 10l DMSO, one was treated with 10g/ml 
doxycycline (Sigma, D9891) for 18 hours, one dish was treated with 10g/ml 
doxycycline and 1M MLN4924 for 18 hours and the final dish was treated with 
10g/ml doxycycline for 18 hours and 10M MG132 for 2 hours prior to harvest. Cells 
were washed twice with ice-cold PBS. 1ml of ice-cold IP buffer was added to each plate 
and cells were harvested by scraping. The lysates were sonicated, 3 x 10 seconds at 
10% power (Branson Digital Sonifier), on ice, before centrifugation at 17,000g for 10 
minutes at 4oC (Heraeus Pico17 centrifuge). BCA protein quantitation assay was 
performed on the supernatant as described in section 2.16. 40l of GFP-trap agarose 
bead slurry (ChromoTek) per IP was washed in 1ml IP buffer. Lysate containing 1.5mg 
of total protein was added to the pre-washed beads and mixed by rotation for 2 hours 
at 4oC. Beads were pelleted by centrifugation at 2,000g for 2 minutes at 4oC and the 
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flow through was retained. The beads were washed three times in 1ml IP buffer. The 
beads were resuspended in 200l ice-cold PBS per IP and transferred to a spin column. 
Beads were dried by centrifugation at 500g at 4oC. The spin columns were transferred 
to clean Eppendorf tubes and the immunoprecipitated proteins were eluted by the 
addition of 50l 1X LDS sample buffer supplemented with 25M TCEP pre-heated to 
65oC. The samples were heated to 65oC for 5 minutes then centrifuged at 500g for 5 
minutes at room temperature. BCA protein quantitation was performed on the flow 
through, and both the start and the flow through were made up to a final 
concentration of 1mg/ml of total protein with 1X LDS sample buffer and 25M TCEP 
for immunoblotting. 
2.10.3 Endogenous immunoprecipitation 
One 15cm dish of cells per IP was grown to 80% confluence. For VprBP and MORF4L1 
IPs, either 1M MLN4924, or 10l DMSO control, was added 16-20 hours prior to 
harvest. Cells were washed twice in ice-cold PBS before scraping cells in 1ml IP buffer 
per dish. Lysates were sonicated for 3 x 10 seconds, 10% power on ice (Branson Digital 
Sonifier 250). Lysates were then centrifuged at 17,000g for 10 minutes at 4oC (Heraeus 
Pico17 centrifuge, Thermo Fisher Scientific). BCA quantitation assay was performed on 
the supernatant (section 2.16). Protein G Dynabeads (Invitrogen, 10003D) were 
vortexed vigorously and 50l of slurry per IP was washed in 1ml IP buffer. The beads 
were pelleted on a Dynal magnet (Life Technologies) and then resuspended in 100l of 
IP buffer per IP and divided into 1.5ml Eppendorf tubes, one for each IP. Lysate 
containing 1.5mg total protein was mixed with either 10g of the rabbit IgG control 
antibody (Jackson Immuno Research Laboratories, 011-000-003), or 10g MORF4L1 
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antibody (Table 2.1). Lysate containing 1mg total protein was mixed with either 3g of 
the rabbit IgG control antibody, or 3g VprBP antibody (Table 2.1).  
The antibody mixtures were added to the Dynabeads and mixed with rotation for 2 
hours at 4oC. The beads were then pelleted on a magnet and the flow through was 
retained. Beads were washed three times with 1ml IP buffer at 4oC. Beads were then 
washed in 1ml ice-cold PBS. Protein was eluted from the beads by incubating in 1xLDS 
sample buffer containing 25mM TCEP at 65oC for 5 minutes. Beads were separated 
from the eluate by pelleting on a magnet and the eluate was then transferred to a 
clean 1.5ml Eppendorf tube. Protein content in the start and flow through material 
was quantified by BCA assay and an aliquot was made up to 1mg/ml total protein with 
1xLDS sample buffer and 25mM TCEP for immunoblotting. 
2.10.4 GST-MRG pull down (non-SILAC) 
Three 15cm dishes of LAP1-7KR MRFAP1 mutant U2OS cells were grown to 80% 
confluence. The cells were washed twice with 20ml of ice-cold PBS. All three plates 
were scraped in a total volume of 1.5ml IP buffer. The lysate was sonicated 3 x 10 
seconds at 10% power (Branson Digital Sonifier 250), on ice, then centrifuged at 
17,000g at 4oC (Heraeus Pico17 centrifuge, Thermo Fisher Scientific). BCA assay was 
performed on the supernatant (as described in section 2.16). Forty micrograms of bead 
bound GST-MRG protein per IP was washed in 1ml IP buffer, pelleted at 2,000g for 2 
minutes (Beckman Coulter SX4750 centrifuge). The beads were resuspended in 500l 
IP buffer and divided between five clean Eppendorf tubes. 4mg, 2mg, 1mg, 0.5mg of 
lysate protein, or just IP buffer alone, was added to the prepared beads and mixed 
with rotation overnight at 4oC. The beads were washed and protein eluted as 
described above in section 2.7.2. BCA assay was performed on the flow through. 
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Aliquots of the starting material and flow through were made up to 1mg/ml with 1X 
LDS sample buffer and 25mM TCEP for SDS-PAGE and immunoblotting as described in 
section 2.6. 
2.10.5 GST-MRG SILAC immunoprecipitation 
LAP1-7KR MRFAP1 mutant U2OS cells were grown in medium containing R0K0, R6K4 
and R10K8 labelled amino acids for three passages (1:6 split) to ensure maximum 
incorporation of labelled amino acids. Two 15cm dishes of each were grown to 50% 
confluence and two plates of R10K8 labelled cells and one of the R6K4 plates were 
induced with doxycycline (10g/ml) for 96 hours prior to harvest. For harvesting, cells 
were scraped in 500l IP buffer per plate, on ice. The lysate was sonicated on ice for 3 
x 10 second bursts at 10% power (Branson Digital Sonifier 250) then centrifuged at 
17,000g for 10 minutes at 4oC (Heraeus Pico17 centrifuge, Thermo Fisher Scientific). 
BCA protein quantitation assay was performed on the supernatant and 4mg of protein 
per treatment group was used for the pull down. 40g of bead-bound protein per 
condition were washed in IP buffer. Non-induced R0K0 cell lysates were incubated 
with GST-MRG beads as a control and induced R10K8 cell lysates were also incubated 
with GST-MRG beads as the treatment group. The part induced/part non-induced R6K4 
lysate was mixed with GST-empty vector beads as a control for non-specific, GST/bead 
interacting proteins. The lysates were mixed with the beads overnight with rotation at 
4oC. Beads were pelleted by centrifugation at 2,000g with slow deceleration (Beckman 
Coulter SX4750 centrifuge), at 4oC and the flow through was retained. The beads were 
then combined and washed together in 1ml of IP buffer at 4oC. Two further washes 
were performed using the same buffer. The beads were then resuspended in 500l of 
ice-cold PBS and transferred to a spin column and centrifuged at 500g for 1 minute at 
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4oC (Heraeus Pico17 centrifuge, Thermo Fisher Scientific). Protein on the dried beads 
was eluted by the addition of 50l of 1XLDS sample buffer with 25mM TCEP (pre-
heated to 65oC). The eluate was collected by centrifugation at 500g for 1 minute into a 
clean Eppendorf tube. 25l of elution was loaded onto two side-by-side lanes of a 4-
12% 10 well 1mM NuPAGE Bis-Tris gel. The gel was run with MES buffer at 200V for 43 
minutes. The gel was stained with SYPRO Ruby protein stain as per section 2.6.4. 
2.11 In-gel digestion  
2.11.1 Solutions 
 0.5M NH4HCO3 (50ml) 
 0.1M NH4HCO3 (50ml) 
 50:50 – 50% CH3CN, 0.25M NH4HCO3 (50ml) 
All stock solutions were made fresh each day and were made using HPLC grade H2O 
(VWR).  
 5% Formic Acid 
 50mM Acetic acid 
2.11.2 Protocol 
The slightly wet, SYRO Ruby stained gel was placed on a clean flat surface (lid of a 
15cm tissue culture plate) and gel bands were viewed under UV light. Gel bands were 
cut into 13 slices from low to high molecular weight. Each slice was cut into 1mm 
cubes and transferred to a Low-bind Eppendorf tube. The gel cubes were washed once 
in 1ml of 50% CH3CN/0.25M NH4HCO3 with slow vortexing for 30 minutes at room 
temperature. Gel bands were dehydrated by the removal of all liquid and the addition 
of 1ml of 100% CH3CN with shaking for 10 minutes at room temperature. All liquid was 
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carefully removed. Trypsin (MS-grade, Roche) was suspended in 50mM acetic acid to a 
final concentration of 1g/ml. Trypsin was diluted to 12.5ng/l in 100mM NH4HCO3 
and 30-40 l was added to each tube. Tubes were centrifuged at 17,000g for 1 minute 
at room temperature (Heraeus Pico17 centrifuge, Thermo Fisher Scientific), then 
incubated overnight at 37oC. 100l 5% formic acid was added to each tube, vortexed 
and incubated for 1 hour at 37oC. 100l 100% CH3CN was added to each tube, 
vortexed and incubated for 1 hour at 37oC. 500l 100% CH3CN was added to each 
tube, vortexed and incubated for 10 minutes at 37oC. The supernatant was moved to a 
new low-bind Eppendorf tube and dried at 30oC overnight using a Savant SPD 2010 
SpeedVac concentrator (Thermo Fisher Scientific). The dried peptides were 
resuspended in 20l 5% formic acid, vortexed and incubated at room temperature for 
30 minutes. CBQCA peptide quantitation was performed as described in section 2.17. 
1g of peptide from each of the 13 vials was used for MS analysis. 
2.11.3 MS-analysis of SILAC pull down samples 
Using a Thermo Fisher Scientific Ultimate 3000 nanoHPLC system, a maximum of 1μg 
of peptides in 5% (v/v) formic acid was injected for each gel slice onto an Acclaim 
PepMap C18 nano-trap column (Thermo Fisher Scientific). After being washed with 2% 
(v/v) acetonitrile, 0.1% (v/v) formic acid, peptides were resolved on a 150mm × 75μm 
Acclaim PepMap C18 reverse-phase analytical column over a gradient from 2% 
acetonitrile to 80% acetonitrile over 100 minutes with a flow rate of 300nl min−1. 
Thereafter, ionisation and MS analysis was performed as described in section 2.7.7 
(SEC non-crosslinked). 
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2.12 Cell immunofluorescence 
2.12.1 Solutions and materials  
 16% methanol free paraformaldehyde (PFA) (Pierce, 28908) 
 Vectashield (Vector Laboratories, H-1400)  
Fixation Buffer:  
3% PFA in PBS, made fresh for each use 
Quench Buffer: Blocking Buffer:  
50mM Glycine in PBS 5% BSA  
 in TBS and 0.1% Tween-20 
Permeabilisation buffer:  
1% Triton X-100 in PBS 
2.12.2 Immunofluorescence protocol 
Cells were grown on 13mm coverslips in 24 well plates. For immunofluorescence 
analysis, medium was aspirated and cells were washed in 1ml PBS per well. The cells 
were fixed in 1ml fixation buffer per well for 20 minutes at room temperature on a 
rocker, then washed in 1ml PBS per well. To block excess PFA, the cells were incubated 
in 1ml quench buffer per well for 5 minutes at room temperature on a rocker. Cells 
were permeabilised with 1ml permeabilisation buffer per well, for 10 minutes at room 
temperature on a rocker. The coverslips were then washed in PBS (1ml/well). Blocking 
buffer (1ml/well) was then added to the coverslips and incubated at room 
temperature for 30 minutes on a rocker. Blocking buffer was removed and then 
primary antibodies (see Table 2.1) were added to the coverslips at the appropriate 
dilutions, diluted in blocking buffer, and incubated for 1 hour at room temperature. 
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Coverslips were washed in PBS (1ml/well) three times, for 5 minutes each, on a rocker 
at room temperature. Alexa-Fluor-labelled secondary antibodies (Table 2.1) were 
prepared in blocking buffer at 1:400 dilution. 500l of diluted antibodies were added 
to each coverslip. DAPI (1:1000) was added to the Alexa-Fluor antibodies and 
incubated for 30 minutes at room temperature on a rocker, covered from light. 
Coverslips were washed in PBS (1ml/well) 3 times for 5 minutes, on a rocker. Control 
slides were incubated with DAPI and secondary antibodies only. Slides were prepared 
by placing a drop of Vectashield mounting medium for each coverslip. Coverslips were 
then placed, cell side down, on the mounting medium and left in the dark at room 
temperature for 24 hours. The coverslips were then sealed with nail varnish and dried 
at room temperature, protected from light. 
2.13 Tissue immunofluorescence 
2.13.1 Solutions 
Blocking buffer: Antigen Unmasking buffer: 
1X PBS Tris base 1.2g   
5% goat serum (Sigma) EDTA 0.37g 
0.3% Triton X-100 in 1L H2O, pH adjusted to 9 with HCl 
 
Permeabilisation buffer: Sodium Borohydrate: 
1% triton X-100 in PBS 1% (w/v) in PBS 
 
Quench buffer: 
50mM Glycine in PBS 
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2.13.2 Immunofluorescence protocol 
To remove paraffin wax, sections were incubated in Histo-clear (National Diagnostics) 
for 2 x 5 minutes. Sections were rehydrated in 100% ethanol for 2 x 5 minutes then 
70% ethanol for 5 minutes. The sections were then rinsed in running tap water for ~1 
minute. Antigen retrieval was performed by heating sections immersed in antigen 
unmasking buffer for 5 minutes in the microwave at full power. Sections were then 
permeabilised in 100l permeabilisation buffer for 15 minutes then rinsed with 3 x 1ml 
PBS. Sections were then incubated in sodium borohydrate solution for 4 x 15 minutes 
with the solution made freshly immediately before each incubation. Sections were 
rinsed 3 x in PBS then quenched in quench buffer for 15 minutes. Sections were 
blocked in 100l blocking buffer for 60 minutes then incubated with primary 
antibodies (Table 2.1) and DAPI 0.5g/ml (Sigma), diluted in blocking buffer. Primary 
antibodies were washed with 3 x 1ml PBS before incubation with fluorochrome-
conjugated secondary antibodies diluted in blocking buffer at 1:400 for 1 hour at room 
temperature in the dark. Control sections were incubated with DAPI and secondary 
antibodies only. Sections were washed in 3 x 1 ml PBS, dried then covered with 
Vectashield mounting medium under coverslips.  
2.14 Microscopy. 
Microscopy was performed on a Leica SP2 confocal scanning fluorescence microscope. 
The pinhole was set to 1 Airy unit. Lasers used were the 405nm blue diode, 488nm 
argon ion laser and 594nm orange diode laser. A 63x objective lens plan Apo was used 
with 1.3 numerical aperture. Images were analysed using Leica LCS Software. 
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2.15 Chloroform methanol precipitation 
This method is useful for concentrating dilute protein solutions in any buffer. SDS was 
added to the protein solution to a final concentration of 2% and heated to 65oC for 10 
minutes to denature proteins. This assists solubilisation of the pellet in the last step. 
400l of 100% methanol was added to 100l of protein containing solution (including 
SDS) and vortexed for 5 seconds. 100l of 100% chloroform was added and vortexed 
again. 300l MilliQ water was added and vortexed for 1 minute. The sample was 
centrifuged at 9,000g for 5 minutes at room temperature (Heraeus Pico17 centrifuge, 
Thermo Fisher Scientific). The top 80% of the upper phase was discarded. 300l of 
100% methanol was added to the tube and vortexed briefly. The sample was 
centrifuged at 17,000g for 5 minutes at room temperature. The entire supernatant was 
removed and the pellet air dried at room temperature. The pellet was then 
resuspended in the desired volume of 1X LDS sample buffer containing 25mM TCEP to 
adjust the final concentration to 1mg/ml. 
2.16 Bicinchoninic acid (BCA) quantitation assay 
2.16.1 Solutions and materials 
 BCA protein assay kit (Pierce, PI-23227) 
 1X PBS  
 BSA protein standards prepared in PBS to final concentrations of: 0.025, 0.075, 
0.2, 0.4, 0.6, 0.8, 1 and 2mg/ml 
2.16.2 Protocol 
25l of PBS (blank) and each protein standard were loaded in triplicate into a flat 
bottomed, clear, 96-well plate (Thermo Fisher Scientific). Proteins samples were 
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diluted 10 or 20 fold in 1X PBS and 25l loaded into wells in duplicate or triplicate. 
200l of BCA working reagent was added to each well, covered and then incubated at 
37oC for 30 minutes. The absorbance was then measured at 562nm on a SpectraMax 
M2E microplate reader (Molecular devices) and SoftMax Pro software (Molecular 
Devices) was used to analyse the results. 
2.17 CBQCA peptide quantitation assay 
2.17.1 Solutions and materials 
 0.1M H3BO3-NaOH pH 9.3 (Borate buffer) 
 CBQCA protein quantitation kit (Invitrogen, C-6667) 
 Black bottom 96-well plate for fluorescence with lid (Thermo Fisher Scientific) 
 BSA peptide standards, trypsin digested, ultrafiltered with 10kDa cut-off, C18 
Sep-pak purified, in borate buffer, in Eppendorf 1.5ml low protein binding 
tubes at concentrations of 655360ng/ml, 163840ng/ml, 40960ng/ml, 
10240ng/ml, 2560ng/ml and 640ng/ml. 
2.17.2 Protocol 
The assay was performed as per manufacturer’s instructions. Briefly, peptides were 
diluted 25-fold in borate buffer in the 96-well plates. Borate buffer blank wells and the 
standards were added to the plate in triplicate. For each well, 95l of borate buffer 
was mixed with 5l of KCN solution and 100l of this mixture was added to each well. 
25l of a 2mM CBQCA reagent stock was added to each well. The plate was covered 
with a lid and incubated on a rocker at room temperature for 1 hour. The fluorescence 
was then read by excitation at 465nm and emission at 550nm with 495nm cut off filter 
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using a SpectraMax M2E microplate reader (Molecular devices) and SoftMax Pro 
software (Molecular Devices) was used to analyse the results. 
2.18 Coomassie Plus (Bradford) quantitation assay 
2.18.1 Solutions and materials 
 BSA standards as per section 2.7.1 
 Coomassie Plus Reagent (Thermo Fisher Scientific, 23236) 
2.18.2 Protocol 
25l of PBS blanks and BSA protein standards were loaded in triplicate onto a flat 
bottomed, clear, 96 well plate. 200l of Coomassie Plus reagent was added to each 
well and mixed gently. The plate was incubated at room temperature for 10 minutes 
then the absorbance was measured at 595nm using a SpectraMax M2E microplate 
reader (Molecular devices). SoftMax Pro software (Molecular Devices) was used to 
analyse the results. 
2.19 EZQ protein quantitation assay 
2.19.1 Solutions and materials 
 Protein standards as per section 2.7.1 
 EZQ Protein quantitation kit (Invitrogen, R33200) 
Rinse Buffer: 
10% methanol 
7% acetic acid  
in MilliQ H2O 
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2.19.2 Protocol 
A sheet of assay paper was fitted to the microplate cassette supplied as part of the 
assay kit. 1l of 1X PBS, protein standards and sample were applied to the paper in 
triplicate. In the case of SEC fractions, the samples were analysed as single replicates 
only. When required, samples were diluted in the same buffer they were dissolved  in. 
The protein samples were dried completely with the aid of a hair dryer. The paper was 
fixed and washed with 40ml 100% methanol in a plastic tray with agitation for 5 
minutes. The paper was then dried using a hair drier. The paper was stained with 40ml 
EZQ staining reagent and incubated at room temperature with agitation for 30 
minutes, covered from light. After staining, the assay paper was rinsed for 1-2 minutes 
in rinse buffer for a total of three rinses. The paper was dried using a hair dryer then 
analysed in a SpectraMax M2E microplate reader (Molecular devices) using 
excitation/emission settings of ~480/590nm. SoftMax Pro software (Molecular 
Devices) was used to analyse the results. 
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Chapter 3: Native protein complex 
analysis by size-fractionation-based 
quantitative proteomics 
3.1 Introduction 
As discussed in Chapter 1, the wide variety of possible protein-protein interactions 
enables the large diversity of cellular protein functions. While a number of protein 
complexes have been widely studied, to date very little is known about the 
composition of many of the protein complexes formed in human cells. The CORUM 
database  forms the largest dataset of protein complexes compiled from available 
literature, and contains information relating to 1,970 protein complexes identified in 
human cells from only ~16% of the known protein-coding genes [Ruepp et al., 2010]. 
Therefore, a huge deficit still exists in our knowledge of the putative complexes 
formed by the remaining proteins. More detailed knowledge of protein complexes and 
the cellular pathways they regulate would be invaluable for the life sciences and 
medical communities. 
To identify protein-protein interactions, affinity purification, typically of tagged protein 
baits, combined with subsequent mass spectrometric analysis of the isolated proteins 
has been widely used. Although this approach gives vast amounts of detail regarding 
the interacting proteins, a significant limitation to these techniques is that they do not 
distinguish the distinct functional complexes the interacting proteins form. It is also 
impractical in terms of time and cost to apply affinity purification methods on a 
106 
Chapter 3: Native protein complex analysis 
 
system-wide scale and the use of tagged proteins limits applications, for example with 
clinical samples. To overcome these limitations, some studies have used blue native 
polyacrylamide gel electrophoresis (BN-PAGE) combined with mass-spectrometry to 
study native protein complexes within either purified subcellular fractions [Heide et al., 
2012], or whole cell lysates [Camacho-Carvajal et al., 2004]. Limitations in this 
technique, however, include the low resolution for complexes <100kDa, both due to 
the high abundance of complexes in this size range and the limited separation distance 
resulting from the acrylamide gradient [Eubel et al., 2005]. In addition, the total 
protein loading capacity (400g per 0.16 x 1cm sample well [Wittig et al., 2006]) and 
reproducibility due to manual implementation of the BN-PAGE technique limit its 
applicability to large scale experiments. More recently, ion exchange chromatography 
(IEX) combined with mass spectrometry has also been utilised to study soluble native 
protein complexes in human cell lines [Havugimana et al., 2012]. 
Size exclusion chromatography (SEC) is a well-established technique used to separate 
proteins in solution on the basis of their size (rotational cross-section) [Wheaton and 
Bauman, 1953]. SEC has been used in previous studies to separate native protein 
complexes in plant chloroplasts [Olinares et al., 2010] and for the study of large 
cytosolic complexes in mammalian cells [Kristensen et al., 2012] but to date, this 
technique has not been extensively applied in combination with mass spectrometry to 
study all of the native protein complexes in soluble whole cell extracts. 
The aim of this chapter was to develop a mass-spectrometry compatible technique 
that would enable the system-wide analysis of native protein complexes including the 
analysis of protein isoforms and post-translationally modified peptides. 
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3.1.1 Hypothesis and aims 
The hypotheses for this work were that 
 Intact protein complexes can be analysed in a high-throughput, mass 
spectrometry based approach 
 Size exclusion chromatography permits the separation of native protein 
complexes in a native buffer  
 Protein isoforms and post translational modifications interact in different 
complexes to their unmodified counterparts 
To test this hypothesis I aimed: 
 To develop a method for the analysis of native protein complexes utilising size 
exclusion chromatography in combination with tandem mass spectrometry 
 To analyse the data at the level of protein isoforms to identify differences in 
protein elution profiles  
 To study whether the elution profiles of post-translationally modified proteins 
differ from their unmodified counterparts 
3.2 Results 
3.2.1 Workflow for the identification of native protein complexes 
To identify and characterise native protein complexes from human U2OS 
osteosarcoma cells, lysis was performed using PBS containing protease and 
phosphatase inhibitors.  No detergents were used to prevent the disruption of protein-
protein interactions (Figure 3.1). The resulting protein complexes were fractionated by 
size (rotational cross-section) using non-denaturing size exclusion chromatography 
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(SEC) and the eluate was collected into 40 sequential fractions (Figure 3.1). Fractions 
were digested with trypsin, desalted and analysed by LC-MS/MS. Peptides were 
identified and quantified using the MaxQuant Andromeda software [Cox and Mann, 
2008; Cox et al., 2011], using standard parameters, as described in the Methods 
chapter (section 2.7.7). From the three biological replicates, it was required that a 
protein be identified in at least two replicates with a minimum of two peptides in each. 
These stringent criteria left over 71,500 peptides, corresponding to 8,168 proteins, for 
further analysis. 
 
Figure 3.1. Native protein complex analysis using a comprehensive proteomics 
workflow.  
Workflow for SEC-based protein complex separation. 
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3.2.2 Fraction level analysis of protein properties 
Protein standards were analysed using the above method to identify the approximate 
molecular weights of each fraction. This showed that the method separated protein 
complexes with molecular weights from ~15kDa to >1MDa (Figure 3.2).  For 
subsequent analysis protein complexes were deemed to be either larger (fractions 7-
23), or smaller (fractions 24-40), using a cut-off between 130 and 440kDa (Figure 3.2). 
 
Figure 3.2. Characterisation of protein complex separation.  
The UV chromatograph from one of the biological replicates indicates the profile 
of the U2OS total cell lysate as it eluted from the Superose 6 SEC column across 
40 fractions. Protein standards of known molecular weights (thyroglobulin, 
ferritin, BSA, RNase) were injected onto the same column, and their elution 
peaks were used to calculate approximate molecular weights for fractions. 
Proteins that eluted in fractions 1-6 were termed the void. Complexes that 
eluted in fractions 7-23 were classed as “larger”, and those in fractions 24-40 
were classed as “smaller”. 
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The elution profile for each protein standard was used to calculate a predicted 
molecular weight for each fraction. Using these predicted molecular weights, a linear 
regression model was generated (Figure 3.3), which enabled the calculation of an 
approximate observed molecular weight of complexes/proteins found in the dataset, 
based on their peak elution fraction.  
 
Figure 3.3. Linear regression model to approximate molecular weight of 
complexes/proteins within each fraction.  
The Log10 of the SEC fraction number was plotted against the Log 10 molecular 
weight of the proteins standards to calculate a linear regression (y=9.561209-
5.449685x). Analysis performed by Dr Yasmeen Ahmad. 
 
Predicted protein molecular weights were extracted from the Uniprot database 
[Consortium, 2013] and compared to the calculated molecular weight, based on the 
linear regression model, for each protein (Figure 3.4). The scatter plot shows that most 
proteins were generally identified at a higher molecular weight than their Uniprot 
molecular weight, which supported my hypothesis that the majority of proteins in the 
human proteome are involved in one or more complexes. 
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Figure 3.4. Comparison of Uniprot predicted protein molecular weight versus 
SEC observed protein molecular weight.  
The linear regression equation was used to calculate an SEC observed molecular 
weight for each protein based on the fraction containing its main elution peak. 
The Log10 observed molecular weight (y-axis in kDa) was then plotted against the 
Log10 predicted molecular weight (x-axis in kDa) as a scatter plot. Analysis 
performed by Dr Yasmeen Ahmad. 
 
To confirm that the SEC method separated intact protein complexes, pairs of 
consecutive elution fractions were combined (resulting in 20 combined fractions in 
total), then separated by molecular weight using SDS-PAGE and stained for total 
protein. This analysis showed that the earliest fractions eluting from the column (larger 
complexes), contained proteins with very heterogeneous sizes, whereas fractions 
eluting later (smaller complexes), contained proteins that mostly migrated either at, or 
close to, their predicted molecular weight (Figure 3.5). This suggests that either small 
complexes are less heterogeneous, or that more monomeric proteins were isolated in 
112 
Chapter 3: Native protein complex analysis 
 
these fractions. I also observed that the first three fractions (labelled void), contained 
similar proteins to the total lysate, likely including complexes larger than the 
separation range of the column. Therefore, these fractions were not included in any 
further analysis (Figure 3.5).  
 
Figure 3.5. Complexes separated by native SEC contain proteins of 
heterogeneous sizes.  
SYPRO ruby total protein stain of proteins in the total cell lysate and 
consecutively combined fractions. 10g of protein was loaded in lane 2 (total), 
and a maximum of 10g of protein was loaded per lane for elution fractions. 
 
In contrast, proteins isolated from U2OS cells using a highly denaturing buffer, migrate 
predominantly at their predicted molecular weight when injected into the same SEC 
column (Figure 3.6).  
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Figure 3.6. Denaturing size exclusion chromatography.  
SYPRO ruby total protein stain of proteins in the total cell lysate and 
consecutively combined fractions. 10g of protein was loaded in lane 2 (total), 
and a maximum of 10g of protein was loaded per lane for elution fractions. 
 
3.2.3 Reproducibility of the SEC elution profiles 
To determine the reproducibility of the protein complex separation by SEC, a pairwise 
comparison was carried out between three biological replicates. In each comparison, a 
Pearson correlation coefficient was calculated to compare normalised protein profiles 
across the 40 fractions.  Each protein profile was normalised using the maximum 
peptide count from any fraction within the profile. Each pairwise comparison is shown 
on a density plot, demonstrating a high correlation (>0.8) for the majority of proteins 
(Figure 3.7A). 
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Figure 3.7. Reproducibility of the SEC elution profiles.  
A, the Pearson correlation coefficient was calculated for the three biological 
replicates (replicate 1 versus replicate 2, replicate 1 versus replicate 3, and 
replicate 2 versus replicate 3). The relative protein density (y-axis) was plotted 
against the Pearson correlation coefficient for each replicate (x-axis). B, the SEC 
elution profiles for selected proteins are displayed as line graphs with the 
normalised peptide count (y-axis) plotted against each elution fraction (x-axis). 
Error bars indicate the standard deviation from the mean across three biological 
replicates. Below each line graph are immunoblots for each protein of interest. A 
total of 10g of protein was loaded in the “total” lane and up to a maximum of 
10g of protein was loaded per lane for each of the combined fractions. The 
annotated molecular weights were estimated from the elution profiles of the 
protein standards injected onto the SEC column. 
 
Many proteins demonstrate one or more ‘peaks’ in their elution profile, as can be seen 
in the MS peptide elution profiles for a selected group of proteins (Figure 3.7B). I 
hypothesised that these peaks correspond to these proteins participating, at least in 
part, in complexes with other proteins co-eluting within that fraction. Many proteins 
showed complex elution profiles, as expected. This is because a combination of protein 
polymers, large and small complexes, as well as monomeric proteins, were detected 
within the cell lysate.  
To characterize further the separation of protein complexes by native SEC, I analysed a 
variety of proteins using the orthogonal technique of Western blotting. For this, the 
pairwise pooled SEC fractions, as described above, were separated via SDS-PAGE and 
immunoblotted to detect five representative proteins with different elution profiles 
displaying profile peaks in different fractions. Regardless of whether the protein was a 
small ubiquitin-like modifier (NEDD8), a protein involved in large complexes (CUL3), a 
protein known to form either multimers (GAPDH), or extended polymers (tubulin), or a 
small DNA damage repair protein (PAF), there was not only a close match within the 
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MS replicate data (i.e. relatively small error bars), but also a close match between the 
MS data and the immunoblot profiles (Figure 3.7B).  
3.2.4 Analysis of protein and complex coverage 
To determine if the dataset was biased, for example against either low, or high, copy 
number proteins, the data from a previous study of general protein abundance 
[Nagaraj et al., 2011] was combined with the CORUM database, which contains known 
protein complexes [Ruepp et al., 2010].  Figure 3.8A shows the normal distribution of 
protein copy numbers for proteins found in complexes, as suggested by the CORUM 
database. The same comparison of protein copy numbers was applied to my dataset 
(Figure 3.8B), demonstrating a normal distribution with little or no bias towards either 
low, or high, protein copy number per cell.  
Proteins identified in each fraction were analysed against known complex components 
in the CORUM database. A protein complex was deemed to be present in my dataset if 
a significant proportion of the components within one elution fraction were identified. 
A significant proportion was defined as being at least 30% for large complexes, but 
defaulted to accepting only a higher percentage for smaller complexes made up of 6 or 
less proteins, using the formula max (0.3,2/n). This SEC approach identified 54% of the 
complexes described in the CORUM database using the strict inclusion parameters 
described (Figure 3.8C).  
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Figure 3.8. Comparison of SEC separated complexes with the CORUM database.  
A, protein copy numbers per cell reported in a previous study [Nagaraj et al., 
2011] were applied to my SEC dataset. The results are displayed as a histogram 
comparing the number of proteins (y-axis) and the Log2 copies of that protein per 
cell (x-axis). B, the protein copy numbers per cell were also applied to the 
proteins listed in the CORUM database and displayed in the same format as in 
part A. C, the proportion of protein complexes found in my SEC dataset that were 
previously described in the CORUM dataset are presented as a Venn diagram. 
 
3.2.5 Comparative analysis of differentially sized complexes 
Subdivision into larger (fractions 7-23), smaller (fractions 24-40), or both size ranges 
for complex size, revealed them to contain 1,720, 2,280 and 4,076 proteins 
respectively (Figure 3.9A). Biological process gene ontology (GO) annotations  were 
used to analyse protein function for the dataset [Huang et al., 2008].  The top 10 
biological process annotation terms for different size subgroups were identified and 
this showed that proteins in the overlap group (smaller and larger complexes) are 
involved in regulatory functions, such as RNA processing and cell cycle regulation 
(Figure 3.9B). In comparison, proteins in larger complexes were primarily involved in 
protein transport, catabolic and regulatory processes, such as GTPase activity (Figure 
3.9C).  I also observed that proteins in smaller complexes were largely involved in 
phosphorylation and metabolic processes (Figure 3.9D).  
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Figure 3.9. Comparative analysis of higher and lower molecular weight 
complexes.  
A, the proportions of proteins identified in the SEC dataset that correspond to 
“larger complex proteins” (eluting in fractions 7-23) and “smaller complex 
proteins” (eluting in fractions 24-40) are presented as a Venn diagram. The 
overlap represents proteins that eluted in both larger and smaller complexes. B-
D, bubble graphs demonstrating the top 10 Gene Ontology terms (biological 
processes) (x-axis) plotted against the -Log10 (EASE score) for proteins eluting in 
both larger and smaller complexes, larger complexes and smaller complexes, 
respectively. 
 
3.2.6 Hierarchical clustering of protein elution profiles 
The identification of putative interacting proteins, which should display similar elution 
profiles, was performed using hierarchical clustering of proteins across the 34 SEC 
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fractions. To determine the number of protein clusters required for this analysis, 1-
1000 clusters were generated using the dataset (Figure 3.10). For each cluster, the 
correlation coefficient for the proteins within that cluster was calculated to determine 
optimum cluster size based on similarity of protein profiles. As shown, generating 200 
separate clusters for the dataset ensured a high correlation co-efficient, i.e. above 0.9 
for each cluster. Choosing a higher number of clusters would overly subdivide protein 
complexes into separate clusters. I therefore chose to use 200 protein clusters as the 
optimum number for follow up analysis. 
 
Figure 3.10. Calculation of the optimum hierarchical cluster number.  
The column graph shows the average Pearson correlation co-efficient (y-axis) 
plotted over a range of cluster numbers between 10 and 1000 (x-axis).   
 
Four example protein clusters from the 200 were selected from across the 34 fractions 
and are indicated on the hierarchical clustering heat map (Figure 3.11, 1-4).  
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Figure 3.11. Hierarchical clustering of protein elution profiles.  
All 8,165 proteins were clustered on the basis of the similarity of their 
normalised elution profiles across 34 SEC fractions, and the results were 
presented as a heat map. The dendogram cut-offs for 200 clusters are illustrated 
to the left of the heat map. The peak elution fraction for each of the protein 
standards was used to estimate the approximate molecular weight of 
proteins/complexes eluting within that specific fraction. Four example clusters 
are highlighted on the heat map to the normalised peptide count.  
 
The components of example clusters were analysed using the STRING database to 
identify previously known protein-protein interactions within the cluster [Snel et al., 
2000; Szklarczyk et al., 2010]. Examination of the components in example cluster 1 
(green annotations), showed that it contained many components of the BBS/CCT 
complex, a hetero-oligomeric complex of about 850 – 900kDa in size [Valpuesta et al., 
2002], which correlates to the elution fraction from the SEC column (Figure 3.12A). In 
addition, interacting elongation factor proteins are also present within this cluster, as 
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are several lamins (Figure 3.12A). Although these complexes show their strongest 
elution peak around fraction 14, they can be clearly differentiated using a heat map 
and the hierarchical tree-based representation of the protein profiles (Figure 3.12B). 
To further demonstrate this, the elution profiles of each protein within example cluster 
1 have been plotted and the average protein profile of each labelled complex has been 
highlighted (Figure 3.12C). This shows that small differences in the overall elution 
profile can differentiate these separate complexes. 
Analysis of sample cluster 2 contains many components of the (80S) ribosome and 
elutes from the column at a molecular weight above 670kDa (Figure 3.13). The 
molecular weight of the intact ribosome is ~4MDa [Verschoor et al., 1996], which is 
out with the accurate range of the SEC column used. However, I believe that my 
analysis detected large, intact fragments of the 80S ribosome with an approximate 
molecular weight of ~1-2MDa, which correlates with a peak in elution fraction 7, as 
seen for this cluster. Components of the EIF3 complex are also identified within this 
cluster (Figure 3.13). As the STRING diagram illustrates, there are many established 
interactions between this complex and the ribosome. This demonstrates that 
interacting complexes can be identified within the same cluster. Components of the 
base unit of the 19S proteasome also elute in this same cluster, demonstrating that 
multiple complexes can exist within one cluster.  
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Figure 3.12. Clusters contain proteins known to interact as part of protein 
complexes.  
A, STRING interaction network for proteins identified in example cluster 1 
(relating to Figure 3.11). B, higher resolution view of the heat map for example 
cluster 1. Individual complexes previously identified in the literature are 
highlighted in grey boxes. C, the elution profiles for all proteins identified in the 
example cluster 1 are illustrated as grey lines with their normalised peptide 
count (y-axis) plotted against the SEC elution fraction number (x-axis). The 
average elution profiles for co-clustering proteins known to be in highlighted 
complexes are overlaid in the following colours: chaperonin containing TCP1 
complex in red, elongation factor complex proteins in blue, and lamins in green.  
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Figure 3.13. STRING diagram for example cluster 2.  
STRING diagram for example cluster 2, relating to figure 3.11. Known, or 
predicted, protein interactions are highlighted by connecting lines between 
protein names. 
 
Example cluster 3 contained several groups of interacting proteins, including several 
components of the DNA synthesome complex.  This is a multi-subunit complex 
involved in DNA repair and chromosomal DNA replication [Coll et al., 1996; Jiang et al., 
2002] (Figure 3.14, box 3). Example cluster 4 (Figure 3.14, box 4) did not contain large 
protein complex networks. Within this group, only occasional pairs of interacting 
proteins were identified, which was expected as the peak elution fraction for this 
cluster is between 15 and 67kDa. 
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Figure 3.14. STRING diagrams for example clusters 3 and 4. 
STRING diagrams for example clusters 3 (purple box) and 4 (yellow box), relating 
to figure 3.11. 
 
3.2.7 Analysis of protein isoforms 
Mass-spectrometry-based analysis enables the unbiased detection of many protein 
isoforms, such as those generated by either pre-mRNA alternative splice site selection, 
proteolytic cleavage, or post-translational modifications such as protein 
phosphorylation. The known isoform annotations for the proteins identified in this 
study were used to determine whether each isoform of a single protein displayed 
distinct SEC elution profiles. This identified examples of specific protein isoforms that 
may participate in different protein complexes. 
Alternative splicing 
The first example is the alternative splicing of heterochromatin protein 1-binding 
protein 3 (HP1BP3). This protein is a component of heterochromatin and has been 
proposed to have a role in modulating chromatin structure and function [Hayashihara 
et al., 2010].  Four isoforms of this protein are known to be formed by alternative 
splicing, all of which were identified by up to 14 peptides spanning 26% (isoform 2), to 
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37% (isoform 5), of the expressed sequences in all four isoforms in this dataset (Figure 
3.15A. Peptide locations are marked with an asterisk). 
 
Figure 3.15. Analysis of protein isoforms formed by alternative splicing.  
A, schematic of the four isoforms of the HP1BP3 protein. Asterisks indicate the 
location of identified peptides. SEC elution profiles for the canonical sequence and 
isoforms 2 and 5 (B) and the SEC elution profile for isoform 3 (C) are demonstrated 
as line graphs with the normalised peptide count (y-axis) plotted for each SEC 
fraction number (x-axis). Error bards denote the standard deviation from the mean.  
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Closer analysis shows a similar elution profile for three of the four isoforms (1, 2 and 5, 
Figure 3.15B) whereas isoform 3 is missing a peak between fractions 22 and 30 (Figure 
3.15C). As none of the peptides were sequence specific, this could not be attributed to 
either low expression, or poor sequence coverage. 
Although very little is known from the literature about the protein interaction partners 
of this protein, it could be inferred from the data that HP1BP3 isoforms 1,2 and 5 
interact with one or more proteins to form a complex which is in the molecular weight 
range of ~30-170kDa, whereas isoform 3 does not form part of this complex. Closer 
analysis of the isoform sequences reveals that a region between amino acids 39 and 
116 is missing in isoform 3, but is present in all other isoforms (Figure 3.15A). I 
hypothesise that this region may be required for an interaction to form the 
complex(es) that show an elution peak between fractions 22 and 30. This will be an 
interesting point to pursue in the future as more information regarding this protein, 
and its isoforms, is uncovered.    
Proteolytic cleavage 
A second isoform example is demonstrated by the NUP98 polyprotein. The NUP98 
mRNA is translated into the NUP98-96 precursor protein, which is then cleaved to form 
the N-terminal NUP98 protein and the C-terminal NUP96 component as separate 
proteins (Figure 3.16A) [Fontoura et al., 1999]. 
The NUP98 pre-mRNA can also undergo alternative splicing to form only the NUP98 
protein.  The NUP98-96 precursor has six known isoforms and specifically, isoforms 3 
and 4 correspond to the NUP98 protein without NUP96.  All six isoforms for the NUP98 
protein were identified in my dataset with NUP96 containing isoforms (1,2,5&6) 
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clustering together. These isoforms had a very different elution profile to isoforms 
3&4, which co-clustered separately.  Figure 3.16B, shows the NUP98 interaction 
partners identified by STRING.  
Figure 3.16C, shows the peptide elution profiles for the isoforms in this dataset. The 
profiles for isoforms 3&4 (NUP98) are illustrated in orange and the green profile is that 
of the four isoforms for NUP96. From these profiles I concluded that protein-protein 
interactions involving NUP96 occurred in fractions 8-17 and those specifically involving 
the N-terminal region of NUP98 occurred in fractions 22-31. The dataset was 
interrogated and some of the protein elution profiles for the interaction partners are 
illustrated in Figure 3.16C.  These profiles demonstrate that some interactors have 
peaks that overlap with the NUP96 component (SEC13, NUP107, NUP133, NUP160, 
NUP37, NUP43 and SEH1L), whereas RAE1 has a peak corresponding to an interaction 
involving the N-terminal NUP98 protein. These data suggest that RAE1 may selectively 
interact with NUP98, but not with NUP96. In addition, these data suggest that the 
respective NUP96 and NUP98 proteins are involved in distinct protein complexes.  
Phosphorylated proteins 
Protein phosphorylation is known to affect many protein-protein interactions. The 
addition of a negative charge can either increase affinity between interaction partners 
and develop new binding sites, or it can reduce affinity and therefore inhibit 
interactions [Nishi et al., 2011]. The proteins in my dataset were searched for 
phosphorylation of serine, threonine or tyrosine residues. The elution profiles of  
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Figure 3.16. Analysis of proteins formed by proteolytic cleavage.  
A, schematic showing that the NUP98-NUP96 polyprotein is cleaved to form the 
separate proteins NUP98 and NUP 96. B, NUP98 interacting proteins as proposed 
by the STRING database. C, average SEC elution profiles for peptides associated 
with specific regions corresponding to the NUP98 protein (orange profile) and 
the NUP96 protein (green profile). The line graphs represent the peptide count 
(y-axis) detected for each SEC fraction (x-axis). D, SEC elution profiles for RAE1 
and NUP133 (x- and y-axes labelled as for part C. The grey boxes highlight 
fractions where I propose RAE1 and NUP98 interact and where NUP133 and 
NUP96 interact. Error bars indicate standard deviation from the mean. 
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proteins with and without these modifications were then compared to assess for any 
discrepancies. 
NUDT5 is a protein known to form a homodimer [Zha et al., 2006] and functions in 
cells to hydrolyse ADP-ribose and other similar molecules such as 8-oxoGDP which can 
be formed by nucleotide damaging events [Ishibashi et al., 2005]. NUDT5 was detected 
in this dataset by 13 peptides, representing 64% sequence peptide coverage spanning 
the full length of the protein (Figure 3.17A). Using this protein as an example, it can be 
seen that the elution profile for all of the identified peptides contains two main peaks, 
one in fraction 21 (molecular weight ~440kDa) and the other in fraction 28 (molecular 
weight ~<67kDa) (Figure 3.17B). Analysis of the dataset for phosphorylated peptides 
identified phosphorylation of serine 3 in NUDT5 in all three biological replicates. The 
phosphorylated peptides were all identified in fractions 26-29, corresponding to the 
second, lower molecular weight peak in the overall protein elution profile (Figure 
3.17B,C), whereas the remaining, unmodified peptides, including the peptide 
containing unmodified serine 3, were identified across the two elution peaks. 
Interestingly, this phosphorylation site has been identified as an S-Q phosphorylation 
motif recognised by the DNA damage response kinases ATM and ATR. These data 
suggest that one or more forms of protein complex containing NUDT5 may be 
regulated, at least in part, by the phosphorylation of serine 3. 
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Figure 3.17. Comparison of unmodified and phosphorylated protein profiles.  
A, graphical representation of the peptides identified for the NUDT5 protein 
(shown in green). The letter “P” in the red circle denotes a phosphorylation site 
on the NUDT5 protein. B, the line graph illustrates the SEC elution profile for the 
NUDT5 unmodified protein. Error bars represent the standard deviation from the 
mean. The letter “P” in a red circle denotes a fraction containing the 
phosphorylated peptide (Ac-MEpSQEPTESSQNGK). C, a screen shot of these data 
presented in the Encyclopedia of Proteome Dynamics. Elution profiles show the 
normalised peptide count on the y-axis plotted against the SEC fraction on the y-
axis. 
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3.3 Discussion 
In this chapter, I have used a proteomic strategy combining size exclusion 
chromatography and mass spectrometry with hierarchical clustering to perform a 
system-wide survey of native protein complexes in human U2OS osteosarcoma cells. 
Using this approach, I have been able to allocate interacting proteins into clusters and 
in addition, I have shown how specific protein isoforms and post-translationally 
modified forms may interact in different protein complexes. This dataset represents 
one of the largest experimental surveys of native protein complexes in whole cell 
extracts, involving the detection and characterisation of the SEC elution profiles for 
more than 71,600 peptides corresponding to over 8,000 human proteins. The data 
presented were derived from three biological replicates, which facilitated statistical 
evaluation in the downstream analysis. This technique demonstrates how the use of a 
dataset can be expanded beyond simple proteome identification to a more detailed 
analysis of post-translational modifications and protein isoforms, and to analyse the 
effects these have on the interactome. The data from this study has been integrated 
into the Lamond laboratory’s ‘Encyclopedia of Proteome Dynamics’ (EPD) 
(www.peptracker.com/encyclopediaInformation/), a freely accessible, searchable, 
online, multi-dimensional data-sharing resource, to give the wider scientific 
community the opportunity to investigate further any protein or complex of interest. 
Hierarchical clustering of protein elution profiles facilitated the identification of 
protein complex components. The three biological replicates demonstrated that this 
methodology is reproducible and provide deep coverage of cellular protein complexes. 
For example, in the native extracts from U2OS cells, I identified more than 50% of 
known protein complexes published in the CORUM database, which is compiled from a 
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cumulative analysis of the published literature, including multiple cell types. I have also 
clearly demonstrated through the use of the STRING database that interacting proteins 
identified from the published literature were clustered together in this dataset. 
Additional proteins that co-eluted with known complex components may represent 
previously unidentified interaction partners, or indeed, may be part of entirely new 
complexes. Importantly, I have also demonstrated that the combined SEC-MS 
approach facilitates the identification of protein isoforms, formed either through 
alternative splicing, proteolytic cleavage and/or by post-translational modifications. I 
have provided examples of each of these and in each case, I have demonstrated that 
individual isoforms may be involved in different complexes to the canonical protein. 
This provides a powerful tool for detecting and annotating protein complexes that 
augments other techniques commonly used to characterise protein complexes, 
including affinity pull-down methods and previously described SEC and ion-exchange 
chromatography methods. I have also demonstrated that the MS-derived elution 
profiles correlate closely with parallel antibody-based protein detection using western 
blotting. By incorporating these data into the EPD, the entire dataset is available to the 
wider scientific community in a searchable form for data mining. 
This is one of the most in-depth studies to date of native protein complexes and this is 
in part due to cumulative technological advances that have been made in mass 
spectrometry techniques and instrumentation over the last 10 years. These 
developments have resulted in large increases in the sensitivity and resolution of 
proteome analyses. However, there is scope for further technical improvements in MS 
technology that will extend the resolution and sensitivity to detect low abundance 
proteins and post translational modifications that are under-represented using current 
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technology. Further developments in software for the analysis of raw MS data will 
undoubtedly enhance the number of proteins, isoforms and PTMs that can be 
identified across the SEC fractions. Despite any limitations in resolution capacity 
associated with SEC, I was able to separate protein complexes at a level that produced 
biologically relevant and useful information. Advances in SEC column technology, such 
as modified column designs and modified silica matrices, in addition to the advent of 
ultra-high performance liquid chromatography (UHPLC) systems, will make this 
technique even more powerful through increased power of resolution. It is anticipated 
that such improvements may even facilitate the separation of different complexes that 
co-elute within one fraction, such as the CCT and elongation factor complexes in Figure 
3.12. These developments will also increase the identification of PTMs and thus 
provide more detail about how the human interactome, and therefore cell function, is 
regulated by changes in protein complexes.  
In comparing different approaches for the analysis of protein complexes, SEC has some 
clear advantages. One advantage is that the technique can be used with a variety of 
different buffer conditions. I elected to use a lysis buffer containing physiological levels 
of sodium chloride to provide insight into the composition of native protein complexes 
and how they may behave in vivo. A different approach is to use Ion Exchange 
Chromatography (IEX) as per Havugimana et al. [Havugimana et al., 2012]. However, 
this technique requires low salt loading buffer to allow binding of the proteins to the 
column, which may be detrimental to proteins held together by hydrophobic 
interactions. None the less, additional SEC analyses under varying salt concentrations 
and potentially the addition of detergent with SEC could provide valuable information 
regarding the stability of interactions. 
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A second benefit of SEC is its relatively high capacity for protein loading. The Superose 
6 column I used can be loaded with up to 500l of sample. The viscosity of the sample, 
rather than an absolute protein concentration, is a limiting factor for SEC separation 
but sample concentrations of up to ~70mg/ml may be tolerated. In addition, the SEC 
approach is highly automated. A highly automated workflow would generate more 
reliably reproducible data than techniques more reliant on manual procedures, such as 
BN-PAGE. In this respect my SEC analysis holds a great advantage over BN-PAGE as the 
SEC column can be integrated with automated HPLC and as a result, protein complexes 
are separated consistently and remain in a continuous solution from cell lysis through 
to digestion. Manual loading and cutting of gels required in the BN-PAGE approach 
introduces variability in the technique, in addition to the risk of sample loss. 
I am confident that future applications of the SEC approach will provide a framework 
for the system-wide analysis of protein complexes under varying conditions. For 
example, this might include the analysis of complexes in response to different drugs, or 
cell cycle stages. Provisional results also suggest that the SEC approach described in 
this chapter can be applied to tissues (Appendix I). Large-scale, high-throughput 
comparative analyses of complexes under these conditions would not be easily 
achievable using tagged-affinity purification methods. The fusion of tags to proteins 
can lead to an alteration in protein function and protein over-expression can also have 
unwanted side effects [Goel et al., 2000; Rumlová et al., 2001]. These complications do 
not arise with affinity purification using endogenous antibodies but large scale 
application of this technique can be limited due to the cost of antibody production, 
antibody specificity and sensitivity, and epitopes overlapping with interaction sites. 
Whether tagged or un-tagged affinity purification was attempted, it is not only 
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financial implications that pose a disadvantage; the sheer complexity of the analysis of 
the many thousands of pull-down experiments would be immense. These 
complications are avoided by using the SEC approach as in this technique it is 
untagged, endogenous proteins in complex that are analysed in parallel. The MS data 
obtained from this SEC analysis also provides details of protein isoforms and PTMs.  
These variants are often recognised by the same antibody, therefore traditional IP 
analyses with western blotting may miss these biologically relevant details. In 
summary, the workflow I describe is eminently suitable for the large scale analysis of 
native protein complexes in physiological conditions without the expense and 
limitations of multiple antibodies and in as automated approach as possible.  
Through SEC-MS analysis, three different types of protein isoform were found to form 
isoform-specific interactions in distinct complexes. One example of this included the 
NUDT5 protein and its phosphorylated variant. NUDT5 is a nucleotide 
pyrophosphatase, which is known to catalyse the hydrolysis of a variety of substrates 
including ADP-ribose, ADP-mannose, ADP-glucose, 8-oxo-dGDP and 8-oxo-GDP. The 
substrates 8-oxo-GDP and 8-oxo-dGDP are produced following the action of reactive 
oxygen species on nucleotides. Without the action of hydrolysing enzymes such as 
NUDT5, the oxidised nucleotides can be incorporated into DNA leading to genetic 
mutations and/or mistranslation of mRNA [Sekiguchi et al., 2013]. NUDT5 is a 25kDa 
protein that is known to form a homodimer, which corresponds to the protein elution 
profile peak seen in fraction 28 of the SEC dataset (Figure 3.17B). Analysis of 
phosphorylated peptides highlighted phosphorylation of serine 3 of NUDT5 in fractions 
27-29 only, overlapping with one of the NUDT5 peaks. This phosphorylation site has 
been identified previously as an ATM/ATR kinase substrate motif in a large-scale study 
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using Phospho-ATM/ATR substrate (S*Q) immunoaffinity beads [Hornbeck et al., 
2012]. Therefore, I propose that phosphorylation of NUDT5 may be required to 
mediate the hydrolysis of nucleotides. In the unmodified elution profile, NUDT5 also 
has a second peak, centred on fraction 21, which corresponds to an approximate 
molecular weight of ~400kDa. I hypothesise that this peak corresponds to larger 
multimers of NUDT5 and/or NUDT5 in complex with additional partner 
proteins/substrates. 
Analysis of the SEC data also highlighted the importance of high peptide sequence 
coverage when identifying proteins. High sequence coverage enhances the ability to 
discriminate between different protein isoforms [Ahmad et al., 2012]. This was 
illustrated by the HP1BP3 protein and its isoform variants in my dataset. No isoform 
specific peptides were identified but the high level of sequence coverage for each 
isoform facilitated the calculation of an elution profile for each isoform. On the basis of 
these results, I propose that the protein sequence between positions 39 and 116 may 
have a role in forming some HP1BP3 protein interactions. HP1BP3 isoform 3, which 
does not contain this sequence, does not have an elution peak in this region, in 
contrast to all the other isoforms. Although very little is known about this protein at 
present, it will be of great interest to investigate further the interaction partners of the 
different isoforms as more information about this protein is discovered in the future. 
I was also able to detect protein isoforms formed by proteolytic cleavage in my 
dataset. The NUP98-96 polyprotein illustrates how these isoforms may also be 
annotated as parts of distinct complexes. The nuclear pore complex (NPC) is an 
extremely large complex comprising approximately 30 different proteins and is highly 
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conserved from yeast to human [Suntharalingam and Wente, 2003]. The molecular 
mass of the NPC has been determined to be ~60MDa in vertebrates [Cronshaw et al., 
2002]. Therefore, due to the capacity of the SEC column and lack of detergent in the 
lysis buffer, the intact NPC, if identified, would elute in the void fractions in this study. 
However, the analysis of NUP98 protein isoforms derived from autoproteolytic protein 
cleavage of the NUP98-96 precursor has enabled me to differentiate the interactions 
and probable complex fractions involving the different isoforms. NUP96, the C-
terminal component of the precursor polyprotein, corresponds to isoforms 1, 2, 5&6  
of the NUP98-96 protein and is involved in the NUP107-160 complex with NUP107, 
NUP133, SEC13, SEH1L, NUP43, NUP47, NUP85 and NUP160 [Fontoura et al., 1999; 
Siniossoglou et al., 2000; Belgareh et al., 2001; Vasu et al., 2001; Lutzmann et al., 2002; 
Harel et al., 2003; Loïodice et al., 2004]. This complex is involved in mRNA export  and 
in the assembly of the NPC itself [Siniossoglou et al., 2000]. In yeast, the NUP84 
complex (homologous to the human NUP107-160 complex), has a mass of 600-700kDa 
as determined by gel filtration [Siniossoglou et al., 2000; Lutzmann et al., 2002; 
Loïodice et al., 2004]. The Y shaped structure of this complex may cause gel filtration 
to over-estimate the mass as ultracentrifugation suggests it has a mass nearer to 
~375kDa [Siniossoglou et al., 2000]. For proteins in the NUP107-160 complex identified 
in this dataset, including NUP96, there is a peak in fraction 11, corresponding to a 
molecular weight >670kDa. I propose that this represents the intact, soluble NUP107-
160 subcomplex as it elutes from the column. Although there is a small peak in the 
NUP98 profile in this fraction, which may represent an intact NUP98-NUP96 
interaction [Hodel et al., 2002], the overall profile is very different to NUP96. A larger 
peak is noted in the NUP98 profile in fraction 26.  A similar peak in this fraction is 
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identified in the profile of RAE1, a protein known to interact with the GLEBS domain in 
the N-terminal region of NUP98 [Pritchard et al., 1999; Ren et al., 2010]. I hypothesise 
that this peak represents these proteins interacting as part of a fragment of the NPC as 
it breaks apart in the SEC column. The larger peak in the RAE1 profile in fraction 31 is 
most likely to represent monomeric RAE1 (molecular weight 40kDa). As NUP98 is 
formed by alternative splicing and proteolytic cleavage, it is predicted that it would be 
more abundant than NUP96 in the cell, but this is not reflected in the profile traces 
illustrated in Figure 3.16C. One reason for this is that NUP98 is present on the 
nucleoplasmic and cytoplasmic sides of the NPC and in the nuclear basket [Radu et al., 
1995; Griffis et al., 2002; Griffis et al., 2003]. As a result, using a PBS lysis buffer with 
sonication only may not extract all NUP98, with a significant proportion retained in the 
pellet. Another possibility is that a significant proportion of NUP98 may also be bound 
to the intact NPC and therefore elutes in the void.  The most striking point is that the 
profiles for the NUP98 and NUP96 isoforms are different and illustrates once again 
how the SEC-MS technique can be used to differentiate protein isoform interactions.  
The analysis of protein isoforms would not be possible if all identified peptides were 
attributed to a single gene. Analysing the data at the evidence level in addition to 
analysing the profiles of phosphorylated peptides in comparison to non-modified 
peptides, provides a vast amount of biologically relevant data, which may also help 
define protein complex interactions and functions in the future. 
For the data analysis, hierarchical clustering was selected as a method to group 
proteins with similar elution profiles, and therefore potentially interacting proteins, 
together.  These clusters were formed on the similarity of peptide elution profiles 
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obtained from the cell lysate across forty fractions.  It is possible that collecting a larger 
number of fractions would increase the resolution of the elution profiles obtained 
from the lysate, thereby increasing the probability that proteins co-eluting are 
interaction partners. However, this benefit is offset by the increase in MS run time 
required to analyse these samples. Increasing the number of clusters may be an 
alternative approach to increase the confidence that co-clustering proteins interact. 
However, there is the significant risk that this would result in losing interaction data, 
particularly regarding intact protein complexes, as these complexes may be 
fragmented in the clustering process. One possible approach to consider in the future 
would be to combine the results from two different approaches, for example 
combining SEC with ion exchange chromatography, and clustering the combined 
results to increase the confidence in the interactions/resolution.  
One limitation of hierarchical clustering relates to proteins that interact as part of 
multiple different complexes. These proteins are predicted to have multiple peaks 
across their elution profile, each peak corresponding to a different complex. Unless a 
potential interaction partner is also a component of the same complexes, the elution 
profiles of the interaction partners will not match and therefore the proteins will 
cluster differently. For known interaction partners, this dataset is still of valid use as 
the individual elution profiles can be compared to look for peak overlaps and thereby 
predict which complex the interaction belongs to. It is envisaged that the development 
of the clustering analysis in the future to accommodate individual peak detection will 
improve the annotation of these multi-complex proteins. 
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One of the very interesting results highlighted by this study is that there were 
differences in biological function, as indicated by GO term analysis, between proteins 
in larger and smaller complexes. This may reflect regulatory differences between these 
sets of processes. The finding that smaller complexes are enriched for terms associated 
with metabolic processes may reflect that these proteins/complexes require fewer 
subunits for regulation and function than the larger complexes. For example, many 
metabolic reactions may generate a single product from a specific substrate, with the 
modification being made to the substrate often by one enzyme, albeit with multiple 
subunits. The resulting product can move by diffusion, without a requirement for any 
additional protein-protein interactions. In contrast, larger complexes were enriched for 
terms associated with RNA processing, protein localisation and intracellular transport. 
These mechanistically complex biological processes may require many proteins to 
work together as part of large, multi-subunit complexes, such as RNA polymerases and 
the exocyst and COG complexes. Large complexes, such as the CUL3 E3 ligase complex, 
may also rely on the interaction of additional protein components to mediate 
regulation of function in response to temporal and/or spatial cues. In contrast, smaller 
enzymatic complexes involved in intermediary metabolism, such as dimeric GAPDH, 
can have their activity controlled by allosteric regulation. As a result, this may require 
fewer, if any additional protein-protein interactions to facilitate substrate recognition 
or regulatory functions and hence integrate their activity with metabolic homeostasis.  
In summary, this study provides a resource identifying soluble, native protein 
complexes in U2OS cells, separated on the basis of size. I have grouped proteins with 
similar elution profiles into 200 clusters, thereby identifying well defined complexes in 
addition to identifying novel protein interaction networks. The data derived from these 
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experiments have been incorporated into a searchable, freely accessible, online 
encyclopedia to provide a useful resource for the wider scientific community. I have 
demonstrated how these proteomic data can be interrogated to compare complex 
formation between different protein isoforms formed by splice variation, proteolytic 
cleavage and post-translational modification. The workflow I have developed lends 
itself to minor adaptations that would not only facilitate the analysis of native protein 
complexes in different subcellular fractions, but also to study the response of the 
native complexes to different salt concentrations, treatment with pharmacological 
agents including chemotherapeutic drugs, and other stress inducing conditions.  
Adapting the workflow to incorporate pulse labelling by SILAC is also a very exciting 
prospect to consider for future analysis as this would facilitate a greater understanding 
of the order of complex formation. All of these will be interesting avenues for future 
research, but the development of this technique to study native protein complexes in 
animal and human tissues would be ground breaking in the field of interactome 
analysis.   
3.4 Distribution of Effort 
Dr Yasmeen Ahmad performed the R-based statistical analysis of the SEC data, 
including the analysis of protein abundance in this dataset and the CORUM database, 
and the gene ontology analysis although I assisted in planning parameters for 
statistical analysis. Dr Mark Larance ran the samples through the Superose 6 SEC 
column and the peptides were analysed on the LTQ Orbitrap Velos mass spectrometer 
in the “FingerPrints” proteomics facility at the College of Life Sciences, University of 
Dundee. Data derived from this study was published in 2013 [Kirkwood et al., 2013] 
(Appendix II). 
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Chapter 4: Protein crosslinking and 
endogenous complex analysis 
4.1 Introduction  
As discussed in the previous chapter, few proteins function alone but instead most 
function as part of protein complexes to carry out cellular functions. Some protein-
protein interactions are transient, such as reversible substrate-enzyme binding, and 
others are very weak, yet still vital to many biological processes. These transient and 
weak interactions are likely to be amongst those not identified in the study of native 
complexes in chapter 3. I believed that the addition of a crosslinker would facilitate the 
preservation and subsequent identification of these interactions, thereby improving 
resolution and depth of coverage of endogenous protein complexes. It is assumed that 
proteins interacting with each other, either directly, or as part of a larger complex, are 
likely to lie in close proximity to one another. Therefore, the addition of a reagent that 
holds these proteins together throughout cell lysis would enable more efficient 
recovery and detection of these complexes. The use of a crosslinker should also reduce 
non-specific interactions, which might arise from cell lysis when proteins mix with 
those from other subcellular compartments, providing a more accurate analysis of 
endogenous protein complexes. In addition, crosslinking proteins enables the use of 
denaturing lysis buffer conditions, thereby increasing the extraction of complexes 
tightly bound to cell substructures, such as membrane proteins, without disrupting 
protein-protein interactions. 
143 
Chapter 4: Endogenous protein crosslinking analysis 
4.1.1 Types of crosslinkers  
Protein crosslinking refers to the formation of a covalent bond either within 
(intramolecular), or between, molecules (intermolecular).  Crosslinking compounds are 
generally bifunctional; meaning that they have two reactive sites separated by a spacer 
region.  The chemical reactivity of the crosslinker will determine its suitability for 
different uses. The length of the spacer/linker portion will also affect the distance 
between sites that can be crosslinked. Several different crosslinkers exist and the most 
commonly used types are listed in the following section defined by their reactive sites 
[Sinz, 2006]. 
 Amine-reactive crosslinkers (NHS esters, Imidoesters, Carbodiimides) 
 Sulphydryl-reactive crosslinkers (maleimides) 
 Photoreactive crosslinkers (aryl azides, diazirines, benzophenones) 
Crosslinkers are generally divided into either homo-bifunctional, or hetero-bifunctional 
agents. Homo-bifunctional crosslinkers have two identical reactive sites (e.g. amine 
reactive-amine reactive, including dithiobis[succinimidyl propionate] (DSP) and 
Bis[sulfosuccinimidyl] suberate (BS3), whereas hetero-bifunctional agents have 
different reactive sites at either end (e.g. sulphydryl reactive-amine reactive; examples 
include succinimidyl-4-[N-maleimidomethyl] cyclohexane-1-carboxylate (SMCC) and N-
succinimidyl 4-[4-maleimidophenyl]butyrate (SMPB).  
The choice of crosslinker depends on the proposed experiment, and factors such as 
membrane permeability, reversibility and spacer arm length should all be considered. 
For topological protein complex analysis using crosslinking and MS, BS3 [Chen et al., 
2010; Kalisman et al., 2012; Robinson et al., 2012; Murakami et al., 2013], DSS [Lasker 
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et al., 2012; Leitner et al., 2012; Nguyen et al., 2013; Tosi et al., 2013] and SMCC have 
been utilised [Rappsilber et al., 2000]. Reversible crosslinkers, such as DSP [Kim et al., 
2002; Meunier et al., 2002; Kim et al., 2006], and formaldehyde [Vasilescu et al., 2004; 
Tagwerker et al., 2006], have also been used to stabilise protein interactions that 
would otherwise be lost upon cell lysis in affinity purification studies. DTBP, a 
membrane permeable crosslinker, has been used to stabilise integrin complexes 
[Humphries et al., 2009; Byron et al., 2012]. Without membrane-permeable 
crosslinking, known integrin-complex components cannot be immunoprecipitated 
[Humphries et al., 2009]. 
4.1.2 Use of crosslinking in protein complex analysis  
Structural protein complex analysis 
Rappsilber et al. first combined protein crosslinking with mass spectrometry to identify 
components of the NUP84 complex [Rappsilber et al., 2000]. Since then protein 
crosslinking has also been used for the targeted study of such complexes as the 19S 
proteasome lid [Sharon et al., 2006], the 26S proteasome [Lasker et al., 2012], the 
Ndc80 complex [Maiolica et al., 2007], GRP94 [Chu et al., 2006], RNA polymerase II 
complexes [Chen et al., 2010; Murakami et al., 2013], the TRiC/CCT subunits [Kalisman 
et al., 2012; Leitner et al., 2012], modules of the transcription factor, Mediator 
[Robinson et al., 2012; Larivière et al., 2013], the ribosomal protein S1 [Lauber et al., 
2012], and  the SWR1 [Nguyen et al., 2013] and INO80 [Tosi et al., 2013] chromatin 
remodelling complexes. These studies all performed crosslinking on purified protein 
complexes and analysed the crosslinked peptides by mass spectrometry. The MS 
results of the crosslinked peptides are cross referenced to a library of all the possible 
peptide modifications for the proteins of interest, which enables the calculation of the 
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complex structure. In general, purification of the complex is deemed necessary, as 
without doing so, the reference library would be too large.   Yang et al. suggest that 
purification of complexes is not essential in crosslinking studies, and propose the use 
of their software program, pLink, as a solution for the analysis of crosslinked peptides 
[Yang et al., 2012]. This software is reported to detect regular peptides, mono-linked 
(crosslinker binds to one reactive group only with the other active site deactivated), 
loop-linked (intramolecular crosslinks) and interlinked peptides (links between two 
peptides). Utilising this software, this group identified 394 interlinks in BS3-treated 
E.coli lysates and 39 interlinked peptides in C.elegans [Yang et al., 2012]. Only two 
previous crosslinking studies had attempted crosslinking using cell lysates, both in 
E.coli, without identifying a higher number of interlinks [Rinner et al., 2008; Xu et al., 
2010]. This illustrates that crosslinking analysis of intact protein complexes for 
structural analysis on a large scale has only been performed to a limited extent. 
Crosslinking in affinity purifications 
Many protein-protein interactions are either transient, or weak, and as a result, cannot 
be detected under normal affinity purification conditions. To counteract this, cell 
permeable crosslinking agents have been added either to live cells [Meunier et al., 
2002; Vasilescu et al., 2004; Tagwerker et al., 2006; Humphries et al., 2009; Byron et 
al., 2012], or to cell lysates [Kim et al., 2002], to stabilise these interactions. Examples 
where such approaches have facilitated the identification of complexes include: raptor 
as an interaction partner of mTOR with a role in nutrient-stimulated signalling and 
regulation of mTOR kinase activity [Kim et al., 2002]; RCC2, a component of an 
integrin-associated complex, as a regulator of Rac1 and Arf6 [Humphries et al., 2009]; 
-subunit-dependent protein recruitment in integrin adhesion complexes [Byron et al., 
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2012]; molecular chaperones as part of a large endoplasmic reticulum-localised 
mulitprotein complex [Meunier et al., 2002]; keratin 17 as an interactor of 14-3-3 to 
regulate cell growth [Kim et al., 2006] and IQGAP1 as an interaction partner of M-
RasQ71L [Vasilescu et al., 2004].  
4.1.3 Formaldehyde and the analysis of protein interactions 
Formaldehyde is a homo-bifunctional crosslinking agent that has been utilised for 
centuries as a fixative to preserve tissue architecture. Due to its small size, 
formaldehyde readily permeates the cell membrane, making it ideal for the study of 
protein interactions in intact cells and tissues. This enables the fixation and crosslinking 
of proteins, DNA and other reactive molecules in both time and space, through the 
formation of covalent bonds. As a result, it has widely been used for the study of such 
features as cellular architecture in immunohistochemistry; protein-DNA interactions in 
chromatin immunoprecipitation (ChIP) assays [Kuo and Allis, 1999; Orlando, 2000]; 
protein-protein interactions by means of single [Vasilescu et al., 2004] and tandem 
affinity purification [Guerrero et al., 2006; Tagwerker et al., 2006], endogenous protein 
purification [Bai et al., 2008], in isotope labelling methods [Guerrero et al., 2006; Bai et 
al., 2008], non-denaturing [Schmitt-Ulms et al., 2004], and denaturing purification 
conditions [Guerrero et al., 2006; Tagwerker et al., 2006], in cell culture and in tissues 
[Schmitt-Ulms et al., 2004; Bai et al., 2008]. The specific crosslinking sites in the above 
experiments were not determined.  
The chemistry of formaldehyde crosslinking is presumed to be more complex than that 
of other crosslinking agents, and the resulting peptides to be much more 
heterogeneous and difficult to assess by mass spectrometry [Toews et al., 2008]. 
Studies investigating formaldehyde crosslink modifications have shown modifications 
147 
Chapter 4: Endogenous protein crosslinking analysis 
of many different amino acid residues following extended formaldehyde exposure, 
over several days [Metz et al., 2004; Metz et al., 2006], which seemingly confirms the 
complexity. However, Toews et al. have claimed that short term exposure to 
formaldehyde, i.e. 10-20 minutes, led to negligible peptide crosslinking [Toews et al., 
2008]. Thirty Dalton increases in peptide mass were only observed as either amino 
group intermediates, or as thiohemiacetal products of cysteine [Toews et al., 2008]. 
The major reaction products observed in this study were increases in multiples of 12Da 
associated with peptide amino-termini, lysine and tryptophan residues [Toews et al., 
2008]. 
4.1.4 Formaldehyde chemistry 
Formaldehyde reacts with water to form methylene glycol, HO-CH2-OH which can form 
polymers, usually containing between 2 to 8 units (Figure 4.1A). Larger polymers of 
formaldehyde (containing up to 100 subunits) are insoluble in water and termed 
paraformaldehyde. Paraformaldehyde can be converted, either to formaldehyde 
monomers, or small polymers, by heating to 60°C in a buffered solution at 
physiological pH (Figure 4.1A). For use as a fixative, the majority of the resultant 
solution must comprise monomeric formaldehyde. It is the aldehyde group in 
formaldehyde (-CHO) that reacts with nitrogen and some other atoms in proteins and 
if the aldehyde group reacts with two atoms in close proximity a –CH2 crosslink, 
(methylene bridge), is formed (Figure 4.1B). As formaldehyde contains only four 
atoms, the linker formed between proteins is very short, in the region of 2.3-2.7Å. 
Formaldehyde crosslinks are less specific in their targets than other crosslinkers, with 
bonds forming between side chains of cysteine, tyrosine, tryptophan, asparagine, 
glutamine, arginine, histidine, lysine and amino termini. It has been shown that under 
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short fixation periods (10 minutes) the majority of the crosslinks involve lysine, 
tryptophan side chains and the amino termini [Toews et al., 2008], however prolonged 
fixation leads to crosslink formation across many amino acid residues [Metz et al., 
2004; Metz et al., 2006]. 
  
Figure 4.1. Formaldehyde chemistry.  
A, formation of methylene glycol, formaldehyde polymers and depolymerisation 
of paraformaldehyde. B, reaction of formaldehyde with proteins. 
 
The ease of formaldehyde crosslink reversal, by heating, is key to the use of this agent 
as a fixative prior to immunohistochemical analysis, a feature that would also be 
important for identifying proteins in complexes using SEC. Taking all of these points 
into account, i.e., ability to permeate cells; rapid onset of crosslink formation; non-
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specificity of the target permitting crosslinking of a variety of subunits;  compatibility 
with MS studies; and strong yet reversible bonds, this is the crosslinker I opted to 
utilise in the first instance. In addition, this also enabled me to use a denaturing buffer 
to improve protein extraction from membrane and nuclear compartments because the 
crosslinks prevent SDS breaking the interactions. 
4.1.5 Hypothesis and Aims 
 Formaldehyde protein crosslinking can be combined with SEC chromatography 
to enhance recovery of complexes and increase resolution in the study of 
protein complexes 
To do this I have: 
 Optimised formaldehyde crosslinking in vitro combined with denaturing cell 
lysis to preserve protein complexes 
 Separated crosslinked protein complexes by size using SEC before crosslink 
reversal and analysis by LC-MS/MS 
4.2 Results 
4.2.1Workflow for the identification of crosslinked protein complexes 
Crosslinking of native proteins was performed in vivo with formaldehyde in PBS for 10 
minutes before quenching the reaction with glycine. Cells were lysed in a buffer 
containing 4% SDS, sonicated then incubated at 37oC for 30 minutes to aid 
denaturation of complexes, whilst maintaining crosslinks. The crosslinked protein 
complexes were then separated by size/shape using denaturing SEC. For this 
experiment, a different SEC column was used to that used in chapter 3, the BioBasic 
SEC1000. This column contains particles smaller in size than the Superose 6 column, 
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each with 1000Å pores. These features improved the resolution of complex separation, 
and as a result, co-eluting proteins were more likely to be true interaction 
partners/components of the same complex. The eluate was collected in 48 equal, 
sequential fractions; the larger number of fractions was selected as an additional 
attempt to improve resolution. The fractions were then heated to 95oC for 30 minutes 
to reverse the crosslinks. For mass spectrometry analysis, eluate fractions were 
digested with both trypsin and endopetidase lysC, because double protease digest has 
been reported to improve sequence coverage [Ly et al., 2014]. Peptide identification 
and data analysis was performed as per native protein complexes described in the 
previous chapter. The general workflow for crosslinked protein complex analysis is 
described in Figure 4.2.    
 
Figure 4.2. Endogenous protein complex analysis using a comprehensive 
proteomics workflow.  
Workflow for SEC-based separation of crosslinked protein complexes. 
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4.2.2 PFA crosslinking preserves protein complexes through SEC 
To assess if crosslinking would hold protein complexes intact through denaturing lysis 
and SEC separation, U2OS cells were incubated with 1% formaldehyde. This 
concentration has previously been utilised for Chromatin-immunoprecipitation (ChIP) 
[Kuo and Allis, 1999] and in other formaldehyde based crosslinking studies [Vasilescu 
et al., 2004; Guerrero et al., 2006; Tagwerker et al., 2006]. Samples were prepared as 
described in the workflow above to the stage of crosslink reversal (Figure 4.2). The SEC 
chromatograms demonstrate that crosslinked proteins started to elute from the 
column approximately four minutes before non-crosslinked proteins and that the 
absorbance in these early fractions is higher for crosslinked proteins than non-
crosslinked. Conversely, the non-crosslinked protein elution profile showed higher 
absorbance in the later eluting fractions compared to the crosslinked profile. These 
results suggested that 1% formaldehyde did crosslink proteins into larger complexes 
compared to untreated cells (Figure 4.3). Protein standards prepared in the same lysis 
buffer were used to calculate the approximate molecular weight/size of complexes 
eluting across the fractions. These show that the BioBasic SEC1000 column can 
separate protein complexes in the range of 1.8MDa to 15kDa.  
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Figure 4.3. Characterisation of protein complex separation.  
The UV chromatograph from one of the biological replicates indicates the profile 
of the U2OS total cell lysate as it eluted from the SEC1000 column across 48 
fractions. Protein standards of known molecular weights (IgM, BSA, RNase) were 
injected onto the same column, and their elution peaks were used to calculate 
approximate molecular weights for fractions. 
 
After crosslink reversal, the same representative aliquots of the eluates from 
crosslinked and non-crosslinked lysates were prepared for SDS-PAGE. SYPRO ruby 
staining of the selected fractions confirmed that early elution fractions without 
crosslinking contain virtually no detectable protein. However, with crosslinking, the 
same fractions contain a range of proteins of variable molecular weight (Figure 4.4). 
These results demonstrate that formaldehyde crosslinks could withstand cell lysis in a 
denaturing buffer and that these crosslinked complexes could be separated by SEC.   
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Figure 4.4. Formaldehyde crosslinks preserve protein complexes in denaturing 
conditions.  
SYPRO ruby total protein stain of proteins in the total cell lysate and selected 
fractions of cells treated without (left panel) and with (right panel) formaldehyde 
crosslinking. 10g of protein was loaded in lane 2 (total), and a maximum of 
10g of protein was loaded per lane for elution fractions. 
 
4.2.3 Six percent formaldehyde is the optimal crosslinking concentration for 
broad range protein analysis combined with SDS lysis 
Although 1% formaldehyde was shown to hold some complexes intact, the 
chromatogram demonstrated the main elution peaks were in low molecular weight 
fractions, raising the possibility that some complexes were still dissociating under 
these conditions. To determine the optimal concentration of formaldehyde to use with 
the SEC analysis, I prepared cells in the presence of 0, 3, 4, 5, 6 or 8% formaldehyde 
prior to lysis. Equal amounts of protein from each sample were then prepared for SDS-
PAGE and immunoblotted for different proteins that are either known to form 
polymeric chains, or to be part of large protein complexes (Figure 4.5). The results 
show that under my experimental conditions, significant amounts of the proteins  
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Figure 4.5. 6% formaldehyde is suitable for broad range protein analysis 
combined with SDS lysis.  
Immunoblots of total cell lysates from U2OS cells treated with varying 
concentrations of formaldehyde. 10g of total protein loaded per lane. Black 
arrows indicate monomeric protein and red arrows indicate crosslinked 
multimers. 
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remain in monomeric form with less than 6% formaldehyde fixation. Eight percent 
fixation showed the potential to over crosslink some proteins (Figure 4.5). Therefore 
6% formaldehyde was selected as the optimum strength of crosslinker for my future 
experiments.  
Comparison of the chromatograms from cells crosslinked with 1% and 6% 
formaldehyde show an increase in UV absorbance detected in early fractions in 6% 
formaldehyde lysates, with a relative decrease in the absorbance detected in later 
fractions (Figure 4.6). These results show that 6% formaldehyde crosslinks more 
proteins in larger complexes than 1% formaldehyde under these experimental 
conditions. 
 
Figure 4.6. Formaldehyde crosslinks proteins in large complexes.  
The UV chromatograms for lysates from cells treated with either 1%, or 6%, 
formaldehyde as they elute from the SEC1000 column across 48 fractions. 
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SYPRO ruby staining of eluate fractions from protein complexes crosslinked with 6% 
formaldehyde confirm that the size separation successfully separated complexes from 
>460kDa to ~14kDa. The estimated size of each fraction based on SEC protein 
standards closely resembles the molecular weight of crosslinked proteins detected by 
SYPRO ruby staining as they migrate during gel electrophoresis (Figure 4.7).  
 
Figure 4.7. Characterisation of protein complexes separated by crosslinking and 
denaturing SEC.  
SYPRO ruby total protein stain of selected fractions run on 3-8% Tris acetate (left 
panel) and 4-12% Bis-tris gels shows close correlation between SDS-PAGE 
estimated molecular weights and SEC protein standard molecular weights. A 
maximum of 10g of total protein was loaded per lane. 
 
4.2.4 Coverage obtained using crosslinking and denaturing techniques 
Using strict inclusion criteria of a minimum identification of two unique peptides in all 
three biological replicates, I identified a mean of 88,568 peptides, corresponding to 
6,425 proteins. Eight hundred and thirty-three of these peptides carried a 
formaldehyde modification resulting in a 12Da mass increase, and 1,712 carried a 
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formaldehyde modification resulting in a mass increase of 30Da [Metz et al., 2004; 
Metz et al., 2006; Toews et al., 2008].  
To assess if the native SEC and crosslinking SEC approaches were biased towards the 
detection of proteins in specific subcellular compartments, the proteins identified in 
the two datasets were compared to a published dataset [Larance et al., 2013]. In the 
reference dataset, cells were subjected to subcellular fractionation prior to mass 
spectrometry based protein identification in each separate fraction [Larance et al., 
2013]. The degree of overlap between the proteins identified in my datasets and the 
reference dataset, for each subcellular compartment, are presented as a percentage in 
Figure 4.8A. This demonstrates that the crosslinking SEC approach led to the detection 
of more cytoskeletal, membrane and nuclear proteins than the native PBS-based 
approach. Although the PBS approach was slightly biased towards the detection of 
cytoplasmic proteins, the overall proportion of proteins detected across the subcellular 
fractions between the two SEC approaches closely matches the distribution of proteins 
in the reference dataset (Figure 4.8B). 
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Figure 4.8. Analysis of identified proteins across different subcellular 
compartments. 
In the reference dataset, taken from Larance et al. [Larance et al., 2013], a 
protein was allocated to the subcellular compartment where 80% or more of the 
protein was detected. Proteins distributed more generally across compartments, 
outwith these criteria, were excluded from the analysis. Proteins identified in the 
two SEC datasets were then compared to the remaining 2,531 proteins in the 
reference dataset. A, bar graphs demonstrating the percentage overlap of 
proteins identified in each of the SEC datasets, compared to the reference 
dataset, for each subcellular fraction. B, bar graphs demonstrating the 
proportion of proteins allocated to each subcellular compartment as a 
percentage of the matched proteins for the SEC datasets and the reference 
dataset. 
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4.2.5 The crosslinked SEC approach is reproducible 
To determine the reproducibility of protein complex separation using formaldehyde 
crosslinking and SDS based cell lysis with size exclusion chromatography, a pairwise 
comparison of the proteomic analysis of all the proteins in each dataset across each of 
the three biological replicates was performed (i.e. replicate 1 vs 2, 1 vs 3 and 2 vs 3). In 
each comparison a Pearson correlation coefficient was calculated, to compare each 
normalised protein elution profile across the 48 SEC fractions. Each comparison is 
shown in a density plot that reveals a high correlation (>0.7) between replicates for the 
majority of proteins (Figure 4.9). 
 
Figure 4.9. Reproducibility of the crosslinked SEC elution profiles.  
The Pearson correlation coefficient was calculated for the three biological 
replicates (replicate 1 versus replicate 2, replicate 1 versus replicate 3, and 
replicate 2 versus replicate 3). The relative protein density (y-axis) was plotted 
against the Pearson correlation coefficient for each replicate (x-axis). 
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4.2.6 Hierarchical clustering of protein elution profiles 
As before, proteins interacting within the same complexes were expected to have 
similar elution profiles across SEC fractions. Therefore, hierarchical clustering was 
performed to identify potentially interacting proteins. Truly interacting proteins would 
be expected to be crosslinked and therefore co-elute in the same pattern in each of 
the three biological replicates. As a result, the clustering analysis was performed across 
the 144 fractions rather than the mean of the three replicates. The generation of 1 to 
1,000 clusters using the crosslinked SEC dataset was performed to determine the 
optimum number of clusters required. The correlation co-efficient for proteins within 
each cluster, based on the similarity of elution profiles, was calculated to determine 
the optimum cluster size (Figure 4.10). Forming 750 clusters kept the similarity of 
elution profiles within a cluster high (correlation coefficient >0.85), whilst minimising 
the subdivision of known interacting proteins. The heat map of the 750 clusters across 
three replicates is presented in Figure 4.11. 
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Figure 4.10. Calculation of the optimum hierarchical cluster number.  
The column graph shows the average Pearson correlation co-efficient (y-axis) 
plotted over a range of cluster numbers between 1 and 1000 (x-axis).  The red 
circle highlights the correlation coefficient for 750 clusters. 
 
162 
Chapter 4: Endogenous protein crosslinking analysis 
 
Figure 4.11. Hierarchical clustering of protein elution profiles.  
All 6,425 proteins were clustered on the basis of the similarity of their elution 
profiles across 144 SEC fractions and the results are presented as a heat map. 
The dendogram cut-offs for 750 clusters are illustrated to the left of the heat 
map. The key shows the colours allocated to the normalised spectral count as it 
varies from 0 (black) to 1 (red). 
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4.2.7 Components of known protein complexes co-elute within the same cluster 
Using the STRING database to analyse proteins clustered together, components of 
known protein complexes can be identified. For example, closer analysis of cluster 167 
shows it to contain multiple components of the minichromosome maintenance (MCM) 
complex (MCM2, MCM3, MCM4, MCM5 and MCM7) (Figure 4.12). This complex 
unwinds duplex DNA and powers replication fork progression during DNA replication 
[Bochman and Schwacha, 2009]. This cluster has an overall peptide elution peak 
between fractions 8-10, corresponding to an approximate size of >1.8MDa, although it 
is noted that the MCM proteins strongest elution peak is in earlier fractions compared 
to other proteins in this cluster. A previous study investigating the archaeal MCM 
complex by SEC has demonstrated the elution peak to be in a region corresponding to 
a dodecamer (~950kDa) [Pape et al., 2003]. Similarly, the MCM2-7 complex has been 
shown to form a double hexamer in xenopus extracts, with an elution peak seen in the 
region of 1MDa [Gambus et al., 2011]. The MCM complex has also been shown to 
interact with Cdc45 and GINS to form the CMG complex [Gambus et al., 2011]. 
Interestingly, both Cdc45 and GINS complex proteins both have elution peaks in 
fractions 1-4. Although the overall elution profiles of these interacting proteins are 
different, it is possible that the CMG complex is crosslinked in my dataset, explaining 
why the MCM complex eluted earlier than would have been expected for a double 
hexamer of this complex alone. It is also likely that DNA fragments remained intact 
through cell lysis and sonication therefore the elution of this complex in a fraction with 
such a large predicted molecular weight, may represent it being bound to residual 
DNA. 
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Figure 4.12. Components of the MCM complex co-elute.  
The heat map for cluster 167 is presented and the profiles for the MCM complex 
proteins are highlighted in the black box (left panel). The normalised spectral 
counts are represented by green colouring for 0 and red for 1. The string diagram 
for the co-clustering proteins demonstrates known protein-protein interactions. 
Analysis of cluster 97 shows it contains multiple subunits of the CCT complex 
(CCT1/TCP1, CCT2, CCT4, CCT5 and CCT7) (Figure 4.13). Crosslinking structural analysis 
of this complex shows the complex comprises two stacked octameric rings, each 
containing CCT subunits numbered 1-8. Interestingly, CCT1,4,2,5,and 7, the proteins 
identified within cluster 97, all interact as adjacent subunits [Kalisman et al., 2012]. 
 
Figure 4.13. Neighbouring subunits can be crosslinked.  
The heat map for cluster 97 is presented and the profiles for components of the 
CCT complex are highlighted in the black box (left panel). The normalised spectral 
counts are represented by green colouring for 0 and red for 1. The string diagram 
demonstrates that known interacting proteins co-cluster (middle panel). 
Structure of the octameric rings of the CCT complex [Kalisman et al., 2012].  
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A third example cluster is number 130 (Figure 4.14). This cluster contains two out of 
three components of the mTORC2 complex, namely mTOR and RICTOR which are 
involved in cytoskeleton regulation [Dos et al., 2004]. In the same complex, TSC1 and 
TSC2 are also present. These proteins interact and act as negative regulators of the 
mTOR pathway [LaSarge and Danzer, 2014]. A second set of interacting proteins in this 
cluster includes IKBKG (NEMO), TRAF6, RBCK1 and ERC1. TRAF6 is involved in 
ubiquitination of NEMO, a regulatory subunit that inhibits NF-B activation [Bonizzi 
and Karin, 2004; Zotti et al., 2014]. RBCK1 is an E3 ubiquitin ligase in the linear 
ubiquitin chain assembly complex (LUBAC), a complex shown to conjugate linear 
polyubiquitin chains to NEMO to regulate NK-B activation [Tokunaga et al., 2009]. 
ERC1 is a regulatory subunit of IB kinase, known to interact with NEMO [Sigala et al., 
2004]. As demonstrated, all of these proteins are involved in regulation of the NF-B 
pathway, but to date have not been unified as part of one complex. These examples 
also demonstrate that different sets of interacting proteins can elute within the same 
cluster. 
 
Figure 4.14. Independent protein complexes can co-cluster.  
Line graph of mTOR and RICTOR with normalised peptide count (y-axis) plotted 
for each fraction (x-axis) (left panel). Error bars indicate the standard error from 
the mean. The STRING interaction networks for the mTOR and NF-B co-
clustering proteins are shown in the right panel. 
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Analysis of these clusters demonstrates that protein crosslinking with formaldehyde 
can hold interacting proteins together in complexes through SDS denaturation and gel 
filtration. 
4.2.8 The crosslinking SEC approach enhances the identification of 
transmembrane proteins 
One of the key aims in developing the crosslinking strategy was to improve the 
detection of factors such as membrane proteins and their complexes, which were 
under-represented using the native extraction conditions, by using a highly denaturing 
lysis buffer. As shown in Figure 4.8, the overall detection of membrane proteins in this 
dataset was higher than the PBS approach. Proteins detected in the crosslinked 
dataset that were not detected in the native complex analysis included numerous 
syntaxin proteins and other components of the SNARE (soluble N-ethylmaleimide-
sensitive-factor attachment protein receptor) complex. SNARE proteins assemble into 
membrane-bridging complexes [Fasshauer, 2003] and are involved in intracellular 
trafficking [Ungermann and Langosch, 2005]. Other transmembrane proteins such as 
GLUT1, a glucose transporter with 12 transmembrane segments were also identified 
and resolved using the crosslinking combined with denaturing cell lysis technique 
[Deng et al., 2014]. This type of protein would be difficult to analyse using a native 
buffer.  Another example of such a complex is represented by integrins. In the 
crosslinked dataset, many integrins co-clustered in cluster 19 (Figure 4.15). These are 
transmembrane proteins, the majority of which were not identified in the non-
crosslinked SEC dataset [Campbell and Humphries, 2011]. Integrins play a vital role in 
sensing changes in the extracellular environment, which enables cells to adapt and 
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modulate proliferation, differentiation and survival [Wolfenson et al., 2013]. Integrins 
form dimers between alpha and beta subunits [Campbell and Humphries, 2011], alpha 
subunits ranging in size from 130-210k and beta subunits 95-130kDa [Hynes, 1987]. 
This cluster contains many alpha subunit proteins (alpha-2, 3, 5, 6, 7, V) and one beta 
subunit protein (beta-3). The elution peak for this cluster is ~500kDa, possibly 
representing the size of an intact heterodimer with the additional size contributed by 
glycosylation of each subunit [Wolfenson et al., 2013], or co-elution with one of the 
many proteins known to interact with integrins such as Src [Shattil, 2005], CD98hc 
[Fenczik et al., 2001] and Talin 1 [Ye et al., 2014].  
 
Figure 4.15. Transmembrane proteins are identified and co-cluster.  
STRING interaction network of co-clustering proteins, including many integrins, 
in cluster 19 (left panel). Line graphs for representative alpha (ITGA2, ITGA5, 
ITGAV) and beta (ITGB3) subunits contained within cluster 19 (right panel). The 
normalised peptide count (y-axis) is plotted for each fraction (x-axis). Error bars 
represent the standard deviation from the mean. 
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4.2.9 Crosslinking with formaldehyde does not crosslink all subunits of the 
proteasome 
On reviewing the clustering data, it was apparent that some proteasome subunits 
clustered differently. Alpha subunits and regulatory subunits demonstrate overlapping 
elution profile peaks around fraction 15, whereas beta subunits are only weakly 
identified here (Figure 4.16). The main elution profile peak for beta subunits forms 
much later, from fraction 25 onwards. Interestingly, some alpha subunits and 
regulatory cap components also peak in these later fractions, but the approximate size 
of complexes eluting in these fractions is too small for the intact proteasome (see 
Figure 4.16 for representative examples). 
 
Figure 4.16. Analysis of proteasome subunits.  
Line graph demonstrating the normalised peptide count (y-axis) for each fraction 
(x-axis) for selected alpha (PSMA2), beta (PSMB4) and regulatory cap (PSMD4) 
proteasomal subunits. Error bars represent the standard deviation from the 
mean. 
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Analysis of proteasome structure from the literature shows that the 20S core particle 
comprises two outer rings of alpha subunits and two inner rings of beta subunits 
[Kunjappu and Hochstrasser, 2014]. The 19S regulatory cap has a base that sits on the 
alpha ring and a lid attached to the cap [Sharon et al., 2006] (Figure 4.17). The SEC 
profile peaks seen around fraction 15 above, correlate closely with the structural data 
and may represent an intact complex of the alpha subunit and regulatory cap. Partially 
crosslinked components comprising regulatory cap, alpha and beta subunits eluted 
later from the column.  
 
Figure 4.17. Structure of the 26S proteasome.  
Schematic diagram of the 26S proteasome, formed by the 20S core and the 19S 
regulatory cap.  
 
4.3 Discussion 
In this chapter I have generated a comprehensive dataset of the protein interactions in 
U2OS cells by protein crosslinking, denaturing cell lysis and size exclusion 
chromatography. This method has proved very effective for the analysis of a wide 
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variety of protein complexes and has improved the detection of membrane proteins 
over the PBS based approach. 
In this study, I elected to use formaldehyde as the crosslinker but as discussed 
previously (section 4.1.1) there are alternative crosslinking agents that could be 
utilised. Formaldehyde crosslinks are less specific in their targets than other 
crosslinkers, which was deemed to be an advantage in this study as it would enable a 
wider range of proteins to be crosslinked under the same conditions. A disadvantage, 
however, is that the spacer arm is very short (2.3-2.7Å) and therefore, interacting 
proteins need to be in very close contact for them to be crosslinked and contain 
residues that react with formaldehyde. This problem possibly contributed to the partial 
crosslinking of the proteasome beta subunits to the alpha subunit and regulatory cap. 
Either increasing the concentration of formaldehyde, or increasing the length of 
crosslinker incubation time, may never improve the crosslinking of complexes if their 
structure means reactive sites do not lie within the size of the spacer arm of the 
crosslinking agent. In future experiments, performing the analysis using a different 
crosslinker, such as DSP, which has a 12Å spacer arm, would perhaps improve the 
detection of intact, large complexes. 
I elected to use 6% formaldehyde concentration to crosslink proteins in vivo in this 
study as provisional experiments demonstrated this held known multimeric proteins in 
complexes. This concentration is higher than the 1% used in ChIP [Kuo and Allis, 1999] 
and immunoprecipitation studies [Vasilescu et al., 2004; Guerrero et al., 2006; 
Tagwerker et al., 2006]. However, I have demonstrated that for some multimeric 
proteins, 6% formaldehyde concentration was required to sufficiently retain protein 
crosslinks under denaturing conditions. It is possible that this concentration over 
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crosslinked some proteins into non-specific complexes. However, these non-specific 
crosslinks would be expected to be more random than specific crosslinks and would 
not be reproduced across the triplicate analysis. None the less, additional analysis of 
crosslinking protein complexes in the presence of varying formaldehyde 
concentrations over different timescales could be beneficial in the future and would 
add confidence in interactions if proteins continued to co-elute together. 
One of the key aims in developing the crosslinking strategy was to improve both the 
overall efficiency of protein isolation in cell extracts and more specifically to enhance 
the detection of factors, such as membrane proteins and their complexes that are 
under-represented in extracts prepared using native extraction conditions. The 
extracts from crosslinked cells typically have higher total protein concentration than 
native extracts, consistent with a higher efficiency of protein isolation resulting from 
the solubilising effects of detergent. Although Figure 4.8 indicates that most 
membrane proteins were also detected in the native extract dataset, I propose that 
many of these membrane proteins were not well resolved by SEC when extracts were 
prepared using the PBS buffer. For example, GLUT1 is a glucose transporter with 12 
transmembrane domains [Deng et al., 2014]. It is known to form a complex with ADD2 
and DMTN through which it is linked to the actin cytoskeleton [Khan et al., 2008]. On 
the basis of molecular weights, this complex would be predicted to have an 
approximate molecular weight of ~177kDa. In the crosslinked dataset, the GLUT1 
elution profile has a peak around fraction 31, which would correlate with it 
participating in a complex of just above 140kDa. GLUT1 was also identified in the PBS 
dataset, but here its main elution peak was in a fraction corresponding to an 
approximate molecular weight of ~1MDa. In a native buffer, with no detergent 
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solubilisation, proteins closely associated with the cell membrane are unlikely to be 
efficiently extracted. However, as a result of sonication, these proteins may be 
contained within lipid vesicles. Consequently, during native complex analysis, these 
vesicle-associated proteins are likely to be predominantly in or near the void fraction 
and hence not efficiently resolved as separable complexes. I propose therefore that 
the use of in vivo crosslinking and denaturing cell lysis has not only improved the 
detection of membrane proteins, but has also enhanced the ability to resolve the 
cognate protein complexes using SEC fractionation.  
As discussed by Salwinski and Eisenberg, to fully utilise the wealth of information 
obtained from interaction networks, models need to incorporate data regarding the 
spatial and temporal dynamics of proteins, as well as PTMs and degradation pathways 
[Salwinski and Eisenberg, 2003]. In the Lamond laboratory, studies have been 
performed to analyse differential protein expression [Ahmad et al., 2012] and 
degradation [Larance et al., 2013] across subcellular compartments, and differential 
protein expression across the cell cycle [Ly et al., 2014]. These studies were performed 
at the level of individual proteins but to date, such analyses have not been attempted 
at the level of protein complexes. The PBS-SEC dataset demonstrates how protein 
isoforms and PTMs can participate in different protein complexes. However, other 
methods of studying native protein complexes, such as native SEC, ion exchange and 
sucrose gradients are limited in their ability to identify truly native complexes in 
different subcellular compartments as the chemical buffers required to isolate each 
fraction are likely to disrupt PPIs. However, the crosslinking technique could easily be 
combined with subcellular fractionation, because the crosslinks would remain intact 
through cell lysis, including variable salt concentrations and denaturing conditions. This 
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would then enable the analysis of protein complex distribution between subcellular 
compartments to give a more complete picture of biological processes within the cell. 
SEC separation of each subcellular fraction would also be likely to increase the overall 
protein identifications, increasing the depth of coverage in the dataset. 
Bottom-up MS approaches combined with crosslinking can be limited by missed 
cleavages [Sinz, 2006; Petrotchenko and Borchers, 2010]. As formaldehyde crosslinks 
form at the site of primary amine groups at lysine residues and at the N-termini of 
proteins, it is possible that trypsin (the most commonly used protease) cannot cleave 
C-terminal to the modified residue. This results in large peptides, which may not be 
identified. Additionally, the loss of a positive charge after modification of the amino 
group by crosslinking can result in products with low charge states being created 
during electrospray ionisation. These ions may have too low a charge state for mass 
spectrometry analysis and as a result, would not be detected [Sinz, 2006]. However, 
studies utilising formaldehyde in other crosslinking strategies combined with MS 
suggest that missed-cleavages are not problematic [Shevchenko et al., 1996; Vasilescu 
et al., 2004; Tagwerker et al., 2006; Sutherland et al., 2008]. In addition, reversal of 
crosslinks prior to protease digestion in my study will have reduced the size of the 
resultant peptides, thereby reducing the impact of these limitations on peptide 
detection by MS. Despite these potential limitations, I detected more than 88,000 
peptides. To improve on this, additional proteases such as cyanogen bromide could be 
added to the workflow. Cyanogen bromide cleaves at the C-terminal side of 
methionine, a site not modified by formaldehyde. Therefore, larger peptides not 
cleaved with trypsin might be cleaved by this protease instead, thereby improving 
detection rates. Improvement in instrument technology through advances in mass 
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resolution and mass accuracy could overcome some of the complications raised by 
crosslinking and mass spectrometry. Top-down approaches for future crosslinked 
protein analysis is a possibility, as intact complexes could be analysed in the mass 
spectrometer. However, ionisation and fragmentation capabilities of the instruments 
can limit the size of the complex being analysed [Petrotchenko and Borchers, 2010]. 
Novak et al. have combined a top-down and bottom up approach, cleaving intact 
protein complexes into larger peptide fragments using cyanogen bromide, and then 
ionising these larger crosslinked peptide fragments for top-down analysis [Novak et al., 
2005]. This approach might be worth considering in the future for a greater depth of 
coverage of crosslinked peptides. 
In this study, hierarchical clustering was performed to identify interacting proteins 
based on the similarity in elution profiles. As many proteins can take part in multiple 
different complexes, this clustering technique can limit the analysis of the different 
complexes. Work is ongoing in the Lamond laboratory to develop analysis software 
that combines hierarchical clustering with “peak picking”. In this approach, each 
peptide peak across an elution profile would be identified separately and matched to 
other proteins, which also peak in the same fraction. For example, VCAM-1/L1CAM 
was clustered in my dataset with several alpha-integrins and beta-3 integrin. However, 
VCAM-1 is known to be recognised by Leu-Asp-Val (LDV)-binding integrins such as 
41 [Humphries et al., 2006; Humphries et al., 2009]. Beta-1 integrin was identified in 
the crosslinking dataset, but in a different cluster, even though the elution profile for 
this protein contains a peak which corresponds to that seen in the elution profile for 
VCAM-1. By combining hierarchical clustering and “peak picking” techniques these 
proteins may have been identified as interaction partners. Therefore, by using this 
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technique, it is envisaged that a higher number of protein interactions could be 
identified. 
Taken individually, this dataset and the PBS based dataset from chapter 3, provide 
powerful tools for the study of protein complexes, particularly when used in 
conjunction with affinity purification studies. However, cross-referencing either 
analogous studies [Byron et al., 2012], or experimental data with interaction databases 
[Jacquemet et al., 2013], enables the determination of whether a protein of interest is 
a component of one or more protein complexes. Such a cross-referencing approach 
also enables the identification of additional complex components and increases 
confidence in the likelihood of a true PPI. Therefore, with the accumulation of more 
datasets based on the same technique, it should be possible to extend the use of my 
datasets to more accurate PPI predictions. For example, if a pair of proteins clustered 
together in the PBS dataset and also clustered together in the crosslinked dataset, the 
confidence that these two proteins were truly interacting is higher than if they only co-
clustered in one of the two datasets. If a scoring system could be devised to calculate a 
probability interaction score for all proteins identified across the two datasets, more 
PPIs, and therefore novel protein complexes, could be predicted with increased 
confidence. A similar approach was applied by Havugimana et al., who included 
predicted interactions from evolutionary data, mRNA co-expression and domain co-
occurrence in addition to their chromatographic and sucrose gradient approaches 
[Havugimana et al., 2012]. If such analysis could be performed using my data in the 
future, a comparative study of predicted interactions between our two approaches 
would be of great interest. 
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4.4 Distribution of Effort 
The SEC and mass spectrometry sample runs were performed by Dr Mark Larance. The 
R-based statistical analysis was also performed by Dr Mark Larance. Dr Yasmeen 
Ahmad performed the statistical analysis of protein subcellular localisation. 
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Chapter 5: Analysis of the MRFAP1-
MORF4L1 interaction 
5.1 Background 
PTMs play a major role in maintaining cell integrity and function through the 
regulation of protein homeostasis – as discussed in Chapter 1. As a result, 
pharmaceutical companies are targeting components of PTM pathways in the 
development of new therapeutic agents. One such compound is MLN4924, a small 
molecule inhibitor that selectively targets the E1 NEDD8-activating enzyme [Soucy et 
al., 2009]. This drug causes DNA re-replication, cell cycle arrest and resultant 
apoptosis. For this reason it is now in Phase 1 clinical trials for the treatment of acute 
myeloid leukaemia (AML) and other non-haematological malignancies [Swords et al., 
2010]. However, there is still limited understanding of the detailed biochemical effects 
of MLN4924 on the proteome.  A quantitative proteomic study utilising stable isotope 
labelling with amino acids in cell culture (SILAC) performed in the Lamond laboratory 
has demonstrated that treatment of U2OS cells with the MLN4924 inhibitor causes up-
regulation of a protein called MORF4 family associated protein (MRFAP1) and one of 
its known interaction partners, MORtality Factor 4-like protein 1 (MORF4L1), amongst 
other proteins [Larance et al., 2012]. Analysis of MRFAP1 and MORF4L1 interaction 
partners through a series of immunoprecipitation experiments suggests that the 
MRFAP1-MORF4L1 interaction occurs as a mutually exclusive event to MORF4L1-
MRGBP binding. 
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5.1.1 MRFAP1 
MRFAP1 is a 14kDa protein containing 127 amino acids. Analysis of its domain 
structure shows it to have an N-terminal MRG-binding domain, a glycine rich flexible 
linker region and a coiled-coil domain towards its C-terminus [Thompson et al., 1994; 
Kelley and Sternberg, 2009; Waterhouse et al., 2009]. MRFAP1 has not been widely 
studied although its interaction with MORF4L1, via the MRG domain, has been 
characterised in in vitro [Zhang et al., 2006b] and affinity purification studies [Leung et 
al., 2001; Pardo et al., 2002; Hayakawa et al., 2007]. It has been suggested that 
MRFAP1 is a component of the MORF4L1-Rb complex to activate the B-myb promoter 
[Leung et al., 2001], but confirmation of a role for MRFAP1 in this process remains to 
be confirmed.  A later study attempted to elucidate the in vivo function of MRFAP1 by 
creating a MRFAP1-deficient mouse model, but no definitive phenotype was identified 
with knockout mice reamining healthy and fertile [Tominaga et al., 2004]. Interestingly, 
MRFAP1 and MORF4L1 were both identified as rapidly turned over proteins in recent 
pulse-SILAC studies [Schwanhausser et al., 2011; Boisvert et al., 2012]. 
5.1.2 MORF4L1 
MORF4L1 is a highly conserved member of the MORtality Factor on chromosome 4 
(MORF4) gene family and is expressed in a wide range of tissues. MORF4L1 is a 41kDa 
protein containing 362 amino acids. It has a N-terminal chromodomain that binds to 
di- or tri- methylated histone H3 on K36 [Zhang et al., 2006a] (Figure 5.1). 
Chromodomains are histone methylated-lysine recognition modules found in a 
relatively small number of proteins [Yap and Zhou, 2011]. In general, these domains 
are involved in chromatin remodelling [Yap and Zhou, 2011]. In MORF4L1, this 
chromodomain has been shown to be important for the formation and activity of 
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histone acetyltransferase and transcriptional regulation through the B-myb promoter 
[Pardo et al., 2002] (Figure 5.1). Evidence suggests that careful control of histone 
acetylation through methylated histone tails prevents inappropriate transcription 
within protein coding regions [Lee and Shilatifard, 2007]. 
MORF4L1 also has a C-terminal MRG domain, through which it interacts with many 
proteins including MRFAP1 [Leung et al., 2001]; MRGBP [Cai et al., 2003; Bowman et 
al., 2006]; Pf1 [Kumar et al., 2011], Rb [Leung et al., 2001] and mSin3A [Kumar et al., 
2011] (Figures 5.1 and 5.2). It is believed that MORF4L1 binds chromatin via its 
chromodomain to bring proteins interacting with its MRG domain into contact with 
chromatin and histones. 
 
Figure 5.1. Structure of the MORF4L1 protein.  
Red arrows indicate where the proteins and protein complexes, in red circles, 
interact with MORF4L1. 
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MORF4L1 has roles in embryonic development and cell proliferation [Tominaga et al., 
2005; Chen et al., 2009]. MORF4L1 has been shown to be involved in activation of 
transcription as a subunit of the histone acetylation NuA4/Tip60 complex through its 
interaction with MRGBP [Cai et al., 2003]. It has also been demonstrated to play a role 
in repression of transcription, as part of the Rb-associated MAF1 complex [Leung et al., 
2001; Pardo et al., 2002], and the histone deacetylation Rpd3S/Sin3S complex [Xie et 
al., 2012]. In addition, roles for MORF4L1 have also been described in homology-
directed repair of chromosomal breaks through an interaction with PALB2 [Sy et al., 
2009; Hayakawa et al., 2010] and in alternative splicing [Luco et al., 2010]. MORF4L1 
has also been proposed to have a role in de-methylation of H3K4 through its 
interaction with RBP2 [Hayakawa et al., 2007] 
 
 
Figure 5.2. Schematic diagram indicating the interaction sites of MORF4L1 
binding proteins.  
The green box indicates the chromodomain. The interaction sites are indicated in 
turquoise. The MRG domain is represented by the grey box. 
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5.1.3 MORF4L1 and the NuA4 complex 
The NuA4 complex is highly conserved in eukaryotes and its functions include 
regulating transcription, DNA repair and chromosome segregation by acetylating 
nucleosomal histones H4 and H2 [Doyon and Cote, 2004].  A complex comprising ~16 
proteins has been characterised, including MORF4L1, MRG-domain binding protein 
(MRGBP), Bromodomain-containing protein 8 (Brd8) and hDomino (p400) [Doyon and 
Cote, 2004] (Figure 5.3). 
 
Figure 5.3. Model of the NuA4 HAT complex.  
 (image from Doyon and Côté [Doyon and Cote, 2004]) 
 
It has been proposed that the interaction of MRGBP and MORF4L1 is important for 
bringing HAT complexes into contact with chromatin [Doyon and Cote, 2004].  
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hDomino and Brd8 are two proteins that may function together in order to remodel 
chromatin through the incorporation of the variant histone H2Az into chromatin in 
place of histone H2A [Doyon and Cote, 2004].  
Chromatin remodelling is a process that involves the disruption of histone-DNA 
contacts in order to expose DNA and facilitate either gene transcription, or DNA repair.  
Spermatogenesis in many animals is a process in which marked chromatin remodelling 
and histone removal occurs. This involves somatic histones being replaced by histone 
variants (some of which are testis specific), which are then displaced after a process of 
hyperacetylation, by transitional proteins.  The transitional proteins are replaced by 
protamines in order to package DNA tightly in the sperm for successful reproduction 
[Govin et al., 2004; Gaucher et al., 2010].  The processes of spermatogenesis and 
associated chromatin remodelling are depicted in Figure 5.4.   
 
Figure 5.4. Seminiferous tubules of the testis schematic.  
Illustration of the cell types present in the seminiferous tubules of the testis, the 
cell cycle stages they represent and how chromatin modification/remodelling is 
mediated during spermatogenesis. 
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5.1.4 Hypothesis and aims 
Hypothesis 
 MRFAP1 and MORF4L1 interact as a separate complex to the NuA4 complex 
 MRFAP1 and MRGBP competitively interact with MORF4L1 
Aims: 
 To validate the SILAC screen findings for MORF4L1 and MRFAP1 using 
analogous techniques 
 To confirm MRFAP1 and MORF4L1 form a distinct complex from the NuA4 
complex utilising the native protein complex SEC technique  
 To use an affinity purification strategy in combination with a SILAC screen to 
assess for a competitive interaction between MRFAP1 and MRGBP for the 
MRG domain of MORF4L1 
 To analyse the immunohistochemical expression profiles of the MRFAP1 
protein and its interaction partner in human tissues  
5.2 Results 
5.2.1 MRFAP1 is up-regulated by NEDD8 inhibition. 
Prior to proceeding with any experiments to validate the MS data, I wanted to ensure I 
was using an antibody specific to the MRFAP1 protein, as this protein has not been 
widely studied by immunoblotting in the literature. To do this,  siRNA knockdown of 
the MRFAP1 protein was performed in HaCaT (keratinocytes), U138MG (glioblastoma) 
and Tera-1 (pluripotent testicular carcinoma) human cell lines followed by 
immunoblotting (Figure 5.5). 
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Figure 5.5. The MRFAP1 antibody shows specific detection via immunoblotting.  
Immunoblotting of total cell lysates from the indicated cell types treated with 
the indicated siRNA for 48 hours (n=2). 10g total protein loaded per lane. Red 
arrow indicates bands representing the MRFAP1 protein. 
 
To confirm the MS data and to see if up-regulation of MRFAP1 and MORF4L1 following 
inhibition of NEDDylation was conserved across different cell lines, the same three cell 
lines were treated with MLN4924. Immunoblotting total cell lysates from each of these 
cell lines using antibodies specific for MRFAP1 and MORF4L1, confirmed up-regulation 
of these proteins in each case (Figure 5.6). On the basis of the immunoblots, MRFAP1 
up-regulation is greater than MORF4L1 up-regulation in response to MLN4924 
treatment, which corroborates the published SILAC data (Log2 2.56 MRFAP1 increase 
and MORF4L1 Log2 1.60).  
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Figure 5.6. MRFAP1 and MORF4L1 are up-regulated in response to NEDD8 
inhibition.  
Immunoblotting of total cell lysates from the indicated cell types with 1M 
MLN4924 for 18 hours or 10l DMSO only (n=2). 10g total protein loaded per 
lane. 
 
Immunofluorescence microscopy (IF) was also performed, using HaCaT cells 
transfected with siRNA targeting MRFAP1 and non-coding, “jumbled” siRNA as a 
control, to analyse the subcellular distribution of the MRFAP1 protein. These images 
showed a marked reduction in the signal following MRFAP1 knockdown, 
demonstrating the specificity of the MRFAP1 antibody for IF (Figure 5.7). This also 
confirmed that in HaCaT cells, MRFAP1 had a predominantly nucleoplasmic 
localisation, in keeping with previous data [Leung et al., 2001].  Secondly, MRFAP1 
signal intensity is vastly increased following treatment with MLN4924, consistent with 
up-regulation of the protein. Interestingly, cell nuclei appear to be larger following 
MLN4924 treatment, which is in keeping with DNA re-replication, a known effect of 
this compound [Soucy et al., 2009; Milhollen et al., 2011].  
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Figure 5.7. The MRFAP1 antibody shows specific detection via 
immunofluorescence.  
Immunofluorescence microscopy of HaCaT cells treated with the indicated siRNA 
for 48 hours and either 1M MLN4924, or 10l DMSO, for 18 h (n=3). 
Arrowheads indicate the change in nuclear size after MLN4924 treatment. The 
scale bar indicates 10m. 
 
5.2.2 MRFAP1 is a rapidly degraded protein and stabilised by MG132 
The NEDD8-Cullin E3 ligase pathway is an important regulator of protein homeostasis, 
with a key role in the degradation of cell cycle regulators and transcriptional control 
networks. As inhibition of this pathway caused up-regulation of the MRFAP1 protein, I 
sought to determine whether MRFAP1 is degraded via the proteasome using a 
cycloheximide time course to inhibit protein synthesis, combined with either MG132 
(an inhibitor of the 26S proteasome), or DMSO control, in U2OS cells (Figure 5.8).  
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Figure 5.8. MRFAP1 is rapidly degraded via the proteasome.  
Immunoblotting of total cell lysates from U2OS cells treated with 10M MG132 
or 10l of vehicle DMSO only. A time course of 40g/ml cycloheximide 
treatment was used to examine protein degradation. MG132 and cycloheximide 
were added at the same time for each time point (n=3). 10g of total protein 
loaded per lane. 
 
These data demonstrated that the MRFAP1 protein is degraded very rapidly, with 
virtually no detectable MRFAP1 protein after two hours of cycloheximide treatment. 
Interestingly proteasomal inhibition did not lead to a significant overall increase in 
MRFAP1 abundance compared to the DMSO control. However, it did show a marked 
decrease in the rate of MRFAP1 degradation, with significant amounts of protein still 
detectable after eight hours of exposure to MG132.  
I noted that in the previous SILAC screen in which the MRFAP1 response to MLN4924 
was reported, there were fewer proteins up-regulated by this drug than I would have 
expected. MG132 is known to mediate the unfolded protein response in U2OS cells, 
which inhibits protein synthesis by eIF2- pSer51 phosphorylation [Jiang and Wek, 
2005].  To investigate if this response was also mediated by MLN4924 treatment, 
thereby providing an explanation for the relatively small number of proteins up-
regulated in response to this compound, U2OS cells were treated with DMSO, 
cycloheximide, MG132 and MLN4924 and immunoblotted to test for phosphorylation 
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of eIF2alpha. This confirmed that MLN4924 treatment affected cells as NEDD8 
conjugation to large proteins was reduced (Figure 5.9). MG132 treatment caused 
upregulation of phosphorylated eIF2alpha protein as expected. However, MLN4924 
did not therefore these data suggest that the UPR is not mediated by MLN4924 
treatment (Figure 5.9). 
 
Figure 5.9. MLN4924 does not inhibit protein synthesis.  
Immunoblotting of total cell lysates from U2OS cells treated with 10l DMSO, 
40g/ml cycloheximide, 10M MG132 or 1M MLN4924 for 6 hours (n=3). 10g 
of total protein was loaded per lane.  
 
5.2.3 Endogenous MORF4L1 may bind MRFAP1  
Although an interaction between MRFAP1 and MORF4L1 has been shown previously in 
in vitro models [Zhang et al., 2006b] and tagged affinity purifications [Leung et al., 
2001; Pardo et al., 2002; Hayakawa et al., 2007], I wanted to investigate whether an 
endogenous interaction could be demonstrated for the first time in mammalian cells. 
Here, U2OS cells were treated for 16 hours with 1M MLN4924 to increase the 
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endogenous MRFAP1 signal. A commercially available antibody raised against 
MORF4L1 was then used to immunoprecipitate the endogenous protein. 
Immunoblotting the immunoprecipitate did not clearly demonstrate that the 
endogenous MORF4L1 protein had been immunoprecipitated as the band in the IP 
lane was obscured by the heavy and light chains of the antibody used in the pull down.  
In addition, -tubulin was co-immunoprecipitatetd with the endogenous protein which 
suggests the pull-down was not entirely specific. Although a clear band for MRFAP1 is 
seen in the IP lane for the MORF4L1 immunoprecipitation and not in the control 
experiment, this pull-down should be repeated with a more efficient pull down of the 
MORF4L1 protein, either with a higher concentration of this antibody, or, a different 
antibody raised against the MORF4L1 protein, to confirm an endogenous interaction 
between these two proteins. It may also be beneficial to use a cross-linking agent in 
the IP to reduce the heavy and light chain artefact (Figure 5.10). 
 
Figure 5.10. MORF4L1 may interact with MRFAP1 by endogenous 
immunoprecipitation.  
10g of MORF4L1 antibody was used to co-immunoprecipitate MORF4L1 
interacting proteins from U2OS cells treated with 1M MLN4924 for 16 hours 
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(n=2). The red arrow indicates the bands corresponding to MORF4L1. 10g of 
protein were loaded per lane for the input and flow through. 10% of the 
immunoprecipitate was loaded in lanes 3 and 7.  
 
5.2.4 MRFAP1 expression is stabilised by MORF4L1 
As MRFAP1 and MORF4L1 are known to interact, I wanted to test whether expression 
of MORF4L1 affected MRFAP1 expression levels and vice versa. To do this MRFAP1, 
MORF4L1 and MRGBP endogenous proteins were knocked down using siRNA and the 
resultant total cell lysates were immunoblotted. This demonstrated that siRNA 
knockdown of MRFAP1 does not affect MORF4L1 expression (Figure 5.11A, lane 4). 
However, knockdown of MORF4L1 leads to a marked reduction in MRFAP1 expression, 
as detected by immunoblot (Figure 5.11A, lane 5). Interestingly, MORF4L1 knockdown 
does not significantly affect the expression of MRGBP (Figure 5.11A, lane 5). Similarly, 
MRGBP knockdown does not affect either MORF4L1, or MRFAP1, expression, as 
detected by immunoblot (Figure 5.11A, lane 6). Statistical analysis of the western blots 
indicates the statistical significance of the knockdown effects. It is noted however, that 
an analysis of the immunoblot signal intensity detected using the software was not 
performed, therefore it was not proven that all immunoblot signal intensities were 
detected within a linear range (Figure 5.11B). 
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Figure 5.11. MRFAP1 expression is stabilised by MORF4L1.  
A, immunoblotting of total cell lysates from U2OS cells treated with the indicated 
siRNA for 48 hours (n=3). 10g of total protein loaded per lane. B, bar graph 
demonstrating the statistical analysis of the three biological replicates. The ratio 
of each siRNA knockdown normalised against sijumble (y-axis) is plotted for each 
siRNA knockdown (x-axis). Error bars indicate the standard deviation from the 
mean. (*=p<0.05, **=p<0.02, ***=p<0.01). 
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5.2.5 MRFAP1 and MORF4L1 interact as part of a small complex, distinct from 
the NuA4 complex 
To investigate if the MRFAP1 and MORF4L1 interaction was part of known, large 
complexes, I interrogated the native SEC data from chapter 3, specifically looking at 
MRGBP as part of the NuA4 complex. This demonstrated that MRFAP1 and MRGBP 
coincide with the MORF4L1 elution profile in distinct and non-overlapping peaks at 
very different size ranges. The elution profile of MRGBP peaked in fraction 12 (Figure 
5.12B) at a molecular weight of 670kDa, which correlates with previously published 
data on the size of the NuA4 complex [Allard et al., 1999]. In contrast, the elution 
profile of MRFAP1 peaked exclusively in fractions 26-28, which corresponds to a 
molecular weight range between 15 and 67kDa (Figure 5.12C), with no peptides 
detected in the high molecular weight range. These data indicate the presence of at 
least two distinct complexes containing MORF4L1, of very different sizes with mutually 
exclusive interactions with either MRGBP, or MRFAP1, respectively. To complement 
the mass-spectrometry-based analysis, the pairs of combined SEC fractions were 
immunoblotted with antibodies for MORF4L1, MRGBP and MRFAP1 (Figure 5.12D). 
The results from the immunoblots closely correlated with the LC-MS/MS peptide data, 
although MRGBP was also detected in immunoblotted fractions 12 and 13. These 
bands likely represented monomeric MRGBP (37kDa), as a complex containing MRGBP, 
MORF4L1 and MRFAP1 would be predicted to elute in a higher molecular weight 
range. It was noted that MRFAP1 was not detected in fractions with a molecular 
weight above 67kDa; therefore, it was unlikely that MRFAP1 formed part of the NuA4 
complex, or indeed any other large complex contacting MORF4L1. The SEC 
fractionation data are thus consistent with the existence of distinct MORF4L1 
complexes containing either MRGBP, or MRFAP1, as mutually exclusive interactive 
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partners, as judged both by MS and immunoblotting analysis to detect the elution 
profiles of the respective proteins. 
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Figure 5.12. MORF4L1 interacts with MRGBP and MRFAP1 as part of two 
distinct complexes.  
The native SEC elution profiles for MORF4L1 (A), MRGBP (B) and MRFAP1 (C) are 
shown as line graphs with normalised peptide counts (y-axis) plotted for each 
SEC fraction (x-axis). Peaks where MORF4L1 and MRGBP overlap are shaded in 
green and those where MORF4L1 and MRFAP1 overlap are in red. Error bars 
indicate the standard deviation from the mean. D, consecutive elution fractions 
were combined for immunoblotting. 10g of protein was loaded in the lane 
labelled “total”, representing the material injected onto the SEC column. A 
maximum of 10g of protein was loaded in the remaining lanes. The open arrow 
indicates the MRGBP protein band whereas the asterisk denotes either a 
modified form, or, a non-specific band.  
 
To test this further, I next performed IP experiments to examine whether MRGBP 
could be detected as a component that co-purifies in a pull down assay with the 
MRFAP1-MORF4L1 complex. To do this, the wild type, doxycycline inducible, LAPI-
MRFAP1 cell line was utilised [Larance et al., 2012] to co-immunoprecipitate proteins 
interacting with MRFAP1. The same immunoprecipitation assay was performed on 
lysates from the same cells treated with MLN4924 (1M for 16h) and MG132 (10M 
for 2h). Immunoblotting of these precipitates with an antibody raised against 
MORF4L1 confirmed that after doxycycline induction, MORF4L1 was recovered 
together with GFP-MRFAP1. It also showed that this co-purification was increased 
when cells had been treated with either MLN4924 or MG132 (Figure 5.13). Additional 
MORF4L1 bands were detected by immunoblotting, at higher molecular weights than 
the unmodified protein. These were most marked in the lysates treated with MLN4924 
and MG132 and are consistent with ubiquitinated forms of the protein. In contrast 
there were no specific bands detected in the EGFP-MRFAP1 immunoprecipitates that 
could be detected using the MRGBP antibody. These data therefore confirm the results 
from both the MS and protein blotting analyses of elution profiles in the SEC dataset. 
Collectively, the data demonstrate that MRGBP-MORF4L1 and MRFAP1-MORF4L1 
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complexes represent distinct functional units containing mutually exclusive interaction 
partners. These data also validate the use of the native SEC approach to profile co-
fractionation of proteins at a system-wide level and thus to predict the existence of 
distinct forms of protein complexes. 
 
Figure 5.13. Confirmation of MORF4L1/MRGBP/MRFAP1 interactions.  
Immunoblots for GFP-IP analysis of GFP-MRFAP1 cell line (n=3). Cells were 
induced with 10g/ml doxycycline and treated with 1M MLN4924 for 16 hours 
where indicated, 10M MG132 where indicated, or 10l DMSO as a control. The 
solid arrow indicates the unmodified MORF4L1 protein band. The asterisks 
indicate possible ubiquitinated forms of the MORF4L1 protein. 
 
5.2.6 MLN4924 treatment may alter MRFAP1 interaction partners 
To investigate the effect of MLN4924 treatment on protein complexes, U2OS cells 
were treated with 1M MLN4924 for 20 hours prior to PBS lysis and sample 
preparation for SEC as previously. Half of the eluted fractions were prepared for 
immunoblotting and the remaining samples were digested and prepared for LC-MS/MS 
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analysis as previously. The lysates were immunoblotted for MRFAP1 and MORF4L1 as 
these proteins are known to be up-regulated in response to MLN4924 treatment. Their 
overall elution profiles remained unchanged in comparison to cells not subjected to 
the compound (Figure 5.14A). Similarly, no striking changes were seen in the 
immunoblots for MRGBP, tubulin and Histone H3. On reviewing the peptide elution 
profiles from the MS data, no significant change was seen between the untreated and 
MLN4924 treated cells in the MORF4L1 profile (Figure 5.14B,C). However, the MRFAP1 
MLN4924 treated profile shows peptide identifications in fractions eluting earlier from 
the column than untreated cells, with prominent peaks in fractions 13 and 18 
corresponding to complexes >670kDa and between 440 and 670kDa in size, 
respectively (Figure 5.14B,C). These results raise the possibility that MRFAP1 forms 
larger protein complexes in the presence of MLN4924.  
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Figure 5.14. The MRFAP1 peptide elution profile changes after NEDD8 
inhibition.  
A, U2OS cells were treated with MLN4924 for 20 hours prior to native SEC 
separation. Consecutive elution fractions were combined for immunoblotting. 
10g of protein was loaded in the lane labelled “total”, representing the material 
injected onto the SEC column. B, the native SEC elution profiles for MORF4L1 and 
MRFAP1 are shown as line graphs with normalised peptide counts (y-axis) 
plotted for each SEC fraction (x-axis) (n=3). Error bars indicate the standard 
deviation from the mean. C, the native SEC elution profiles for MORF4L1 and 
MRFAP1 after 20 hours of MLN4924 treatment are shown as line graphs with 
normalised peptide counts (y-axis) plotted for each SEC fraction (x-axis) (n=1). 
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5.2.7 MRFAP1 interacts with VprBP in the presence of MLN4924  
As cullins are one of the main substrates of NEDD8, a member of this family was 
deemed likely to play a role in MRFAP1 regulation. CUL4B and VprBP, a known CUL4B 
substrate-binding protein [Le Rouzic et al., 2007; Wen et al., 2007], were identified as 
putative interaction partners of MRFAP1 in a previous SILAC GFP-MRFAP1 IP [Larance 
et al., 2012]. A commercially available antibody was used to immunoprecipitate 
endogenous VprBP from a total cell lysate of U2OS cells treated with MLN4924 for 18 
hours. Immunoblotting the immunoprecipitate for CUL4B confirmed co-
immunoprecipitation of a known VprBP interaction partner (Figure 5.15, lane 8). In 
addition, immunoblotting the immunoprecipitate for MRFAP1 confirmed an 
endogenous interaction between these two proteins as shown by the detection of a 
band corresponding to the MRFAP1 protein in the VprBP immunoprecipitate, with no 
protein detected in the rabbit IgG control immunoprecipitate (Figure 5.15, lanes 7&8).  
 
Figure 5.15. Endogenous VprBP binds MRFAP1.  
3g of VprBP antibody was used to co-immunoprecipitate VprBP interacting 
proteins from U2OS cells treated with 1M MLN4924 for 16 hours. 10g of 
protein was loaded per lane for the inputs and flow throughs. 10% of the 
immunoprecipitates were loaded in lanes 7 and 8 (n=2).  
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To investigate whether the additional high molecular weight peptide peaks for 
MRFAP1 in MLN4924 treated cells correspond to an interaction with VprBP and CUL4B, 
I interrogated the SEC data for these proteins in the presence of MLN4924. The elution 
profiles show an overlap for VprBP and MRFAP1 in fractions 12-14 but there is no clear 
overlap for CUL4B in these fractions (Figure 5.16). This raises the possibility that the 
MRFAP1 peak in this region represents the assembly of a complex containing VprBP 
and MRFAP1, but not CUL4B, in the setting of NEDD8 activating enzyme inhibition 
(Figure 5.16, grey box). However, these results would need to be investigated further 
through biological replicates and additional immunoprecipitation experiments to 
confirm a possible interaction.  
 
Figure 5.16. SEC elution profiles for VprBP interacting proteins in the presence 
of MLN4924.  
Line graphs of the native SEC elution profiles for the specified proteins in the 
lysate of U2OS cells treated with MLN4924 for 20 hours. Normalised peptide 
counts (y-axis) were plotted for each fraction (x-axis). The grey box indicates the 
fractions in which peaks for MRFAP1 and VprBP proteins overlap. 
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5.2.8 MRFAP1 is expressed in spermatogonia 
To investigate the possible function of the MRFAP1-MORF4L1 complex, I wanted to 
study the expression profile of these proteins in human tissues. The same validated 
antibody for the MRFAP1 protein was used by my collaborators in the Human Protein 
Atlas Project (www.proteinatlas.org) to screen tissue micro-arrays of both normal and 
malignant human tissues for the expression of the MRFAP1 protein. Analysis of these 
results show that the MRFAP1 protein is not widely expressed, with strongest staining 
identified in neuronal cells (cytoplasmic), ciliated epithelial cells of the bronchus and 
fallopian tubes (cytoplasmic and nuclear) and spermatogonia of the testis (nuclear) 
(Figure 5.17).  
 
Figure 5.17. MRFAP1, MORF4L1 and MRGBP are expressed in human tissues.  
Graph demonstrating the expression of MRFAP1, MORF4L1 and MRGBP in 
human tissues. Scoring was based on the strength of immunohistochemical 
staining of histological sections (0=no staining, 1=weak, 2=moderate, 3= strong 
staining). Data obtained from the Human Protein Atlas Project 
(www.proteinatlas.org) [Uhlén et al., 2005]. 
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Interestingly, MRFAP1 was also noted to be expressed in a small number of 
malignancies including testicular tumours and glioblastomas. Analysis of the HPA data 
for MORF4L1 also demonstrated positive staining within the nuclei of spermatogenic 
cells of the testis, with an expression pattern that overlapped with MRFAP1 
expression. MRGBP was also expressed in testis but in different cell subtypes to those 
expressing MRFAP1. MRGBP was expressed in occasional spermatocytes, but 
predominantly spermatids (Figure 5.18) 
 
 
Figure 5.18. MRFAP1, MORF4L1 and MRGBP are all expressed in human testis.  
Immunohistochemical staining of human testes for the stated antibodies. 
Spermatids (black arrows), spermatogonia (red arrows) and spermatocytes (blue 
arrows) are identified in each image. The brown colour indicates positive 
staining. Images courtesy of the Human Protein Atlas Project 
(www.proteinatlas.org) [Uhlén et al., 2005]. 
 
These data provide possible physiological evidence in support of the mutually exclusive 
MORF4L1-containing complexes, involving MRFAP1 and MRGBP, within one organ 
system. I therefore proceeded to use immunofluorescence microscopy to study the 
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expression pattern of MRFAP1, MORF4L1 and MRGBP in human testes from archived, 
formalin fixed, paraffin embedded resection specimens.  
 
Figure 5.19. Expression of MRFAP1 in normal human testes.  
Immunofluorescence microscopy of human testicular tissue. Strong nuclear 
staining for MRFAP1 is identified in spermatogonia (white arrowheads). MRFAP1 
and MORF4L1 are both expressed in spermatogonia (white arrows). MRGBP and 
MORF4L1 co-localise in the nuclei of spermatocytes (red arrowheads) and 
spermatids (red arrows). Scale bars represent 10m. 
 
The sections showed that MRFAP1 expression was strongest in the nuclei of peripheral 
spermatogonia and spermatocytes, but showed no staining in elongated spermatids 
(Figure 5.19). MORF4L1 also shows positive nuclear staining in the same cell types and 
it is also present in spermatids. MRGBP, however, shows only minimal co-localisation 
with MRFAP1 in some spermatocytes, with strongest expression in spermatids, where 
it appears to co-localise with MORF4L1. 
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Analysis of human seminomas, a testicular cancer derived from malignant 
transformation of germ cells (spermatogonia) [Mitchell et al., 2014], shows expression 
of MRFAP1 in the malignant cells but minimal expression of MRGBP (Figure 5.20). 
These prominent staining patterns seen in the testis raise the possibility that the 
mutually exclusive interaction of MRFAP1 and MRGBP for binding MORF4L1 relates to 
specific, distinct biological roles in spermatogenesis. 
 
Figure 5.20. MRFAP1 is expressed in seminoma cells.  
Immunofluorescence microscopy of human testicular seminoma. Nuclear 
positivity for MRFAP1 and MORF4L1 is identified in seminoma cells (white 
arrowheads). Scale bar represents 20m. 
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5.2.9 Altered MRFAP1 expression may displace known interactors of the MRG 
domain 
In view of the different expression patters of MRFAP1 and MRGBP in testis, and their 
interaction with MORF4L1 as part of separate complexes, I wanted to investigate 
whether there was competition between these two proteins for MRG domain binding. 
To do this, I expressed and purified the MRG domain, tagged with GST, in bacteria and 
coupled this to sepharose beads (Figure 5.21A,B). GST-empty vector was also 
expressed and bound to beads as a control. To overexpress MRFAP1 in isolation, I 
utilised the LAPI-7KR MRFAP1 cell line. This is a U2OS derived cell line expressing a 
doxycycline inducible GFP-tagged MRFAP1 mutant construct in which all seven lysine 
residues were converted to arginine. This rendered the MRFAP1 protein more resistant 
to ubiquitination. Cell lysate from un-induced LAP1-7KR cells was added to 40l of 
1mg/ml GST-MRG beads in varying concentrations to establish the saturation point for 
endogenous MRFAP1-MRG binding (Figure 5.21C). These results show endogenous 
MRFAP1 in the flow through when the pull-down was performed using 4mg total 
protein cell lysate, indicating that saturation of the MRG domain for MRFAP1 binding 
had occurred. 
The beads were then used to immunoprecipitate MRG domain-binding proteins from 
cell lysates, both with and without MRFAP1 overexpression, to investigate whether 
increasing free MRFAP1 had an effect on MRGBP-MRG co-immunoprecipitation. 
Immunoblots demonstrate that MRFAP1 overexpression did increase the MRG-
MRFAP1 interaction markedly. However there was no significant reduction in the band 
intensity for MRGBP in the immunoprecipitate to suggest MRFAP1 had displaced 
MRGBP from the MRG domain (Figure 5.22, left panel, lanes 10&11). To assess the 
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converse, an experiment using siRNA knockdown of the MRFAP1 protein and non-
coding “jumbled” siRNA was performed in U2Os cells, and the MRG domain was again 
immunoprecipitated using the beads. Immunoblots show that there was no 
demonstrable change in MRGBP co-immunoprecipitated following MRFAP1 
knockdown suggesting that, at least under these experimental conditions, there is no 
competitive interaction between MRFAP1 and MRGBP for the MRG binding domain of 
MORF4L1 (Figure 5.22, right panel, lanes 8&9).  
 
Figure 5.21. Generation of GST-MRG.  
A, the MRG domain previously crystallised by Bowman et al. [Bowman et al., 
2006] was fused to GST and expressed in E.coli. B, SYPRO ruby protein stain of 
the expressed GST-tagged protein and empty vector. C, Immunoblots of the GST-
IP performed in LAP1-7KR MRFAP1 cells. 10g of protein was loaded per lane for 
the flow through and 10% of the immunprecipitate was loaded in the GST-IP 
lanes.    
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Figure 5.22. Analysis of MRFAP1 and MRGBP binding of the MRG domain.  
A, immunoblots of GST-IPs performed in LAP1-7KR MRFAP1 cells either with, or 
without 10g/ml doxycycline induction for 16 hours (n=2). B, immunoblots of 
GST-IPs performed in U2OS cells treated with the indicated siRNA for 48 hours. 
10g of total protein was loaded per lane for the start and flow through and 10% 
of the immunoprecipitate was loaded in IP lanes (n=2). 
 
A triple SILAC pull-down experiment to assess changes in the proteins binding to the 
beads between uninduced 7KR-LAP1 MRFAP1 cells (light) versus doxycycline induced 
(heavy) cells was then performed as an unbiased approach to identify any potential 
competitive interaction between MRFAP1 and other MRG-domain binding proteins. 
The experimental design is described in Figure 5.23.  
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Figure 5.23. Experimental design of triple SILAC GST-MRG analysis. 
 
The results of the SILAC analysis shows ten proteins to have low M/L ratios (Log2 <-1, 
therefore specific interactors to the MRG domain) and low H/L ratios (Log2 <-0.9, 
therefore a reduction in the amount binding the MRG domain in response to MRFAP1 
overexpression) (Figure 5.24A,B). Of these proteins, four (Poly (rC)-binding protein 2, 
Retinoic acid-induced protein 3, Heat shock protein HSP90-alpha and Signal-induced 
proliferation-associated protein 1) have been identified in a previous SILAC study as 
interactors of the MORF4L1 protein [Larance et al., 2012]. Interestingly, Sin3B was 
shown to be a specific interactor of the MRG domain (M/L -1.0999), with a H/L Log2 
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ratio of -0.909. This protein has been identified as a MRG domain interactor in a 
previous study [Hayakawa et al., 2007] and has recently been shown to have a role in 
mitigating histone acetylation and RNA polymerase II progression within transcribed 
loci as part of a complex containing MORF4L1 [Jelinic et al., 2011]. These results raise 
the possibility that MRFAP1 may competitively bind the MRG domain of MORF4L1 to 
regulate histone acetylation, but these results would need to be validated on obtaining 
a suitable antibody raised against Sin3B. 
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Figure 5.24. Analysis of competitive binding for the MRG domain.  
A, a SILAC GST-MRG-IP analysis of U2OS cells stably expressing LAP1-7KR 
MRFAP1. The Log2 normalised ratio of the control (GST-empty vector/GST-MRG 
without doxycycline induction, M/L) (x-axis) is plotted against Log2 GST-MRG 
induced/not induced (H/L) (y-axis). The mutant 7KR MRFAP1 protein is indicated 
in red. B, MRG- binding proteins with a H/L Log2 normalised ratio of <-1 and M/L 
Log2 normalised ratio of <0.9. 
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5.3 Discussion 
In this chapter, I have been able to investigate further the interaction between the 
MRFAP1 and MORF4L1 proteins, replicating and validating the findings of our previous 
large scale SILAC experiments. I have demonstrated that MRFAP1and MORF4L1 are 
upregulated in response to NEDDylation inhibition secondary to MLN4924 treatment, 
across a range of cell types derived from a range of human organs systems. I was 
surprised that only a small subset of proteins were identified as being up-regulated in 
response to MLN4924 mediated NEDD8-activating enzyme inhibition in the initial 
SILAC screen. Confirmation that phosphorylation of eIF2-alpha is not up-regulated in 
response to MLN4924 suggests that overall protein synthesis is not inhibited by this 
compound. This is contrary to MG132, which has been shown to inhibit protein 
synthesis by activation of the unfolded protein response pathway via activation of 
eIF2-alpha phosphorylation [Larance et al., 2013]. Another study investigating 
downstream targets of the NEDDylation pathway using MLN4924 in A375 melanoma 
cells, found up-regulation of a larger number of proteins [Liao et al., 2011]. This may 
reflect differences between cell lines and/or differences in MLN4924 incubation time. 
None the less, Liao et al. also demonstrated up-regulation of MRFAP1 and MOR4L1 
[Liao et al., 2011], providing increased evidential support for these proteins as 
downstream targets of the NEDDylation pathway.  
I have demonstrated that under normal conditions, MRFAP1 is rapidly degraded by the 
proteasome in a matter of hours and that its expression is stabilised by proteasomal 
inhibition. In addition, I have also demonstrated for the first time at an endogenous 
level, that MRFAP1 expression is stabilised by MORF4L1 and this interaction may 
enhance MRFAP1 stability in the context of MLN4924 treatment. Hayakawa et al. 
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[Hayakawa et al., 2007] suggest that overexpression of MRGBP may have a role in 
regulating either MORF4L1 synthesis, or stability, but this was not supported by my 
data on endogenous protein responses.  
I have also demonstrated how the SEC protein complex analysis approach could be 
developed to study the effect of drugs on protein complexes. By comparing the elution 
profiles of MRFAP1 peptides in the untreated cells with the peptide elution profile for 
this protein in cells treated with MLN4924, clear differences are noted, with two peaks 
identified in the treated cells in fractions corresponding to large protein complexes, in 
addition to the main MORF4L1-MRFAP1 interaction peak. It is possible that the overall 
increase in MRFAP1 abundance caused the change in profile. However, if this were the 
case, it would be expected that the MORF4L1 peptide elution profile would alter too as 
this protein is also upregulated by MLN4924. I have demonstrated by endogenous 
immunoprecipitation that MRFAP1 binds to VprBP in the presence of MLN4924. The 
peptide elution profiles for MRFAP1 and VprBP partially overlap in MLN4924 treated 
cells, indicating that a complex containing these proteins may accumulate following 
the inhibition of the NEDD8-activating E1 enzyme. Although the elution profile for 
CUL4B does not closely overlap with that for VprBP, these proteins are known to 
interact as part of a ubiquitin E3 ring ligase complex, which regulates the replication 
factor Mcm10 in response to UV irradiation [Kaur et al., 2012]. From these data, I 
propose a model in which MRFAP1 degradation is mediated by NEDDylation via cullin 
4B and its interaction with the substrate binding protein VprBP. Although the 
MLN4924 SEC complex analysis has only been performed as a single replicate, and 
additional studies would need to be performed to validate reproducibility in the 
results, these data serve as a proof of principle that this technique could be used to 
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analyse the effect of different stimuli, or experimental parameters, on protein 
complexes, on a proteome wide scale. The wider application of this technique to 
analyse changes in protein complexes in response to either different compounds, or 
environmental stimuli, would be an extremely interesting avenue for future research. 
Size exclusion chromatography allows the separation of individual proteins that 
participate in multiple complexes of different sizes and/or shapes. In this chapter, I 
have demonstrated this separation through the analysis of the MORF4L1 adaptor 
protein, which is an example of a protein that is a component of several large 
complexes, including the NuA4 [Doyon and Cote, 2004], Sin3A [Yochum and Ayer, 
2002], and BRCA1-PALB2 complexes [Hayakawa et al., 2010]. The MRFAP1 protein was 
known to interact with MORF4L1 [Tominaga et al., 2004], but the resulting complex 
had not been characterized. In my SEC dataset, the elution profiles of the MORF4L1 
and MRFAP1 proteins were seen to overlap only in the small size fractions. This 
showed that the interaction occurred in a small complex that was separable and 
clearly distinct from the larger MORF4L1-containing complexes mentioned above. 
From the literature, it is apparent that when analysed via immunoaffinity purification, 
all of the MORF4L1 complexes and interaction partners co-purified together. In this 
case the use of SEC provided the size resolution and pre-fractionation of the separate 
forms of complexes necessary to help delineate differences in their protein 
compositions. 
Contrary to my hypothesis, I was not able to demonstrate a competitive interaction 
between MRFAP1 and MRGBP, or Pf1 for the MRG domain of MORF4L1, by MS, in the 
context of stabilised-MRFAP1 overexpression in a cell line. In fact, the in vivo analysis 
suggested that the MRG domain can bind both MRFAP1 and MRGBP simultaneously. 
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These data are supported by mutagenesis studies, which show that although MRFAP1 
and MRGBP bind the MRG domain, their specific interaction sites do not overlap 
[Bowman et al., 2006; Zhang et al., 2006b]. MRG binding sites for Pf1 do overlap in 
part with MRFAP1. However, the pull down analysis did not show a competitive 
interaction between this protein and MRFAP1 for the MRG domain. Sin3A binding sites 
for MORF4L1 may overlap with MRFAP1 [Bowman et al., 2006; Zhang et al., 2006b] but 
sin3A was not identified in the MRG-IP analysis. Therefore, a competitive interaction 
for this protein could not be assessed by MS. Interestingly, sin3B binding of the MRG 
domain did decrease following MRFAP1 overexpression, raising the possibility of a 
competitive interaction between these proteins for the MRG domain. Sin3B has 
previously been identified as an interactor of the MRG domain [Hayakawa et al., 2007] 
and interacts with MORF4L1 as part of a HDAC complex, although it is believed that 
the binding of Sin3B to MORF4L1 is indirect and occurs via the Pf1 – MORF4L1 
interaction [Jelinic et al., 2011]. Concurrent binding of both MRFAP1 and Pf1 may alter 
the Pf1-Sin3B binding domain sufficiently to impair this interaction.  Further validation 
of this competitive interaction would be required using an antibody specific for Sin3B. 
However, these provisional data support a role for the MRFAP1-MORF4L1 interaction 
in transcription regulation because impairing the ability of a HDAC complex to form as 
a consequence of increasing the stability of the MRFAP1-MORF4L1 interaction, will 
affect chromatin re-modelling, and subsequently transcription, as a result. 
Another possible role for the MRFAP1-MORF4L1 interaction relates to transcription 
elongation. The chromodomain of MORF4L1 binds to methylated tails of histone H3, a 
PTM that is very important for transcription elongation. It is possible that the MRFAP1-
MORF4L1 interaction is important to protect these sites, ensuring their preservation 
214 
Chapter 5: Analysis of MRFAP1 
and availability for chromatin modifying complexes. Although my data suggest that 
MRFAP1 and MRGBP can bind the MRG domain simultaneously on the basis of in vitro 
analysis, this is not supported by immunoprecipitation data. However, it remains 
possible that in the setting of the full length MORF4L1 protein, MRFAP1-MORF4L1 
binding inhibits MORF4L1 binding MRGBP and/or Sin3 homologues, thereby inhibiting 
the chromatin binding capacity of large chromatin modifying complexes. Repeating the 
competitive interaction assay with full length MORF4L1-GST, rather than just the MRG 
domain, would address this further.  
In the absence of knowledge about the absolute levels of the MRFAP1, MORF4L1 and 
MRGBP proteins within a cell, it is possible that the concentration of purified MRG 
domain used in the in vitro assay was too high, thus providing an alternative 
explanation for why no definite competitive interaction could be identified between 
different proteins for the MRG domain. In the future, to investigate this further, it 
would be beneficial to perform a more biochemical assay, namely a direct binding 
assay, using recombinant MRFAP1 and another recombinant MRG-binding protein. 
After calibrating the interaction of the individual recombinant proteins in solution with 
MORF4L1 immobilised on beads, the recombinant proteins (e.g. MRFAP1, MRGBP, Pf1) 
could be mixed in varying concentrations in solution with known quantities of 
MORF4L1 protein in the solid phase. Changes in the ratio of protein binding would 
identify any potential competitive interaction more accurately. 
As MORF4L1 is a component of multiple different complexes with potentially opposing 
roles in transcription regulation, greater understanding of absolute protein 
quantitation and stoichiometric analysis of this protein and its interaction partners 
could potentially go some way to addressing any possible competitive interactions. The 
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development of protein epitope signature tags (PrESTs) [Zeiler et al., 2012], 
quantification concatamer (QconCAT) [Beynon et al., 2005; Pratt et al., 2006], protein 
standard absolute quantification (PSAQ) [Brun et al., 2007] and absolute SILAC 
facilitate absolute protein quantitation [Hanke et al., 2008] in line with mass 
spectrometry. If MORF4L1 copy numbers per cell are vastly greater than MRGBP and 
MRFAP1, it could explain why the distinct complexes are identified without evidence of 
competition between them.  
Analysis of the human tissue expression pattern of MRFAP1 shows it to be expressed in 
only a few cell types, including spermatogonia, ciliated epithelial cells and neurones. 
Closer examination of the testis expression pattern of MRFAP1 and MRGBP show an 
anti-correlated pattern (Figure 5.19). MRFAP1 is co-expressed with MORF4L1 in 
spermatogonia and spermatocytes. Spermatogonia undergo mitosis to produce both 
primary spermatocytes and more spermatogonia, to maintain the germ cell 
population. Careful regulation of DNA transcription is required at this level to maintain 
the genetic integrity of future spermatogenesis. Therefore, it is tempting to speculate 
that a MORF4L1-MRFAP1 interaction at this point may have a regulatory role in germ 
cell differentiation. Only after subsequent differentiation into spermatocytes and 
spermatids did I see MRGBP expression co-localising with MORF4L1 expression, 
suggesting that the recruitment of NuA4 histone acetyltransferase activity to 
chromatin via MORF4L1 might be important for later stages of spermiogenesis. This is 
because only the cells in later stages of spermatogenesis co-express MRGBP and 
MORF4L1 but do not express MRFAP1.  
Previous studies have shown in a number of animals, including rats and mice, that 
hyperacetylation of histone H4 is critical for spermatogenesis [Christensen and Dixon, 
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1982; Christensen et al., 1984; Govin et al., 2004]. These studies showed that 
hyperacetylation of histone H4 leads to chromatin decondensation, which is thought 
to allow for histone replacement by protamines and thereby facilitate the extensive 
chromatin compaction needed in the small sperm nucleus (Figure 5.4). I propose that 
the NuA4 histone acetyltransferase complex, which contains MRGBP and BRD8, plays a 
critical role in spermatogenesis by mediating the hyperacetylation of histone H4. One 
of the other MORF4L1-interacting proteins observed in the initial SILAC study was 
EP400, which as part of the human NuA4 complex may also play a role in the exchange 
of histone H2A for histone H2A.Z during spermatogenesis [Auger et al., 2008].  
The testis provides a physical representation of two different MORF4L1 complexes, 
suggesting that complex function and temporal protein expression in cell 
differentiation may regulate protein-protein interactions. In support of this is the 
striking protein expression pattern seen in testicular seminomas. Testicular seminomas 
are derived from testicular germ cells and expression of MRFAP1 is still detected in 
these tumours, whereas MRGBP is not. This model suggests that subtle alterations in 
gene expression, possibly as a result of MRFAP1-MORF4L1 interactions, may facilitate 
malignant transformation, thereby arresting cellular differentiation and subsequent 
chromatin remodelling. Tominaga et al. report that MRFAP1 knockout mice are fertile 
and healthy but it would be interesting to see what the effect of an additional DNA 
insult has on these animals, particularly spermatogenesis [Tominaga et al., 2004]. Of 
course, it is also possible that mice deficient in the MRFAP1 protein compensate for 
loss of function through recruitment of another protein. No reports of the effects of 
MLN4924 on human spermatogenesis have been reported but it would be interesting 
to see if this compound changes the expression profiles of MRFAP1, MORF4L1 and 
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MRGBP. The effect of the compound on MRFAP1 in other tissues would also be of 
great interest, particularly those involving rapid cell division, such as the gut 
epithelium and skin, as this might help to shed more light on the functional role of the 
MRFAP1-MORF4L1 interaction. 
Figure 5.25 summarises the findings of my work investigating the MRFAP1-MORF4L1 
interaction, from the regulation of its degradation by NEDDylation via a pathway 
involving VprBP and CUL4B, to proposals for the function of the MRFAP1-MORF4L1 
interaction. 
 
Figure 5.25. Schematic diagram of MRFAP1 and MORF4L1 interactions. 
MRFAP1 is degraded by the proteome via an interaction with CUL4B and VprBP. 
MRFAP1 may compete with sin3B for the MRG domain of MORF4L1 and as a 
result, may regulate chromatin re-modelling by altering histone acetylation and 
deacetylation. MRFAP1 may also act to protect methylated histone sites for HAT 
complexes. 
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5.4 Distribution of effort 
The mass spectrometry samples were run on the LTQ Orbitrap Velos by the 
“FingerPrints” proteomic facility at the College of Life Sciences, University of Dundee. 
Tissue sections were cut by Mr Calum Thomson of the microscopy facility, University of 
Dundee. Statistical analysis of the siRNA proteins in Figure 5.11 was performed in 
conjunction with Dr Nick Schurch of the Data Analysis Group, College of Life Sciences, 
University of Dundee. Data arising from the work described in this chapter contributed 
towards a publication [Larance et al., 2012] (Appendix II). 
219 
Chapter 6: Future Directions 
Chapter 6: General discussion and future 
directions 
As I have described in the preceding chapters, proteins are the building blocks of all 
living things and they help to define the structure, function and regulation of cells. 
Many techniques have been developed to study proteins and their interactions. 
However, it is clear that there is a pressing need to continue to move beyond single 
protein identification and analysis, into the study of complex proteome dynamics. This 
progression is the key to a deeper understanding of cell biology. 
In this thesis, I have described a strategy for the study of native protein complexes 
using a combination of size exclusion chromatography and tandem mass spectrometry 
with hierarchical clustering. I have shown using the techniques described that co-
fractionating proteins can form part of known protein complexes and I have validated 
the results through correlation with available literature and information in public 
databases. Using this approach for the system-wide analysis of untagged proteins, I 
have also demonstrated that protein isoforms, formed either through alternative 
splicing, proteolytic cleavage and/or post-translational modifications, can be identified. 
I have provided an example for each case, demonstrating that these protein variants 
can be involved in different complexes from the canonical protein. These data highlight 
the importance of studying protein interactions at this depth and the technique 
described in this thesis demonstrates how this can be achieved in a reproducible, rapid 
and high-throughput approach.  
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In the analysis of the MRFAP1-MORF4L1 protein interaction, I was able to correlate 
immunoprecipitation data with the native SEC dataset to establish that the MORF4L1-
MRFAP1 interaction formed a distinct complex to the MOR4L1-MRGBP/NuA4 complex. 
In addition, I have also demonstrated, through proof of principle experiments, that this 
approach for the study of native complexes can be used to investigate the effect of a 
pharmaceutical agent, such as MLN4924, on protein interactions. On the basis of these 
results, I propose that MRFAP1 is degraded via the proteasome through an interaction 
with VprBP, because in the presence of the NEDD8 activating enzyme inhibitor, higher 
molecular weight peaks were seen in the MRFAP1 elution profile, which corresponded 
to a peak in the VprBP peptide elution profile. This proposal has been supported by 
immunoprecipitation data which confirm an endogenous interaction between MRFAP1 
and VprBP in the presence of MLN4924. Provisional results described in Appendix I 
also demonstrate that this technique could be applied to the analysis of protein 
complexes in whole tissues, which is a very exciting prospect because large scale, high-
throughput comparative analyses of complexes under different conditions, e.g. 
starvation or drug treatment, would not be easily achievable using affinity purification 
methods. In addition, this type of analysis would produce more clinically relevant 
results as many cancer cell lines no longer accurately reflect their disease of origin. 
I proceeded to develop the native protein complex analysis described in chapter three, 
by the addition of in vivo protein crosslinking, denaturing cell lysis and denaturing SEC, 
prior to MS/MS analysis. This development led to the more efficient recovery of 
proteins underrepresented in the native SEC dataset and as a result, improved my 
ability to resolve membrane complexes, such as integrins, many of which were not 
identified by the native SEC approach. It would be of great interest in the future to 
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perform a comparative analysis between the crosslinked dataset and the PBS dataset 
from chapter three, to confirm that protein crosslinking has improved the overall 
resolution and increased the identification of protein complexes, over and above the 
native approach. In addition, by analysing the protein complexes identified in lysates 
obtained from cells crosslinked by varying concentrations of formaldehyde, e.g. 1% 
and 4%, it would be useful to use these results, in combination with the native 
analysis, to score and validate protein interactions, and to facilitate the identification 
of potential novel protein interactions and protein complexes. 
In the study of endogenous protein complexes, the use of a crosslinker can increase 
the efficiency of protein recovery. Formaldehyde has proved to be a very useful 
reagent for analysis of endogenous protein complexes. However, it remains rather a 
“blunt tool”, as there is very little control over the position of inter-protein crosslinks 
formed. In addition, truly interacting proteins may not have been crosslinked by 
formaldehyde purely as a result of the linker arm being too short to bridge the reactive 
residues. In the future, performing the crosslinking with a reagent with a longer linker 
arm, such as DSP (12Å), may enable more protein complex subunits to be crosslinked, 
such as the  and  subunits of the proteasome.  
Very limited crosslinking studies analysing protein interaction sites have been 
performed in whole cell lysates [Rinner et al., 2008; Xu et al., 2010; Yang et al., 2012], 
partly due to the complexity of the reference library of potential crosslinked peptides. 
As I was not studying the specific sites of protein crosslinking for structural analysis of 
the complexes and as I reversed crosslinks prior to MS analysis, some of the limitations 
of crosslinking-MS/MS approaches were not as problematic in my study. Of course, 
should the SEC crosslinking technique be extended to include this information in the 
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future, a different crosslinker would need to be selected to facilitate the enrichment of 
crosslinked peptides, as without enrichment, crosslinked peptides can be difficult to 
detect in protein digests due to low ion signals [Petrotchenko and Borchers, 2010]. For 
example, by utilising a crosslinker with an affinity tag within the spacer arm it is 
possible to enrich for crosslinked peptides by affinity purification [Hurst et al., 2004; 
Petrotchenko et al., 2011]. As an additional feature, isotopically labelling the 
crosslinker provides doublet peaks for crosslinked peptides, which can then be 
detected in complex mass spectra [Müller et al., 2001]. Selection of a crosslinker, 
which could be reliably cleaved within the spacer arm, directly in the mass 
spectrometer, would enable specific crosslinked peptides to be identified without the 
need for a crosslinked peptide reference library. Combining the affinity purification 
and controlled cleavage approaches would increase the detection of specific protein-
protein interactions and identify their crosslinking sites. This combined approach was 
used by Petrotchenko et al. to analyse the structure of the protein heterodimer of HIV 
reverse transcriptase using the crosslinker, cyanurbiotindipropionylsuccinimide 
(CBDPS) [Petrotchenko et al., 2011]. However, the use of combined isotopic labelling, 
affinity tagging and directed linker cleavage in mass spectrometry has not yet been 
applied to analyse complex structures at a proteome wide level and this would be a 
very exciting avenue for future study. 
In addition to the development of new crosslinking agents to improve this 
methodology even further, ongoing development of SEC column technology, such as 
modifications to column design and the development of new silica matrices, will also 
improve our ability to resolve protein complexes even further. A significant advantage 
of crosslinking protein complexes is that the interactions are not perturbed by 
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different buffer conditions. Havugimana et.al. developed an approach for the study of 
soluble protein complexes, which involved a combination of ion exchange, isoelectric 
focusing and sucrose gradient separation [Havugimana et al., 2012]. The multi-pronged 
approach is a significant strength of this analysis. However, the different buffer 
conditions across the techniques may have resulted in some protein interactions not 
being replicated across the techniques. It would be an exciting prospect to analyse 
crosslinked proteins in a 2 dimensional approach, first separating complexes by ion 
exchange chromatography and then separating each fraction again by size using SEC. 
Buffer conditions would not perturb the crosslinked proteins and this methodology 
would permit even further resolution of complexes. In particular, complexes which co-
elute by SEC on the basis of size, without interacting, would be unlikely to have the 
same charge and therefore would be likely to be resolved in different fractions at the 
end of the 2D analysis.  
For the crosslinking analysis, the method used for hierarchical clustering was modified 
to cluster the proteins across the 144 fractions, rather than clustering on the mean of 
three biological replicates, as was done for the native dataset in chapter three. As a 
result, more complexes could be resolved within separate clusters without breaking 
down known interacting proteins. In future, statistical analysis by means of ROC curve 
calculation, which would utilise a false positive and false negative calculation to select 
the optimum cluster number, will improve the value of the analysis even further. 
Another area, which is currently undergoing development in the Lamond laboratory, is 
the development of software which will help to identify more interacting proteins. This 
software is designed to identify peaks in an elution profile and would match proteins 
peaking within the same elution fraction. This development will particularly help to 
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identify proteins that are involved in more than one complex. Other research groups 
have utilised publicly available datasets to refine and validate protein interaction 
studies obtained from mass spectrometry experiments [Byron et al., 2012]. Applying a 
similar comparative analysis to identify co-fractionating proteins between the two 
datasets contained in this thesis, and/or comparing the results to protein-protein 
interactions identified in other large scale protein complex analyses [Havugimana et 
al., 2012], would provide a wealth of knowledge about previously unidentified protein-
protein interactions. 
This thesis has mainly focussed on method development. However, I have also 
demonstrated how the SEC/MS approach for protein complex analysis could be 
applied to the study of the effect of drugs on complexes and for the study of protein 
complexes within tissues. There are many more applications that would be ideally 
suited for this approach. For example, Larance et.al. used subcellular fractionation to 
compare protein degradation rates between subcellular compartments [Larance et al., 
2013]. The crosslinking SEC method described in this thesis could be combined with 
subcellular fractionation to identify the localisation of protein complexes throughout 
the cell. Similarly, methods described by Ly et.al., in the quantitative analysis of protein 
variation across the cell cycle, could also be combined with the crosslinking technique 
[Ly et al., 2014]. This type of analysis could provide additional biologically relevant data 
that would not be highlighted from single protein identifications alone. For example, 
the total abundance of a protein in a cell may not change across the cell cycle. 
However, it is entirely feasible that the interaction partners, and therefore the protein 
complexes, that a given protein interacts with do change, and, as a result, this change 
will affect cellular functions. Also, the ability to analyse modified proteins and their 
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involvement in protein complexes will provide an additional depth to the analysis. By 
incorporating an additional parameter, such as a quantitative labelling technique (e.g. 
tandem mass tags), either in the cell cycle analysis, or across subcellular 
compartments, it would be possible to study protein complex assembly over different 
time points. My methods for the analysis of protein complexes could also extend 
beyond tissue culture and into the clinical setting. Individual proteins may not change 
in overall abundance in response to either environmental stimuli, or disease states, but 
protein interactions can vary, and, as a result, studying the proteome at the level of 
protein complexes may give a clearer picture of the intracellular landscape.  
These are just a small number of examples that demonstrate just how powerful the 
endogenous protein complex, SEC/MS approach could be. This approach permits the 
analysis of an additional dimension in proteomics: the study of protein abundance, 
post-translational modifications and now protein interactions are all possible.
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Appendix I 
Native SEC can be used to study protein complexes in testis 
To test whether the SEC approach I developed could be utilised in whole tissues, I 
lysed whole testes from mice aged 48 days and 160 days in PBS and prepared them for 
SEC as previously for U2OS cell lysates (see section 2.7.3). The lysate chromatogram 
was strikingly similar to those in U2OS cells indicating that the range of protein 
complex sizes is similar in tissues to the cell culture system. Forty fractions were 
collected and consecutive fractions were combined as before for ease of 
immunoblotting. The fractions were immunoblotted for MRFAP1, MORF4L1 and 
MRGBP in addition to histone H3 and tubulin (Appendix Figure 1.1). Comparison of the 
two sets of immunoblots demonstrated a very close correlation in the results 
indicating that the SEC separation of the proteins from tissues is reproducible. 
Interestingly, in contrast to the U2OS human cell line there is a greater overlap 
between MORF4L1 and MRGBP in the smaller molecular weight fractions, with only 
very weak MRFAP1 bands seen in these fractions. It is known that MRGBP is not widely 
expressed in tissues and that its strongest staining pattern is seen in the testis. 
Therefore, the altered MRGBP profile in the SEC fractions may reflect this. This 
experiment demonstrates that the native protein complex SEC approach could be 
applied to study changes in protein complexes, in an organ specific set-up. 
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Appendix Figure 1.1. Native complex separation by SEC in murine testes.  
Murine testes from mice aged 160 days (top panel) and 48 days (bottom panel) 
were prepared for native SEC separation. Consecutive elution fractions were 
combined for immunoblotting. 10g of protein was loaded in the lane labelled 
“total”, representing the material injected onto the SEC column. Up to 10g of 
protein was loaded in each of the remaining lanes. 
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